



US008628922B2

(12) **United States Patent**  
**Mellor et al.**

(10) **Patent No.:** **US 8,628,922 B2**  
(45) **Date of Patent:** **Jan. 14, 2014**

(54) **SCREENING METHOD FOR CELL AGING**

(75) Inventors: **Elizabeth Jane Mellor**, Oxford (GB);  
**Michael Youdell**, Oxford (GB); **Anitha Nair**, Oxford (GB); **Alexandre Akoulitchev**, Ewelme (GB)

(73) Assignee: **Chronos Therapeutics Limited** (GB)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/382,629**

(22) PCT Filed: **Jul. 8, 2010**

(86) PCT No.: **PCT/GB2010/051128**

§ 371 (c)(1),  
(2), (4) Date: **Feb. 17, 2012**

(87) PCT Pub. No.: **WO2011/004197**

PCT Pub. Date: **Jan. 13, 2011**

(65) **Prior Publication Data**

US 2012/0270213 A1 Oct. 25, 2012

(30) **Foreign Application Priority Data**

Jul. 8, 2009 (GB) ..... 0911885.2

(51) **Int. Cl.**  
**C12Q 1/68** (2006.01)

(52) **U.S. Cl.**  
USPC ..... **435/6.11; 435/375; 435/7.1; 435/7.9; 540/456**

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2003/0207325 A1 11/2003 Guarente et al.  
2006/0234250 A1 10/2006 Powers, III et al.

**OTHER PUBLICATIONS**

Fujii et al. (Human Mol. Genetics 2003, vol. 12: 1791-1800).\*  
Pray-Grant (Molecular and Cellular Biol. 2002: 8774-8786).\*  
Guelman et al. (Molecular and Cellular Biol. Mar. 2009: 1176-1188).\*  
International Search Report, PCT/GB2010/051128 (Nov. 23, 2010).

Kim et al., The histone acetyltransferase GCN5 modulates the retrograde response and genome stability determining yeast longevity, Biogerontology; 5:5, 305-316 (Oct. 2004).

Barros et al., Higher Respiratory Activity Decreases Mitochondrial Reactive Oxygen Release and Increases Life Span in *Saccharomyces cerevisiae*, J Biol Chem, 279:48, 49883-49888 (Nov. 26, 2004).

Lin et al., Sip2, an N-Myristoylated  $\beta$  Subunit of Snf1 Kinase, Regulates Aging in *Saccharomyces cerevisiae* by Affecting Cellular Histone Kinase Activity, Recombination at rDNA Loci, and Silencing, J Biol Chem, 278:15, 13390-13397 (Apr. 11, 2003).

Lorenz. et al., A network biology approach to aging in yeast, PNAS, 106:4, 1145-1150 (Jan. 27, 2009).

Powers III et al., Extension of chronological life span in yeast by decreased TOR pathway signaling, Genes Dev., 20:2, 174-184 (Jan. 2006).

Ashrafi et al., Sip2p and its partner Snf1p kinase affect aging in *S. cerevisiae*, Genes Dev., 14:15, 1872-1885 (Aug. 1, 2000).

Friis et al., A glycolytic burst drives glucose induction of global histone acetylation by picNuA4 and SAGA, Nucleic Acids Research, 37:12, 3969-3980 (Apr. 30, 2009).

Baker et al., The SAGA continues: expanding the cellular role of a transcriptional co-activator complex, Oncogene, 26:37, 5329-5340 (Aug. 13, 2007).

Sterner et al., SALSAs, a variant of yeast SAGA, contains truncated Spt7, which correlates with activated transcription, PNAS, 99:18, 11622-11627 (Sep. 3, 2002).

Jiang et al., Global assessment of combinatorial post-translational modification of core histones in yeast using contemporary mass spectrometry, J Biol Chem, 282:38, 27923-27934 (Sep. 2007).

Kunz et al., Cyclosporin A, FK506 and rapamycin: more than just immunosuppression, TIBS 18, 334-338 (1993).

Pray-Grant et al., The novel SLIK histone acetyltransferase complex functions in the yeast retrograde response pathway, Mol Cell Biol 22:24, 8774-8786 (2002).

Wu et al., Analysis of Spt7 function in the *Saccharomyces cerevisiae* SAGA coactivator complex, Mol Cell Biol 22:15, 5367-5379 (2002).

Smith et al., Calorie restriction extends the chronological lifespan of *Saccharomyces cerevisiae* independently of the Sirtuins, Aging Cell 6, 649-662 (2007).

Lo et al., Snf1—a Histone Kinase That Works in Concert with the Histone Acetyltransferase Gcn5 to Regulate Transcription. Science 293, 1142-1146 (2001).

\* cited by examiner

*Primary Examiner* — Kimberly Chong  
(74) *Attorney, Agent, or Firm* — Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

(57) **ABSTRACT**

The present invention relates to a method for increasing the chronological lifespan of a cell comprising disrupting the function of at least one of the SAGA1 SLIK and/or SALSAs complexes in said cell.

**4 Claims, 22 Drawing Sheets**

Figure 1




Figure 1 (cont)






Figure 1 (cont)





Figure 2




Figure 2 (cont)




Figure 3







Figure 3 (cont)






Figure 4





Figure 4 (cont)




Figure 5




Figure 6




Figure 6 (cont)




Figure 6 (cont)




Figure 7




Figure 8





Figure 9

**a** *HMS2 promoter*K14ac/H3



**b** *CIT2 promoter*K14ac/H3






Figure 10









Figure 10 (cont)

e



f



g




Figure 11




Figure 12




Figure 12 (cont)




Figure 13




Figure 14





Figure 15



## SCREENING METHOD FOR CELL AGING

## FIELD OF INVENTION

The present invention relates to methods of screening to identify compounds which have an effect on ageing of a cell, more particularly chronological ageing of a cell, methods of diagnosing disorders related to a change in the chronological life span of a cell.

## BACKGROUND

The target of rapamycin complex, TORC1, is conserved from yeast to man and has critical roles in sensing and signalling the nutrient and stress status of the cell, thus controlling the balance between cell growth<sup>1-5</sup> and cell survival<sup>6-11</sup>. In budding yeast TORC1 promotes fermentative growth on glucose and down regulates respiration<sup>12, 13</sup>. TORC1 contains a phosphatidylinositol kinase (PI3-K)-related kinase, either Tor1 or Tor2. The macrolide rapamycin<sup>14</sup>, in a complex with Fpr1 (Fk506-sensitive Proline Rotamase), binds to Tor1/2 causing cells to enter a state that resembles nutrient limitation<sup>15</sup> probably due to a change in the substrate specificity of the Tor kinase<sup>16</sup>. This new state of the cell is associated with changes in patterns of gene expression, particularly genes required for respiration and stress resistance<sup>6,10,17,18</sup>. The expression of many TORC1 genes is dependent on the SAGA family of transcriptional co-activator complexes including SAGA (Spt-Ada-Gcn5-Acetyltransferase)<sup>19,20</sup>, SLIK (SAGA-like)<sup>21</sup> and SALSAs (SAGA altered, Spt8 absent)<sup>22-24</sup>. SAGA, SLIK and SALSAs contain the lysine acetyltransferase (KAT) Gcn5<sup>21-23</sup>, with lysine 14 on histone H3 (H3K14ac) as a substrate, but differ in their abundance, the genes they regulate and subunit composition<sup>19,24</sup>.

The inventors have discovered that H3K18 acetylation, is central to a mechanism that controls the balance between cell growth and longevity. They have also identified a number of genes involved in the SAGA SLIK and SALSAs complexes whose disruption results in an increase in chronological lifespan.

## SUMMARY OF THE INVENTION

According to a first aspect of the present invention there is provided a method for increasing the chronological lifespan of a cell comprising disrupting the function of at least one of the SAGA, SLIK and/or SALSAs complexes in said cell.

According to a second aspect of the present invention there is provided a method for identifying a potential modulator of the chronological life span (CLS) of a cell, comprising the steps of

- i) contacting a cell having a known Histone 3 Lysine 18 (H3K18) acetylation status with a test compound; and
- ii) determining if said compound has an effect on the acetylation status of H3K18 in said cell;

wherein, a change in the acetylation status of H3K18 in the cell indicates that the compound modulates CLS.

According to a third aspect of the present invention there is provided a modulator of the CLS of a cell identified by the method of the second aspect.

According to a fourth aspect of the present invention there is provided a method for identifying the replication status of a cell comprising identifying the acetylation state of H3K18, wherein the presence of an acetyl modification of H3K18 indicates that the cell is an actively replicating cell and the absence of an acetyl modification of H3K18 indicates a cell which is no longer replicating.

According to a fifth aspect of the present invention there is provided a method of identifying a change in the CLS of a cell comprising identifying the acetylation state of H3K18 in the cell and comparing this to the acetylation state of a control cell, wherein loss of H3K18Ac when compared to the control cell indicates an increased CLS and acquisition of H3K18Ac when compared to the control cell indicates a reduced CLS.

According to a sixth aspect of the present invention there is provided a method of diagnosing a disorder associated with a change in the CLS of a cell, said method comprising identifying the acetylation status of H3K18 in a cell previously isolated from a subject and comparing said acetylation status to the acetylation status of a control cell.

## DETAILED DESCRIPTION OF THE INVENTION

It will be understood that any preferred embodiments described herein in relation to one aspect of the present invention can, where appropriate, be equally applicable to any other aspect of the invention.

According to a first aspect there is provided a method for increasing the chronological lifespan of a cell comprising disrupting the function of at least one of the SAGA, SLIK and/or SALSAs complexes in said cell.

As used herein the term chronological life span refers to the time cells in a stationary phase culture remain viable.

It will be understood that the function of the at least one of the SAGA, SLIK and/or SALSAs complexes may be disrupted directly or indirectly. These complexes play a crucial role in controlling of the acetylation state and CLS of a cell, but differ in their levels depending upon the status of the cell and its environment.

As used herein the terms directly and indirectly in relation to interaction with the recited complexes refer to an interaction with either the complex itself, or with a gene product from a gene encoding a peptide which forms part of the complex, or with the gene product from a gene which allows the complex to form.

Preferably, disruption is effected through disruption of at least one gene or a product of at least one gene selected from the group consisting of Spt3, Rtg2, Gcn5, Ubp8, Spt7, Spt8 and/or Snf1 or their homologues.

The term homologue as used herein refers to an analogous gene from a different organism which performs the same function and in general shows some degree of sequence homology. The skilled person will understand that the above genes from *S. cerevisiae* have homologues in other organisms including mammals. For example, Spt3 shows homology to human SUPT3H-203; Gcn5 shows homology to human KAT2B-001 and KAT2A-001; Spt7 shows homology to human SUPT7H and SNF1 shows homology to PRKAA1 and PRKAA2.

It will be understood that these genes encode products which form part of the SAGA, SLIK and/or SALSAs complexes, or interact with said complexes in manner so as to affect acetylation of histones in a cell.

Preferably, the disruption is effected through disruption of SPT7 (SEQ ID NO:11) or SPT7-217 (SEQ ID NO:19).

As used herein the term "disrupting the function", "disruption of the function" or "disrupts the function" when used in relation to a gene or gene product refers to disrupting the expression of the gene or disrupting the activity of the encoded polypeptide. It will be further understood that any stage of gene expression between initiation of transcription and production of a mature protein can be disrupted. The skilled person will understand that this will include epigenetic means of controlling gene expression through control-



ling chromatin structure as well as transcriptional, translational and post translation means of controlling gene expression.

It will be understood that by disrupting expression of a gene as used herein is meant preventing or inhibiting production of a functional polypeptide by any means known in the art and that disrupting the activity of the encoded polypeptide refers to disrupting interaction of the functional polypeptide with one or more of its binding partners such that the polypeptide does not perform its function. The production or function may be fully or partially prevented. In one embodiment, preferably the production or function of the gene product is fully prevented, i.e. there is no active gene product. In some instances the production or function of the gene product may be disrupted such that there is only about 5%, about 10% about 20%, about 30%, about 50%, about 60%, about 70%, about 80%, about 90% or about 95% of the wild type level of expression remaining.

As used herein by inhibiting production of a functional polypeptide it is meant that the production of the gene product may be prevented or inhibited by (a) knocking out said gene; (b) post-transcriptionally silencing said gene through for example the use of iRNA or antisense RNA (gene silencing); (c) transcriptionally silencing said gene by, for example, epigenetic techniques; (d) preventing or altering the function of the gene product by the introduction of at least one point mutation; (e) post translationally inactivating the gene product.

In one preferred embodiment, expression of the gene or homologue is disrupted by iRNA.

Preferably, the cell is transformed with a plasmid/vector encoding an iRNA under control of a promoter. It will be apparent that this promoter may be a constitutive promoter and/or a tissue specific promoter.

As used herein the term iRNA refers to RNA interference (RNAi). This is a method of post-transcriptional gene silencing (PIGS) in eukaryotes induced by the direct introduction of dsRNA (Fire A, et al., (1998)).

In a further preferred embodiment expression of the gene is disrupted at the transcriptional/DNA level. Preferably, said disruption is effected by insertion of at least one nucleotide into the gene or deletion of at least one nucleotide from the gene.

In a further embodiment, the disruption of the gene is effected by introduction of at least one point mutation.

It will be understood that in the case of disruption of the interaction of the polypeptide with one or more of its binding partners. this disruption can be by any suitable means, for example, competitive inhibition, non-competitive inhibition, mixed inhibition or uncompetitive inhibition.

The present invention encompasses the use of sequences having a degree of sequence identity or sequence homology with amino acid sequences of the polypeptides defined herein or of any nucleotide sequence encoding such a polypeptide (hereinafter referred to as a "homologous sequence(s)"). Here, the term "homologous" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can be equated with "identity".

The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.

In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 50, 60, 70, 75, 80, 85 or 90% identical, preferably at least 95%, 97%, 98% or 99% identical to the subject sequence. Typically, the

homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions).

In the present context, a homologous sequence is taken to include nucleotide sequence which may be at least 50, 60, 70, 75, 80, 85 or 90% identical, preferably at least 95%, 97%, 98% or 99% identical to a nucleotide sequence encoding a polypeptide of the present invention (the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions).

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

% homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the Vector NTI (Invitrogen Corp.). Examples of software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al 1999 Short Protocols in Molecular Biology, 4th Ed—Chapter 18), BLAST 2 (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and [tatian@ncbi.nlm.nih.gov](mailto:tatian@ncbi.nlm.nih.gov)), FASTA (Altschul et al 1990 J. Mol. Biol. 403-410) and AlignX for example. At least BLAST, BLAST 2 and FASTA are available for offline and online searching (see Ausubel et al 1999, pages 7-58 to 7-60).

Suitably, the degree of identity with regard to a nucleotide sequence is determined over at least 20 contiguous nucleotides, preferably over at least 30 contiguous nucleotides, preferably over at least 40 contiguous nucleotides, preferably over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 100 contiguous nucleotides.

Suitably, the degree of identity with regard to a nucleotide sequence may be determined over the whole sequence.

As used herein, the term fragment refers to a fragment of the sequence which provides and/or encodes a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.

When referring to a polypeptide fragment, preferably, the fragment is at least 50 amino acids in length. More preferably, the fragment comprises at least 100, 200, 300, 400 or 500 600, 700, 800, 900 or 1000 continuous amino acids from the subject sequence, for example SEQ ID NO:19, up to and including a polypeptide comprising one amino acid less than the full length protein.

When referring to a polynucleotide fragment, preferably the fragment comprises at least 100 nucleotides, more pref-

erably, at least 200, 500, 800, 1000, 1500 or more nucleotides, up to and including a polynucleotide comprising one nucleotide less than the full length polynucleotide.

It will be understood by the skilled person that polynucleotides encoding a particular polypeptide can differ from each other due to the degeneracy of the genetic code. Included herein are the use of such polynucleotides encoding the polypeptide of the present invention.

It will be further apparent to the skilled person that the term homologous sequence in relation to a polynucleotide sequence can refer to a sequence which binds under stringent conditions to the polynucleotide sequence.

Hybridisation conditions are based on the melting temperature ( $T_m$ ) of the nucleotide binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol. 152, Academic Press, San Diego Calif.), and confer a defined "stringency" as explained below.

Maximum stringency typically occurs at about  $T_m - 5^\circ \text{C}$ . ( $5^\circ \text{C}$ . below the  $T_m$  of the probe); high stringency at about  $5^\circ \text{C}$ . to  $10^\circ \text{C}$ . below  $T_m$ ; intermediate stringency at about  $10^\circ \text{C}$ . to  $20^\circ \text{C}$ . below  $T_m$ ; and low stringency at about  $20^\circ \text{C}$ . to  $25^\circ \text{C}$ . below  $T_m$ . As will be understood by those of skill in the art, a maximum stringency hybridisation can be used to identify or detect identical nucleotide sequences while an intermediate (or low) stringency hybridisation can be used to identify or detect similar or related polynucleotide sequences.

In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention under stringent conditions (e.g.  $65^\circ \text{C}$ . and  $0.1 \times \text{SSC}$  { $1 \times \text{SSC} = 0.15 \text{ M NaCl}$ ,  $0.015 \text{ M Na}_3\text{Citrate pH 7.0}$ ). Where the nucleotide sequence of the invention is double-stranded, both strands of the duplex, either individually or in combination, are encompassed by the present invention. Where the nucleotide sequence is single-stranded, it is to be understood that the complementary sequence of that nucleotide sequence is also included within the scope of the present invention.

Nucleotide sequences which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of sources. In addition, other viral/bacterial, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of the nucleotide sequence set out in herein under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the amino acid and/or nucleotide sequences of the present invention. In another aspect of the present invention there is provided a method for identifying a potential modulator of the chronological life span (CLS) of a cell, comprising the steps of

- i) contacting a cell having a known Histone 3 Lysine 18 (H3K18) acetylation status with a test compound; and
- ii) determining if said compound has an effect the acetylation status of H3K18 in said cell;

wherein, a change in the acetylation status of H3K18 in the cell indicates that the compound modulates CLS.

It is known that modification of the histone components of chromatin often reflect whether genes are active or repressed and these changes are globally regulated by enzymes that deposit or remove specific modifications. On active genes, the chromatin is often modified by lysine (K) acetylation (ac) or methylation (me), particularly of histone H3. The inventors have identified a new lysine in histone H3 whose modification status appears to play a critical role in determining the lifespan of a cell.

As used herein, the term modulator of the chronological life span refers to a compound which has an effect on the CLS of the cell. This effect may be to increase the CLS of the cell or to decrease the CLS of the cell. It will be understood that, dependent upon the purpose to which the compound is to be put, either effect may be desirable.

It will be understood that the compound referred to herein may be any suitable compound and may be, for example, a small molecule compound or equally a biological molecule such as a peptide or nucleic acid.

Preferably, the compound interacts with at least one gene or a product of at least one gene selected from the group consisting of Spt3 (SEQ ID NO: 22), Rtg2 (SEQ ID NO: 4), Gcn5 (SEQ ID NO: 6), Ubp8 (SEQ ID NO: 10), Spt7 (SEQ ID NO: 12), Spt8 (SEQ ID NO: 14) and/or Snf1 (SEQ ID NO: 16) or their homologues.

It will be apparent to the skilled person that the gene with which the compound interacts can be identified through the use of various knock out mutant strains.

Methods of producing such strains are well known to the skilled person and include for example, insertion of one or more nucleotides into the coding region of the gene. It will be understood that, as used herein, the term product of at least one gene refers to either a nucleic acid, e.g. mRNA, or peptide product.

In a further preferred embodiment, the compound interacts with the gene designated Acs1 (SEQ ID No: 18) or a product of the gene designated Acs1.

It will be further apparent to the skilled person that the acetylation status of H3K18 can be identified by any suitable means known in the art.

In one embodiment, the acetylation status is determined by measurement of mitochondrial respiration.

It will be understood by the skilled person that any suitable method for measuring mitochondrial respiration can be used. For example, mitochondrial respiration can be measured by incubating the cells in the presence DIOC6 and visualising the cells.

In an alternative embodiment, the acetylation status is determined by indirect immunofluorescence with monoclonal antibodies against H3K18ac on live or fixed cells.

The present invention also provides methods for identifying the replication status of a cell or identifying a change in the CLS of a cell.

As used herein, the term identifying the replication status refers to identifying whether a particular cell or population of cells is actively dividing, or capable of actively dividing or whether the cell or population of cells are no longer able divide.

As used herein, the term identifying a change in the CLS of a cell refers to identifying a step change in a cell or population of cells from a state in which it/they is/are capable of actively dividing to a state in which it/they can no longer divide or vice versa.

It will be understood that this change can be deliberately induced or can occur naturally or through exposure to environmental factors.

Preferably, the cell is a mammalian cell. More preferably, the cell is a human cell. In one preferred embodiment, the cell is an induced pluripotent stem cell.

The skilled person will understand that an induced pluripotent stem cell is typically a somatic cell which has been caused to regress to a pluripotent state either by exposure to certain chemicals or through transfection with, for example, various viruses.

In a further preferred embodiment the cell is a cell suspected of being neoplastic and/or cancerous. Preferably, the cell is a cell from a sample which has previously been isolated from a patient suspected of having or at risk of developing cancer.

In a further aspect, there is provided a method of diagnosing a disorder associated with a change in the CLS of a cell, said method comprising identifying the acetylation status of H3K18 of a cell previously isolated from a subject and comparing said acetylation status to the acetylation status of a control cell.

As used herein, the term control cell refers to a cell of the same tissue type as that isolated from the subject, the control cell being isolated from healthy tissue and having a known acetylation status.

Preferably, said disorder is selected from the group comprising an age related disorder, cancer, a blood disorder, Parkinson's disease or Alzheimer's disease.

The invention will be further described with reference to the figures. References to strains in the figures refer to the strains disclosed in Table 1. In the figures:—

FIG. 1 H3K14ac by SAGA reflects growth. FIG. 1 shows Western blots showing levels of various post-translational modifications to histone H3, in various backgrounds including HA-Spt7 and Gcn5 in total cell extract prepared from cells mock-treated or treated with 10  $\mu$ M rapamycin for up to 180 minutes in the BY4741 background (a, b, c, d), FY168 and FY571 (e, h), FY2 and FY2030 (f) and JR-52A (g). In panel e The version of Spt7 expressed from the spt7-217 allele in FY571 is truncated at amino acid 1119 and has lost 213 C-terminal residues.

FIG. 2 SAGA and K14ac influence ageing. Western blots showing levels of K14ac (a) and HA-Spt7 (b) in total protein prepared from  $1 \times 10^8$  cells of the FY2030 background (a, b) or FY168 and FY571 (c), subject to biotinylation, growth for 10 or 20 generations in exponential culture (YPD) and isolation using magnetic streptavidin beads. Young cells (majority less than 5 generations old) were prepared from the remaining non-biotinylated cells. \* indicates a processed version of histone H3.

FIG. 3 Control of SAGA, SLIK and K14ac. Western blots showing levels of H3K14ac Gcn5 or HA-Spt7 in total cell extracts prepared from the strains indicated (genotype shown in Table 1) after growth in the presence of 10  $\mu$ M rapamycin (+) or mock-treated (-) for 3 hours. WT strains are BY4741.

FIG. 4 Rtg2 and SLIK determine chronological lifespan. a FY168 (WT), FY571 (Spt7-217) and rtg2 $\Delta$  derivatives in exponential phase stained with DiOC6 to assess mitochondrial membrane potential ( $\psi$ ). Scale bar is 10  $\mu$ m. b Serial ten-fold dilutions of cells from strains indicated grown with aeration to stationary phase in CSM containing 3% glucose and plated onto YDP on the day shown to assess viability. The average lifespan (time in days to 50% drop in viability) was calculated from colony counts. c Fluorographs of total protein extracts in exponential phase treated without or with cyclohexamide to inhibit cytoplasmic translation and pulse labelled for 15 minutes with 35S methionine.

FIG. 5 shows Western blots showing levels of various post-translational modifications to histone H3 in total cell extract prepared from BY4741 in exponential or early stationary phase.

FIG. 6 a shows the effect of expressing a C-terminally truncated version of Spt7 (Spt7-217) in strain FY571 and derivatives on K14ac and gene expression. FIGS. 6b-i show the effect of growth phase and the presence of RTG2 on the induction of various genes.

FIG. 7 shows HA-Spt7 undergoes C-terminal processing in cells entering stationary phase.

FIG. 8 shows K14ac is reduced as cells age.

FIG. 9 shows the effect of Rapamycin on K14ac at CIT2 (SLIK induced) or HMS2 (not induced) by ChIP normalised to histone H3. ChIP monitored by real time PCR<sup>53</sup>, expressed as a percentage of input and normalised to levels of histone H3 in three preparations of chromatin, at the 5' region of the genes shown.

FIG. 10 shows that Snf1 is required for the rapamycin dependent reduction in K14ac on rapamycin treatment. a-d Western blots showing levels of modifications at H3 on total cell extracts prepared from the strains indicated in the LPY8056 background (d), BY4741 (a-b, f-g) or FY3 (c). n=3 for all experiments shown. e Indirect immunofluorescence with FITC tagged anti-HA antibody (right panel) or DAPI (DNA) (left panel) of Gal83-HA. Cells were treated +/-10  $\mu$ M rapamycin for up to 3 hours.

FIG. 11 shows Rtg2 is required for optimal levels of K14ac but K14ac is rapamycin sensitive in a rtg2 $\Delta$  strain. Western blots showing levels of modifications at H3 (a) and Gcn5 (b) in total cell extracts prepared from the strains indicated in the BY4741 background. Cells were treated +/-10  $\mu$ M rapamycin for up to 3 hours. Rtg2 is negatively regulated by the Lst8 component of TORC1<sup>66</sup> and this repression is relieved by loss of TORC1 signalling or rapamycin treatment. Rtg2 is a component of SLIK<sup>11</sup> required for the induction of the retrograde responsive genes in quiescent cells.

FIG. 12 shows the effect of loss of Sch9 on the inducibility of CIT2, ATG1 and ACS1 in stationary phase. This figure shows reverse transcription real time PCR quantitation of RNA for the genes shown. The results suggest that Sch9 is required to maintain the integrity of SALSAs and SLIK in stationary phase cultures. Consistent with this we show that the induction of ACS1 is independent of Sch9 (data in FIG. 9 suggests that this gene is dependent on Rtg2 dependent nuclear uptake of Rtg1/3 but not on SLIK). By contrast, CIT2 (SLIK/Rtg2—dependent) and ATG1 (SALSA but not SLIK dependent) require Sch9 for their expression.

FIG. 13 is a western blot showing that disruption of the SAGA complex results in an increase H3K18 acetylation.

FIG. 14 is a graph showing that disruption of SAGA extends the chronological lifespan of yeast cells.

FIG. 15 is a graph showing that disruption of H3K18 acetylation results in a significant reduction in chronological lifespan of yeast cells.

#### Materials and Methods

Details of strains are provided in the Table 1. Yeast were grown at 30° C. in rich medium (YPD), 1% bactopeptone, 1% Difco yeast extract (BD and Co.), 2% glucose to a density of  $0.4 \times 10^9$  cells/ml and treated with 10  $\mu$ M rapamycin in 90% ethanol/10% Tween20 or mock treated for up to three hours. Details for preparation of whole cell extracts, western blotting and antibodies used, preparation of RNA and RNA quantitation, chromatin immunoprecipitation (ChIP), protocols for ageing, assessment of ERCs and chronological ageing assays are set out below.

TABLE 1

Strain	Parent	Genotype	Origin
RMY200 WT		MATa; ade2-10; 1 his3Δ200; lys2-801; trp1Δ901; ura3-52; hht1, hhf1::LEU2; hht2, hhf2::HIS3 plus pRM200 (CEN TRP1 HHF2 HHT2)	Michael Grunstein
H3 K14R	RMY200	Plus pRM200 (hht2 K14R)	Michael Grunstein
H3 K18R	RMY200	plus pRM200 (hht2 K18R)	Michael Grunstein
YSL151 WT		ura3-5; his3Δ20; leu2Δ; trp1Δ63 lys2-128A(hht1-hhf1)::LEU2; (hht2-hhf2)::HIS3; pTRP1-HHT2-HHF2	Shelley Berger
H3 K4A YZS276	YSL151	Plus pTRP1 (hht2 K4A) MATa; hta1-htb1A::LEU2 hta2-htb2A leu2-3,-112 his3-11,-15 trp1-1 ura3-1 ade2-1 can1-100 (pZS145 HTA1-Flag-HTB1 CEN HIS3)	Shelley Berger David Allis
H2B K123R LPY8056	YZS276	Plus pZS14 (htb1 K123R) MATa; his3Δ200; leu2Δ1; ura3-52; trp1Δ63; lys2-128δ; (hht1-hhf1)Δ::LEU2 plus pRS314B (HHF2 HHT2)	David Allis Shelley Berger
H3 S10A H3 K14A H3 S10A K14A BY4741	LPY8056 LPY8056 LPY8056	Plus PRS314B (hhf2 S10A) Plus PRS314B (hhf2 K14A) Plus PRS314B (hhf2 S10A K14A)	Shelley Berger Shelley Berger Shelley Berger
gcn5Δ spp1Δ S288c	BY4741 BY4741	MATa; his3Δ; leu2Δ; met15Δ; ura3 gcn5::KanMX spp1::KanMX	Euroscarf Euroscarf Open Biosystems
fpr1A fpr2A fpr3A fpr4A rim15Δ rtg2A msn2Δ msn4Δ snf1A sch9A dot1A L5487 sch9A Gal83-HA Gcn5-HA	BY4741 BY4741 BY4741 BY4741 BY4741 BY4741 BY4741 BY4741 BY4741 BY4741 L5487 BY4741 JR-52A	fpr1::KanMX fpr2::KanMX fpr3::KanMX fpr4::KanMX rim15::KanMX rtg2::KanMX msn2::KanMX msn4::KanMX snf1::KanMX sch9::KanMX dot1::KanMX MATa, ura3-52, leu2::hisG sch9::URA3 GAL83-HA-His3MX6 Plus pRS314 (GCN5 3HA::his5+)	Euroscarf Euroscarf Euroscarf Euroscarf Euroscarf Euroscarf Euroscarf Euroscarf Euroscarf Euroscarf Aaron Mitchell Paul Nutton This study Shelley Berger
spt20A spt8A FY3 FY2030 HA-Spt7	BY4741 BY4741 FY3 FY3	spt20::KanMX spt8::KanMX MATa; ura3Δ0 MATa; ura3Δ0; leu2Δ1; trp1Δ63; his4-917 δ; lys2-173R2 HA-SPT7-URA3	Euroscarf Euroscarf Fred Winston Fred Winston
HA-Spt7 snf1A HA-Spt7 sch9A FY168	FY2030 FY2030	snf1::KanMX sch9::KanMX	This study This study
FY168 rtg2A FY571 spt7-217		MATa; leu2Δ1; his4-917 δ; lys2-173R2 rtg2::KanMX MATa; ura3Δ0; leu2Δ1; trp1Δ63; his4-917 δ; lys2-173R2 spt7-217	Fred Winston This study Fred Winston
FY571 rtg2A	spt7-217	rtg2::KanMX	This study

## Preparation of Yeast Whole Cell Extracts.

25 ml of cells were grown in YPD to an OD of ~0.4 A<sub>600</sub> and harvested by centrifugation. For rapamycin treated cells, cells were grown to mid-log followed by the addition of 10 μM rapamycin (Sigma R0395-1 MG) for up to 3 hours and harvested by centrifugation. Cell pellets were resuspended in

300 μl 8 M urea and broken by vortexing for 5 mins following the addition of 200 μl acid-washed glass beads (Sigma). Lysates were boiled for 5 mins in standard laemmli loading buffer.

## 5 Western Blotting.

Protein extracts were subject to electrophoresis on polyacrylamide gels using standard Tris-glycine running buffer (40% (w/v) glycine, 0.25 M Tris-base, 10% (w/v) SDS) following heating at 90° C. for 3 min. Proteins were transferred onto a nitrocellulose membrane using semi-dry transfer (Bio-Rad). Successful transfer of protein was verified by Ponceu S staining (0.1% Ponceu S, 5% acetic acid). Membranes were then blocked in PBS containing 5% dry milk or BSA for 1 hour, followed by incubation with primary antibody: 1:3000 anti-H3 (Abcam ab1791), 1:5000 anti-H3 K9ac (Upstate 07-352), 1:3000 anti-H3 K14ac (Upstate 07-353), 1:5000 anti-H3 K18ac (Upstate 07-354), 1:10,000 anti-H3 K23ac (Upstate 07-355), 1:3000 anti-H3 K27ac (Upstate 07-360), 1:5000 anti-H3 K4me1 (Upstate 07-436), 1:2000 anti-H3 K4me2 (Upstate 07-030), 1:5000 anti-H3 K4me3 (Upstate 07-473), 1:500 anti-Gcn5 (Santa Cruz sc-9078), 1:5000 anti-Tubulin (Abcam ab6160), 1:1000 Anti-HA (Roche clone 3F10 11867423001) in 5% dry milk/PBS/0.5% Tween 20. Membranes were then washed for 6×5 min in PBS and incubated for 1 hour with horseradish peroxidase conjugated secondary antibody in 5% dry milk/PBS/0.5% Tween 20, and washed for 6×5 min in PBS/0.5% Tween 20. Bound antibody was visualised using a Pico West chemiluminescence kit (Pierce Biotechnology Ltd) according to manufacturer's instructions. Multiple exposures of each film were made to ensure signals detected were not saturated. Each experiment was repeated at least 3 times.

## RNA Extraction and Northern Blotting.

Extraction of RNA was performed using hot phenol extraction. 15 μg of total RNA was separated on 1.1% formaldehyde gels and transferred to Magna nylon membranes and baked at 80° C. for 2 hours. The membranes were blocked by incubation for 2 hours at 65° C. with PerfectHyb Plus (Sigma). Membranes were typically exposed for 24 hours unless otherwise stated. Levels of total RNA loaded was monitored by the rRNA species, which are equal across samples unless indicated.

## Isolation of Yeast at 10 or 20 Generations of Growth.

1×10<sup>8</sup> cells from a culture at OD<sub>600</sub> of 0.2 were washed in PBS, biotinylated with 3 mg of sulfo-NSH-LC-biotin at room temperature for 15 minutes, washed 6 times with PBS and added to 1 liter of pre-warmed YPD containing 2.5% glucose and incubated for 10 generations. Harvested cells were washed in PBS. 400 ul of streptavidin beads were added and incubated with the cells on ice for 2 hours in PBS. A magnetic sorter was used to select beads with biotinylated cells attached for 20 minutes on ice with occasional mixing. The mixture was washed and reselected five times using PBS. The sorted cells were added to a second liter of prewarmed YPD and grown for an additional 10 generations, sorted and washed exactly as before. Protein or DNA was isolated from the yeast using urea and glass beads (see above) for analysis by Western blotting or by preparing sphaeroplasts and extracting total DNA by phenol chloroform extraction exactly as described<sup>51</sup>. The total DNA extract was separated on a 0.8% agarose gel. DNA was visualized by hybridization to radiolabelled probes.

## Labelling Yeast with 35S Methionine.

Exponential cultures in synthetic complete medium with glucose were treated with or without cycloheximide (250 μg/ml in 10 ml of culture), and the incubation was continued for 5 min prior to the 15-min incubation with 100 μCi of

## 11

[<sup>35</sup>S]methionine (PerkinElmer Life Sciences). Total protein was separated on a 10 or 15% SDS-PAGE gel. The gel was then treated with Enlightening (PerkinElmer Life Sciences), dried, and exposed to x-ray film for 40-72 h.

## Microscopy.

Cells in exponential growth or after 2.5 days in culture (stationary phase) were incubated with the membrane-potential-sensitive dye 3,3'-dihexyloxacarboxyanine iodide (DiOC6) obtained from Molecular Probes at a concentration of 20 ng/ml for 30 minutes, washed in PBS and visualised using exposure of 1000 ms (exponential cells) or 250 ms (stationary phase cells) the FITC channel on an Olympus IX-81 fluorescence microscope with a 150 W xenon-mercury lamp and an Olympus 150X Plan NeoFluor oil-immersion objective. Brightfield images (DIC) were captures for each field.

## Optimizing Conditions for Treating Cells with Rapamycin

Cells in exponential phase of growth were treated with 10  $\mu$ M rapamycin in 90% ethanol/10% Tween 20 for up to 180 minutes and levels of H3K14ac and histone H3 examined. Alternatively, cells were treated with up to 20  $\mu$ M rapamycin for 30 minutes. A standard set of conditions were determined and for all work in this paper involved treatment of exponentially growing cells ( $0.4 \times 10^7$  cell/ml) for 2 to 3 hours with 10  $\mu$ M rapamycin.

Assay Showing the Dependency of Post-translational Modifications to histone H3 on the Integrity of Factors Known to Influence Modifications on Histone H3.

Total cell extracts were prepared from LPY8056 cells expressing histone H3 with alanine (A) substitutions at S10 or K14 or both residues, BY4741 carrying deletions of SPP1, encoding a factor required specifically for H3K4me3<sup>52</sup> or DOT1, the methyltransferase for H3K79<sup>53,54</sup>, or YZS276 carrying a substitution at H2BK123<sup>55</sup>, required for H3K4me2 and H3K4me3. The modifications of lysines on histone H3 were monitored by Western blotting of total cell protein extracts using antibodies specific for each modification.

HA-Spt7 Undergoes C-terminal Processing in Cells Entering Stationary Phase or Treated with Rapamycin.

Strain FY2030, expressing an N-terminally tagged version of Spt7 from the SPT7 locus and FY3, an untagged control were used for these experiments (n=9 for a). Cells were grown in YDP to mid-log phase, post-diauxic phase or early stationary phase and total protein extracts prepared, subject to western blot using the 3F10 monoclonal antibody to reveal the HA epitope. Positions of the molecular weight markers are shown and a blot developed to reveal histone H3 levels to act as a loading control. Three high molecular weight form of HA-Spt are present, consistent with full length Spt7 in SAGA, a C-terminally truncated form missing approx 200aa found in SLIK and form 3 who function is not known<sup>27,25</sup>. In addition a form that migrates at 50 kDa is also evident in these and other preparations when levels of full length Spt7 drop. b A repeat of the experiment shown above showing more extensive C-terminally truncated version of Spt7 in all three growth conditions. About three of nine experiments show a profile such as this while six show more discrete bands as in a.

## Indirect Immunofluorescence

The acetylation/methylation status of a cell was assessed using indirect immunofluorescence according to the following protocol. 10-50 ml of a fresh mid-log culture of cells per sample was used. Make fresh 30% formaldehyde (3g p-formaldehyde in 5 ml PEM, add 4M NaOH until dissolved and make up to 10 ml with PEM) and add  $\frac{1}{10}$ <sup>th</sup> volume of 30% formaldehyde to the culture with agitation (in conical flask). 30s later add glutaraldehyde solution to a final concentration

## 12

of 0.2% (w/v). Shake at incubation temp for 90 min. Spin cells 2K 5 min then wash 3 $\times$  in PBS or PEM (100 mM Pipes pH 6.9; 1 mM EGTA, 1 mM Mg2SO4). Resuspend cells in 10 ml of PEMS (PEM in 1M Sorbitol) and add 500  $\mu$ l of ICN Yeast Lytic Enzyme (10  $\mu$ g/ml). Incubate at 37 $^{\circ}$  C. until ~80% of cells are digested (about 15 min). Wash 3 $\times$  in 10 ml of PEMS. Resuspend in 10 ml of 1% Triton X100 in PEM for 30s. Wash 3 $\times$  in 10 ml PEM. Roughly assess the volume of the final pellet. Resuspend in 2 ml of PEMBAL (PEM, 0.1M L-lysine, 1% BSA (globulin free), 0.1% Na Azide) and transfer a volume which will give a 20-30  $\mu$ l pellet upon a subsequent spin to each of 2 Eppendorf tubes. Put on a rotating wheel for 30 min at room temp. Spin for 10 sec. Resuspend in 50  $\mu$ l of primary antibody in PEMBAL (test suitable dilution) and incubate for 16 hours on rotating wheel. Wash 3 $\times$  in 1 ml PEMBAL. Resuspend in 1 ml of PEMBAL and rotate on a wheel for 30 min. Resuspend in 50  $\mu$ l of Goat anti-mouse Texas Red at 20 mg/ml in PEMBAL. Incubate 16 hours on rotating wheel. Wash 3 $\times$  in PEMBAL. Resuspend pellet in 100  $\mu$ l PEMBAL and mount on poly L-Lysine coated coverslips. Dry with hairdryer and invert on 1  $\mu$ g/ml DAPI in 100% glycerol if required. Alternatively use a FITC secondary antibody at 1/200 and incubate for 1 hour at room temperature on a wheel. N.B. cover tubes with foil during incubations with secondary antibody. The cells were then visualised

## EXAMPLES

## H3K14ac by SAGA Reflects Growth

The type of post-translational modification on the histone components of chromatin often reflects whether genes are active or repressed and these changes are globally regulated by enzymes that deposit or remove specific modifications. On active genes, the chromatin is often modified by lysine (K) acetylation (ac) or methylation (me), particularly on histone H3<sup>27</sup>. In order to identify post-translational modifications on histone H3 that reflect cell growth, we prepared total protein extracts from yeast in exponential or early stationary phase. Large and reproducible differences in the signals on Western blots allow us to correlate changes in acetylation and methylation with cell physiology. Cells in stationary phase show reductions in K14ac, K18ac and trimethylation (me3) of K4 that are not a consequence of cell-cycle arrest (FIG. 5). These changes are similar in exponentially growing cells treated with the macrolide rapamycin, which blocks growth and proliferation<sup>14</sup> (FIGS. 1a and 10-11), suggesting that the presence of these modifications reflects the proliferative capacity of the cells.

Gcn5 is the major acetyltransferase for K14 and K18 (FIG. 1b). Furthermore, the rapamycin-sensitive K14ac detectable by Western blotting is mediated by Gcn5 in SAGA (FIG. 1c). Strains lacking Spt8, specific to SAGA<sup>22</sup> or Spt20, required for the integrity of SAGA and SLIK/SALSA<sup>23,31,32</sup>, have low levels of K14ac that do not detectably change when treated with rapamycin. In contrast, K14ac is resistant to rapamycin in a strain lacking Ubp8, a component of SAGA with ubiquitin protease activity required for processing the C-terminal region of Spt7<sup>23,25</sup> (FIG. 1b). Western blots showing levels of modifications at H3 on total cell extracts prepared from the strains indicated all in the BY4741 background are shown in FIGS. 1c-e. Cells were treated +/-10  $\mu$ M rapamycin for up to 3 hours. A strain expressing Spt7 lacking the C-terminal 213aa, known as Spt7-217<sup>33</sup> also shows rapamycin resistant K14ac, suggesting that SLIK and SALSA are resistant to rapamycin (FIG. 1e). It is important to note that in this strain, the truncated Spt7 is expressed at levels similar to full length Spt7<sup>33</sup>, hence the high levels of K14ac. Levels of truncated

Spt7 in SLIK and SALSA are normally much lower than full length Spt7 and make a minimal contribution to global levels of K14ac<sup>22,23,25</sup>. Moreover, this resistance to rapamycin is consistent with roles in the activated, but not basal, expression of TATA box genes<sup>34</sup> that function to promote growth when glucose is depleted<sup>18,21</sup> (FIG. 6). Furthermore, this implicates the C-terminal 213aa of Spt7 in the rapamycin sensitivity of K14ac by SAGA as Spt8, a SAGA specific subunit, is recruited through this region<sup>22,23</sup>. Thus rapamycin may have differential effects on SAGA and SLIK/SALSA. SAGA is active in glucose grown cells while SLIK and SALSA are active in nutrient limited cells when TORC1 signalling is reduced (FIG. 6).

The FY168 WT strain has been engineered to express only Spt7 containing a C-terminal truncation (FY571 Spt7-217) similar to that found naturally in the SLIK/SALSA complex. The Spt7 protein is expressed at similar level to full length Spt7<sup>10</sup>. we investigated levels of K14ac in this strain and the influence of Rtg2, the retrograde regulator and component of SLIK on the activity of this strain. FIG. 6a to shows that the K14ac is not significantly reduced in this strain when a deletion of RTG2 is introduced. Rtg2 is required for the H3 directed HAT activity of the SLIK complex<sup>11</sup>. This may reflect the naturally low levels of SLIK in cells compared to this complex. In addition we tested transcriptional responses (using reverse transcription coupled to real time PCR using primers to the loci indicated; No indicates reaction with no RTase added to reaction to control for DNA contamination) in this strain in exponential growth (log) and in early stationary phase (Stat or SP). Levels of transcript were normalised to U4snRNA. Levels of this transcript drop by half in stationary phase cells (data not shown). b Levels of rDNA transcription, monitored using a primer set to the intergenic region between the 25S and 18S regions, are reduced over 7 fold in stationary phase. c The retrograde responsive gene CIT2<sup>12</sup> is induced in the stationary phase cells and is dependent on Rtg2 in the WT Spt7(FY168) and Spt7-217 (FY571) backgrounds, as expected. d Induction of ACS1, encoding mitochondrial acetyl CoA synthase is induced in stationary phase and is Rtg2-dependent. In cells containing high levels of the SLIK/SALSA complex the gene is not induced. SLIK/SALSA may repress ACS1 expression or alternatively, the high levels of SLIK/SALSA may sequester Rtg2 creating an RTG2 null. e The induction of ATG1, a regulator of the autophagy<sup>13</sup>, another starvation induced response, shows no dependence on Rtg2. Instead, the strains expressing Spt7-217 show a more than two fold increase in ATG1 mRNA levels under starvation conditions suggesting a role for the SALSA complex. The patterns of expression of these three genes may define how the SLIK/SALSA complexes contribute to gene regulation. We propose that ATG1 is dependent on SALSA and independent of SLIK and Rtg2. By contrast, CIT2 requires the SLIK complex for its activation while ACS1 is dependent on Rtg2 but not SLIK (The Rtg2 function to regulate nuclear uptake of Rtg1/3 as activators). Expression at a number of other loci is also monitored (f-i) in log phase. Modifications of lysines on histone H3 are monitored by Western blotting of total protein extracts using antibodies specific to the modification or protein indicated. n=2 for each experiment. Total protein and RNA were prepared from the same cultures for the experiment shown.

We used an N-terminally HA tagged version of Spt7 to examine its levels and integrity in rapamycin treated (FIG. 1f) or stationary phase cells (FIG. 7). Reduced levels and C-terminal truncation of Spt7 occurs in both conditions and, by compromising the integrity of SAGA<sup>23</sup>, explains the reduced K14ac. Thus the integrity of SAGA is controlled by C-termi-

nal truncation of Spt7 that occurs when cells enter stationary phase or on rapamycin treatment. Levels of Gcn5, but not its RNA<sup>18</sup>, also drop significantly in rapamycin treated WT cells (FIG. 1g). in contrast, Gcn5 levels are higher in rapamycin-treated cells expressing Spt7-217 (FIG. 1h). Thus the reduction in Gcn5 is likely to be a consequence of the C-terminal truncation and reduction in levels of Spt7.

#### SAGA Decreases with Age in Growing Cells

The data suggests that SAGA activity is a marker of growth and proliferation. As cells age both proliferative capacity and mitochondrial function are reduced. Experiments were undertaken to assess if SAGA changes during ageing by assessing levels in young cells (generally <5 generations old) compared to cells after 10 or 20 generations of growth. As cells age, levels of K14ac drop (FIG. 2a) and this is associated with an overall decrease in HA-Spt7 levels, in particular a drop in full length HA-Spt7 and increased truncated forms of HA-Spt7 supporting loss of SAGA function during ageing (FIG. 2b). By contrast, in the strain expressing only C-terminally truncated Spt7 (Spt7-217) K14ac does not drop in old cells (FIG. 2c). Total protein preparations were made from young cells or biotinylated cells after 20 generations of growth in exponential phase in rich medium, isolated using streptavidin magnetic beads. Western blot of levels of K14ac in total protein extracts prepared from FY168 (WT) and FY571 expressing Spt7-217. Levels of histone H3 were assessed to control for loading. It can be seen from FIG. 8 that there are differences in the amount of protein isolated. Levels of K14ac drop in the old WT strain but not in the strain expressing Spt7-217 suggesting that the C-terminal region of Spt7 is required for the reduction in K14ac and that SAGA is the target of this regulation. Note in this preparation there is less histone "clipping" evident than in other experiments (See FIG. 2a). These cells also contain increased levels of a smaller form of histone H3, possibly clipped<sup>36</sup>. This suggests that the mechanism by which SAGA and K14ac are reduced as cells age is similar to that occurring in rapamycin treated cells and involves processing of the C-terminal region of Spt7.

#### TORC1 F Maintains K14ac in Growing Cells

We sought to define how rapamycin influences acetylation by SAGA. There are four targets of rapamycin in yeast, Fpr1-4<sup>37</sup>. In the presence of rapamycin, Fpr1 inhibits functions associated with the PI3-related kinases Tor1 or Tor2 within the TORC1 complex<sup>38</sup>. This supports TORC1-dependent signalling controlling the global levels of K14ac, K18ac and K4me3 by maintaining SAGA function in proliferating cells. inhibition of TORC1 by rapamycin during the early stages of growth results in upregulation of SLIK/SALSA regulated genes that promote efficient respiration of glucose and stress resistance (FIG. 9)<sup>20,39</sup>. As can be seen in FIG. 9b, levels of CIT2 expression, regulated by the TORC-1 complex are increased upon addition of rapamycin.

AMPK is generally considered to negatively regulate mammalian mTOR, resulting in down regulation of TORC1 signalling when glucose becomes scarce and intracellular levels of AMP increase<sup>63</sup>. The yeast AMPK Snf1 as can be seen from FIG. 10 may function in a similar way as it is required for the rapamycin-dependent reduction in K14ac (a). Levels of K14ac in a snf1Δ strain are reduced to about 50% of those in a WT strain, due to Snf1 directed phosphorylation of serine 10 on histone H3 that promotes K14 acetylation by Gcn5<sup>64</sup>. Importantly, K14ac (a) and Gcn5 (b) and some of the HA-Spt7 in the cell (c) are resistant to rapamycin in the snf1Δ strain. Note that track five\* is under loaded in c. Note that the integrity of S10 on histone H3, phosphorylated by Snf1, does not influence the rapamycin sensitivity of K14ac although as with the snf1Δ, level of K14ac is reduced in this background

(d). We asked is Snf1 is functioning in the nucleus or cytoplasm. Gal83 is required for the nuclear uptake of Snf1<sup>65</sup> and HA tagged-Gal83 moves from the cytoplasm to the nucleus in rapamycin treated cells as demonstrated by indirect immunofluorescence in fixed cells (e). However, the relationship between Gal83 and Snf1 is not straightforward as gal83Δ strains show WT levels of K14ac in untreated cells and some resistance to rapamycin (f). Similar results are observed for Gcn5 protein in the gal83Δ strain (g). Thus it appears that Gal83 is required for the rapamycin dependent reduction in K14ac and Gcn5 suggesting that this is a nuclear function for Snf1.

#### SLIK Controls CLS Through Rtg2

We examined mitochondrial membrane potential ( $\psi$ ) and CLS in the strain expressing only truncated Spt7 (Spt7-217), and thus expressing high levels of SLIK/SALSA complexes during exponential growth. Both  $\psi$  (FIG. 4a) and average CLS (FIG. 4b) are increased compared to WT but the strain then appears to undergo a rapid and complete loss of viability around day 12 in culture that may reflect imbalances in patterns of gene expression. Rtg2 is repressed by the TORC1 complex<sup>26</sup> and has at least two distinct functions, one as a regulator of retrograde response, and a second as a component of SLIK<sup>13</sup>. The high levels of truncated Spt7 might result in sequestration of Rtg2 into a SLIK complex, resulting in an rtg2 null for other functions. In support of this, an rtg2 strain shows increase  $\psi$  in exponential phase (FIG. 4a), increased mitochondrial protein synthesis (FIG. 4c) and enhanced CLS (FIG. 4b). This suggests that Rtg2 functions to repress mitochondrial function when TORC1 is active and that the formation of SLIK is linked to reduced TORC1 signalling, leading to truncation of Spt7 and relief of Rtg2-dependent repression of respiration. This provides an additional way to extend CLS. Interestingly, both Spt7 and Rtg2 are reported to be mitochondrially associated proteins<sup>13,47</sup>. Finally, we show that the most marked increase in CLS is observed when RTG2 is knocked out of FY571(Spt7-217) (FIG. 4b), perhaps reflecting strong induction of genes for autophagy, known to prolong lifespan, by SALSA, as this is Rtg2 independent. It should be noted that this rtgΔ phenotype can also be produced by the addition of inhibitors of mitochondrial respiration.

In summary, we show that the SAGA family of transcriptional regulators control the balance between growth and chronological lifespan. Metabolic changes resulting in up- or down-regulation of respiration are differentially controlled by TORC1 and Sch9 signalling to these complexes. TORC1 coordinates mitochondrial function with gene expression through the activities of Spt7 and Rtg2 and the chromatin modification at K14 on histone H3, providing a TORC1 signalling to SAGA and SLIK highly efficient mechanism by which cells switch fate in order to control the balance between growth and longevity.

#### Disruption of SAGA Results in Increased H3K18 Acetylation and an Extension in Chronological Lifespan.

FIG. 13 is a western blot showing the increase in H3K18 acetylation in strains in which the SAGA complex has been disrupted. As can be seen in the top rows of both panels, the amount of H3K18ac present in whole cell yeast extracts in stains in which the SAGA complex has been disrupted are increased compared to wildtype. The strains used in these experiments were either ΔSPT8 or Spt7 truncated.

FIG. 14 shows that *S. cerevisiae* strains having a disrupted SAGA complex have an increased chronological lifespan. As show in the figure strains FY631 and FY2030 are wild type, strain FY571 expresses a truncated Spt7 protein which lacks the SAGA specific Spt7 region, strain FY2037 is ΔSPT8 (Wu, P.Y. and Winston, F., Mol Cell Biol., 22(15), p5367-5379).

Lifespan was determined as described in Murakami, C. and Kaerberlein, M., (2009) J. Vis. Exp., 27. Briefly, chronological lifespan of yeast refers to the profile of viability of an ageing yeast culture over time. A yeast culture is grown in liquid media until the glucose carbon source is exhausted and the cells stop dividing. At this point the proportion of cells which are alive and able to divide is measured by observing the outgrowth characteristics of a fresh inoculate of the aging culture using a Bioscreen C machine. Viabilities at various time points are compared to determine the chronological lifespan of the culture.

FIG. 15 shows that in a H3K18Q mutant in which acetylation at this position is disrupted chronological lifespan, as measured using the method above, is reduced compared to wild type. In the H3K18Q yeast strain, both endogenous copies of the H3 gene have been deleted and replaced by a single copy of the H3 gene containing a substitution of lysine 18 with glutamine. In the wild type strain shown in the figure, the deleted H3 genes have been replaced with a single wild type copy of the gene.

All publications mentioned in the above specification are herein incorporated by reference in their entirety. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be with in the scope of the following claims.

#### References

- De Virgilio, C. & Loewith, R., Cell growth control: little eukaryotes make big contributions. *Oncogene* 25, 6392-6415 (2006).
- Martin, D. E. & Hall, M. N., The expanding TOR signaling network. *Curr Opin Cell Biol* 17, 158-166 (2005).
- Rohde, J. R., Bastidas, R., Puria, R. & Cardenas, M. E., Nutritional control via Tor signaling in *Saccharomyces cerevisiae*. *Curr Opin Microbiol* 11, 153-160 (2008).
- Ljungdahl, P. O., Amino-acid-induced signalling via the SPS-sensing pathway in yeast. *Biochem Soc Trans* 37, 242-247 (2009).
- Wullschlegel, S., Loewith, R. & Hall, M. N., TOR signaling in growth and metabolism. *Cell* 124, 471-484 (2006).
- Bonawitz, N. D., Chatenay-Lapointe, M., Pan, Y. & Shadel, G. S., Reduced TOR signaling extends chronological life span via increased respiration and upregulation of mitochondrial gene expression. *Cell metabolism* 5, 265-277 (2007).
- Fabrizio, P., Pozza, F., Pletcher, S. D., Gendron, C. M. & Longo, V. D., Regulation of Longevity and Stress Resistance by Sch9 in Yeast. *Science* 292, 288-290 (2001).
- Powers, R. W., 3rd, Kaerberlein, M., Caldwell, S. D., Kennedy, B. K. & Fields, S., Extension of chronological life span in yeast by decreased TOR pathway signaling. *Genes Dev* 20, 174-184 (2006).
- Kaerberlein, M. et al., Increased life span due to calorie restriction in respiratory-deficient yeast. *PLoS Genet* 1, e69 (2005).
- Lavoie, H. & Whiteway, M., Increased respiration in the sch9Delta mutant is required for increasing chronological life span but not replicative life span. *Eukaryot Cell* 7, 1127-1135 (2008).

- 11 Medvedik, O., Lamming, D. W., Kim, K. D. & Sinclair, D. A., MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in *Saccharomyces cerevisiae*. *PLoS Biol* 5, e261 (2007).
- 12 Kim, D. H. et al., mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* 110, 163-175 (2002).
- 13 Liu, Z. & Butow, R. A., Mitochondrial retrograde signaling. *Annu Rev Genet* 40, 159-185 (2006).
- 14 Kunz, J. & Hall, M. N., Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. *Trends Biochem Sci* 18, 334-338 (1993).
- 15 Heitman, J., Movva, N. R. & Hall, M. N., Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. *Science* 253, 905-909 (1991).
- 16 Peterson, R. T., Beal, P. A., Comb, M. J. & Schreiber, S. L., FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. *J Biol Chem* 275, 7416-7423 (2000).
- 17 Cheng, C., Fabrizio, P., Ge, H., Longo, V. D. & Li, L. M., Inference of transcription modification in long-live yeast strains from their expression profiles. *BMC Genomics* 8, 219 (2007).
- 18 Smets, B. et al., Genome-wide expression analysis reveals TORC1-dependent and -independent functions of Sch9. *FEMS Yeast Res* 8, 1276-1288 (2008).
- 19 Baker, S. P. & Grant, P. A., The SAGA continues: expanding the cellular role of a transcriptional co-activator complex. *Oncogene* 26, 5329-5340 (2007).
- 20 Biddick, R. K., Law, G. L., Chin, K. K. & Young, E. T., The transcriptional coactivators SAGA, SWI/SNF, and mediator make distinct contributions to activation of glucose-repressed genes. *J Biol Chem* 283, 33101-33109 (2008).
- 21 Pray-Grant, M. G. et al., The novel SLIK histone acetyltransferase complex functions in the yeast retrograde response pathway. *Mol Cell Biol* 22, 8774-8786 (2002).
- 22 Sterner, D. E., Belotserkovskaya, R. & Berger, S. L., SALSIA, a variant of yeast SAGA, contains truncated Spt7, which correlates with activated transcription. *Proc Natl Acad Sci USA* 99, 11622-11627 (2002).
- 23 Wu, P. Y. & Winston, F., Analysis of Spt7 function in the *Saccharomyces cerevisiae* SAGA coactivator complex. *Mol Cell Biol* 22, 5367-5379 (2002).
- 24 Belotserkovskaya, R. et al., Inhibition of TATA-binding protein function by SAGA subunits Spt3 and Spt8 at Gcn4-activated promoters. *Mol Cell Biol* 20, 634-647 (2000).
- 25 Hoke, S. M., Liang, G., Mutiu, A. I., Genereaux, J. & Brandi, C. J., C-terminal processing of yeast Spt7 occurs in the absence of functional SAGA complex. *BMC Biochem* 8, 16 (2007).
- 26 Giannattasio, S., Liu, Z., Thornton, J. & Butow, R. A., Retrograde response to mitochondrial dysfunction is separable from TOR1/2 regulation of retrograde gene expression. *J Biol Chem* 280, 42528-42535 (2005).
- 27 Berger, S. L., The complex language of chromatin regulation during transcription. *Nature* 447, 407-412 (2007).
- 28 Nakanishi, S. et al., A comprehensive library of histone mutants identifies nucleosomal residues required for H3K4 methylation. *Nat Struct Mol Biol* 15, 881-888 (2008).
- 29 Martin, D. G., Grimes, D. E., Baetz, K. & Howe, L., Methylation of histone H3 mediates the association of the NuA3 histone acetyltransferase with chromatin. *Mol Cell Biol* 26, 3018-3028 (2006).

- 30 Taverna, S. D. et al., Yng1 PHD finger binding to H3 trimethylated at K4 promotes NuA3 HAT activity at K14 of H3 and transcription at a subset of targeted ORFs. *Mol Cell* 24, 785-796 (2006).
- 31 Grant, P. A. et al., Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex. *Genes Dev* 11, 1640-1650 (1997).
- 32 Sterner, D. E. et al., Functional organization of the yeast SAGA complex: distinct components involved in structural integrity, nucleosome acetylation, and TATA-binding protein interaction. *Mol Cell Biol* 19, 86-98 (1999).
- 33 Gansheroff, L. J., Dollard, C., Tan, P. & Winston, F., The *Saccharomyces cerevisiae* SPT7 gene encodes a very acidic protein important for transcription in vivo. *Genetics* 139, 523-536 (1995).
- 34 Huising a, K. L. & Pugh, B. F., A genome-wide house-keeping role for TFIID and a highly regulated stress-related role for SAGA in *Saccharomyces cerevisiae*. *Mol Cell* 13, 573-585 (2004).
- 35 Santos-Rosa, H. et al., Histone H3 tail clipping regulates gene expression. *Nat Struct Mol Biol* 16, 17-22 (2009).
- 36 Dolinski, K., Muir, S., Cardenas, M. & Heitman, J., All cyclophilins and FK506 binding proteins are, individually and collectively, dispensable for viability in *Saccharomyces cerevisiae*. *Proc Natl Acad Sci USA* 94, 13093-13098 (1997).
- 37 Lorenz, M. C. & Heitman, J., TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. *J Biol Chem* 270, 27531-27537 (1995).
- 38 Yorimitsu, T., Zaman, S., Broach, J. R. & Klionsky, D. J., Protein kinase A and Sch9 cooperatively regulate induction of autophagy in *Saccharomyces cerevisiae*. *Mol Biol Cell* 18, 4180-4189 (2007).
- 39 Urban, J. et al., Sch9 is a major target of TORC1 in *Saccharomyces cerevisiae*. *Mol Cell* 26, 663-674 (2007).
- 40 Wei, M. et al., Tor1/Sch9-regulated carbon source substitution is as effective as calorie restriction in life span extension. *PLoS Genet* 5, e1000467 (2009).
- 41 Kaerberlein, M. et al., Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. *Science* 310, 1193-1196 (2005).
- 42 Smith, D. L., Jr., McClure, J. M., Matecic, M. & Smith, J. S., Calorie restriction extends the chronological lifespan of *Saccharomyces cerevisiae* independently of the Sirtuins. *Aging cell* 6, 649-662 (2007).
- 43 Bonawitz, N. D., Rodeheffer, M. S. & Shadel, G. S., Defective mitochondrial gene expression results in reactive oxygen species-mediated inhibition of respiration and reduction of yeast life span. *Mol Cell Biol* 26, 4818-4829 (2006).
- 44 Burtner, C. R., Murakami, C. J., Kennedy, B. K. & Kaerberlein, M., A molecular mechanism of chronological aging in yeast. *Cell Cycle* 8, 1256-1270 (2009).
- 45 Shamji, A. F., Kuruvilla, F. G. & Schreiber, S. L., Partitioning the transcriptional program induced by rapamycin among the effectors of the Tor proteins. *Curr Biol* 10, 1574-1581 (2000).
- 46 Roosen, J. et al., PKA and Sch9 control a molecular switch important for the proper adaptation to nutrient availability. *Mol Microbiol* 55, 862-880 (2005).
- 47 Sickmann, A. et al., The proteome of *Saccharomyces cerevisiae* mitochondria. *Proc Natl Acad Sci USA* 100, 13207-13212 (2003).
- 48 Vellai, T., Autophagy genes and ageing. *Cell Death Differ* 16, 94-102 (2009).



- 49 Nagy, Z. & Tora, L., Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. *Oncogene* 26, 5341-5357 (2007).
- 50 Rodgers, J. T., Lerin, C., Gerhart-Hines, Z. & Puigserver, P., Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. *FEBS Lett* 582, 46-53 (2008).
- 51 Kent, N. A. & Mellor, J., Chromatin structure snap-shots: rapid nuclease digestion of chromatin in yeast. *Nucleic Acids Res* 23, 3786-3787 (1995).
- 52 Morillon, A., Karabetsou, N., Nair, A. & Mellor, J., Dynamic lysine methylation on histone H3 defines the regulatory phase of gene transcription. *Mol Cell* 18, 723-734 (2005).
- 53 Ng, H. H. et al., Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. *Genes Dev* 16, 1518-1527 (2002).
- 54 van Leeuwen, F., Gafken, P. R. & Gottschling, D. E., Dot1p modulates silencing in yeast by methylation of the nucleosome core. *Cell* 104, 745-756 (2002).
- 55 Lee, J. S. et al., H1stone crosstalk between H2B monoubiquitination and H3 methylation mediated by COMPASS. *Cell* 131, 1084-1096 (2007).
- 56 Saleh, A. et al., TOM1p, a yeast hec domain protein which mediates transcriptional regulation through the ADA/SAGA coactivator complexes. *J Mol Biol* 282, 933-946 (1998).
- 57 Duncan, K., Umen, J. G. & Guthrie, C., A putative ubiquitin ligase required for efficient mRNA export differentially affects hnRNP transport. *Curr Biol* 10, 687-696 (2000).
- 58 Pray-Grant, M. G. et al., The novel SLIK histone acetyltransferase complex functions in the yeast retrograde response pathway. *Mol Cell Biol* 22, 8774-8786 (2002).

- 59 Scott, R. C., Juhasz, G. & Neufeld, T. P., Direct induction of autophagy by Atg1 inhibits cell growth and induces apoptotic cell death. *Curr Biol* 17, 1-11 (2007).
- 60 Reinders, A., Burckert, N., Boller, T., Wiemken, A. & De Virgilio, C., *Saccharomyces cerevisiae* cAMP-dependent protein kinase controls entry into stationary phase through the Rim15p protein kinase. *Genes Dev* 12, 2943-2955 (1998).
- 61 Fabrizio, P., Pletcher, S. D., Minois, N., Vaupel, J. W. & Longo, V. D., Chronological aging-independent replicative life span regulation by Msn2/Msn4 and Sod2 in *Saccharomyces cerevisiae*. *FEBS Lett* 557, 136-142 (2004).
- 62 Pedruzzi, I. et al., TOR and PKA signaling pathways converge on the protein kinase Rim15 to control entry into G0. *Mol Cell* 12, 1607-1613 (2003).
- 63 Hardie, D. G., AMPK and Raptor: matching cell growth to energy supply. *Mol Cell* 30, 263-265 (2008).
- 64 Lo, W.-S. et al., Snf1—a Histone Kinase That Works in Concert with the Histone Acetyltransferase Gcn5 to Regulate Transcription. *Science* 293, 1142-1146 (2001).
- 65 Vincent, O., Townley, R., Kuchin, S. & Carlson, M., Subcellular localization of the Snf1 kinase is regulated by specific beta subunits and a novel glucose signaling mechanism. *Genes Dev* 15, 1104-1114 (2001).
- 66 Giannattasio, S., Liu, Z., Thornton, J. & Butow, R. A., Retrograde response to mitochondrial dysfunction is separable from TOR1/2 regulation of retrograde gene expression. *J Biol Chem* 280, 42528-42535 (2005).
- 67 Butow, R. A. & Avadhani, N. G., Mitochondrial signaling: the retrograde response. *Mol Cell* 14, 1-15 (2004).
- 68 Howitz, G. A. et al., Adenovirus Small e1a Alters Global Patterns of Historic Modification. *Science*, 321, 5892, 1034-1085 (2008).

## Sequence Listing

sch9

SEQ ID No: 1

```

1  MMNFFTSKSS  NQDTGFSSQH  QHPNGQNNGN  NNSSTAGNDN  GYPCKLVSSG  PCASSNNGAL
61  FTNFTLQAT  PTTAISQDLY  AMGTTGITSE  NALFQMKSMN  NGLSSVNNNN  SNTPTIIITS
121  QEETNAGNVH  GDTGGNSLQN  SEDDNFSSSS  TTKLLSSTS  SLSINQREAA  AAAYGPDTDI
181  PRGKLEVTII  EARDLVTRSK  DSQPYVCTF  ESSEFISNGP  ESLGAINNNN  NNNNNNQHNQ
241  NQHINNNNEN  TNPDAASQHH  NNSGWNWSQ  LPSIKEHLKK  KPLYTHRSS  QLDQLNSCSS
301  VTDPSKRSSN  SSSGSSNGPK  NDSSHPIWHH  KTFDFVLGSH  SELDISVYDA  AHDHMFGLQV
361  RLYPMIHNLA  HASQHQWHS  KPRVIDEVVS  GDILIKWYTK  QTKKRHYGPQ  DFEVLRLLGK
421  GTFGQVYQVK  KKDTORIYAM  KVLSSKVIK  KNEIAHTIGE  RNILVTTASK  SSPFIVGLKF
481  SPQTPDLYL  VTDYMSGGEL  FWHLQKEGRF  SEDRAKFYIA  ELVLALEHLH  DNDIVYRDLK
541  PENILLDANG  NIALCDFGLS  KADLKDRTNT  FCGTTEYLAP  ELLLDETGYT  KMDVFWSLGV
601  LIFEMCCGWS  PFFAENNQMK  YQKIAFGKVK  FPRDVLSEQE  RSVFKGLLNR  NPKHRLGAID
661  DGRELRAHPF  FADIDWEALK  QKKIPPPFKP  HLVSETDSN  FDPFTTAST  SYMNKHQPM
721  TATPLSPAMQ  AKFAGFTFVD  ESAIDHEVNN  NRKFLQNSYF  MEPGSFIPGN  PNLPPDEDVI
781  DDDGDEDIND  GFNQEKNNMN  SHSQMDFDGD  QHMDFEVS  RFEI

```

Sch9

&gt;YHR205W Chr 8

SEQ ID No: 2

```

Atgatgaattttttacatcaaaatcgtcgaatcaggatactggatttagctctcaacaccaacatccaatggac
agaacaatggaacaat aatagcagcgcgctggcaacgacaacggat acccatgtaactgttgctccagtgggcc
ctgcgcttcatcaataatgggtgcctttttacgaattttactttacaactgcaacgccgaccacccgctattagt
caggacttatatgcaatgggcacacaggaataacatcagaaaatgccccttttcaaatgaaagcaatgaaatg
gaatatcatcagtttaataaacaacagcaacacccctacgattattaccacgtcacaggaagaactaatgctgg
aaatgtacatggcgataccgggtggcaattctttgcaaaattctgaagatgacaacttttctccagttctaccac
caaatgcttactctctcactctctcgtatcaataaatcaacagagaagcagcagcagctgcttattggtccagat
accgatattctaggggtaactagaagttacaataatagaagcagctgacctagctcactagatcaaaaggattcac
agccttatgttgtttgtacttttgagagttcagagttcatttctaatggctcctgagtcactagggcgcattataa
taacaacaataaacaacaataatcagcataatcaaaaccagcatattacaacaacaacgaaaaatccaaccct
gagcgtgtagccagcatcaataaacaagtggttggaaacgggtctcagttaccatcgatcaaaagcacttga
agaaaaaccctttatcacacagatcatctccaattagatcagctaaactctgctcttcagtaaccgatcc
gagcaaacgttcttcaattctcgtcggttctcaaatgggtccaaagaatgatagttccatccaatagggat
cacaagacaacgtttgatgttttgggatctcactcggaattagatatttctgtttatgatgctgccaccgacata
tgttcttaggccaagttgactgtatccaatgatcataatttagcacatgcttccaacaccaatggcacagttt

```

-continued

## Sequence Listing

gaaacctcgcgttattgatgaagttgtgctcgggtgatattttaatcaaatggacttcaaacagacaagaagaaaga  
 cattatggccccacaagatttgaagttcttcgatatttgggtaagggtactttggccaagtctaccaagtttaaga  
 agaaagacactcaagaatttatgcaatgaagttctctccaagaaagttattgtcaagaaaaatgagatcgccca  
 cacaattggcgaaagaaatctcctagtcacgacagcgtccaaatcgtccccattcattgtcggattggaagtttcc  
 tttcaaacaccaacagatctgtatttggctactgattatagagtggtggagaattatctggcatttcaaaaagg  
 agggcggcttttcggaagacagagcgaattctatctcgtgagttagcttagcgttagaacatttacacgataa  
 cgatcgtttacagggacctaaagcctgaaaacattctactcagatgccaacggtaacatcgctctttgcgattt  
 ggtctttctaaagctgacttgaaggtagaacaacacattttgctggcaccacggaatccctggcaccagaattgt  
 tactggacgaacccggctacacaaaatggtcgattctcgtctctaggtgttttgatattgaaatgtgtgtgg  
 ttggtccctctctttgcggaataatcaaaaaatgtaccaaaaatggctttggtaaagtcaaatccccaga  
 gacgtactgtcacaagaggggaggtcttttgaagggtttactaaacagaaaccccaaacatagactcgggtgcca  
 ttgatgatggaagagaactacgagctcattctttcgcagatctcagctgggaggcctgaaagcagaaaaaat  
 tccaccacctttcaaacctcacctagctcgggagacggatccctcgaattttgaccagagttcacaacagcttca  
 actcacaacatgaaacagcaccggatgactgctaccccgctatctccagccatgcaagcaaaagtttggctg  
 gttcacctttggtgatgagtcggcctcagatgaacacgttaatacaaacagaaaaatcctacaaaactcgtactt  
 atggaaacctgggttcttctccgggaaatcaaacctacctccagacgaagatgctcagatgatgacggggac  
 gaggacatcaatgatggattcaaccaagagaaaaatagaacaacagccatcgcagatggactcgcagggcgacc  
 aacacatggatgacgaatttctcagtggaagattcgaatatga

Rtg2

SEQ ID No: 3

1 MSTLSDSDTE TEVVSRLNCG IVDIGSNGIR FSISSKAAHH ARIMPCVFKD RVGLSLYEVO  
 61 YNTHTNAKCP IPRDIKEVC SAMKRFLKIC DDFGVPETSV RVIATEATRD AINADEFVNA  
 121 VYGSTGWKVE ILGQDETRV GIYGVVSSFN TVRGLYLDVA GGSTQLSWVI SSHGEVKQSS  
 181 KPVSLLPYGAL LLRRMRD TD NRALFYEIKE AYKDAIEKIG IPQEMIDDAK KEGGFDLWTR  
 241 GGGLRGMGHL LLYQSEGYP I QTIINGYACT YEEFSSMSDY LFLKQKIPGS SKEHKIFKVS  
 301 DRRALQLPAV GLFMSAVFEA IPQIKAVHFS EGGVREGLSY SLLPKAIRAQ DPLLIASRPY  
 361 APLLTEKYL LRLTSIPQED IPEIVNERIA PALCNLAFVH ASYPKELQPT AALHVATRGI  
 421 IAGCHGLSHR ARALIGIALC SRWGGNIPES EEKYSQELEQ VVLRREGDKAE ALRIVVMWTKY  
 481 IGTIMYVICG VHPGGNIRDN VDFHVKRS EVETSLKELI IDDANTTKVK EESTRKNRGY  
 541 EVVVRISKDD LKTSASVRSR IITLQKKVRK LSRGSVERVK IGVQFYEE

Rtg2

&gt;YGL252C Chr 7

SEQ ID No: 4

atgtcaacacttagcagatagtgataccgagactgaggtcgtgctcgagaaacttgtgtggaatcgtcgacataggtt  
 ctaatggattctgttttagtatacttccaaggtgcacatcagcaagaattatgccttgtgttttaagatag  
 ggttggctcttctctatcagaagttcaataatcacatcagcaagcaaaatgccctattccagagatattata  
 aaagaggtttgctcgcctgaagagattcaaatcaatctcgcagatatttgggtactcgaactagtgtcagag  
 taattgcaacagaagccacgcgagatgctattaacgcggatgaaatttgttaatgctgttaccggtagcactggctg  
 gaaagtagaatattaggccaggaagatgaaactagggtcggcatatagggtgtgttctcatttaacagta  
 agaggtctatctagatgtggcaggtggtagtactcagttatcagggtaataagctcgcacggagaagtcagc  
 aatccagcaaacctgtatcttggccatggagctggaactctttgagaagaatgagaacagatgataatagggc  
 actttttatgagattaagaagcgtacaaagatgagattgaaaaaattggatcctcagcaagaatgatgagc  
 gcaagaagaaggtggatttgacctttggaccctgggggtgggttaagaggtatgggacatctgctcttacc  
 agtccgaaggttaccatccaaacaataataacggatgcttgcacttatgaagaattctcgtctatgtcaga  
 ttatctatcctaaaaacaaaaataccaggttcttcaaaagagcataaaaatattaaaggttctgatagaagggt  
 ttacaactcctcgcctgggtttgtctcagatgctgttttgaagcagatccccagatcaaaagctgtacatttt  
 gtgaggggtgttgcagaggggttcaactttatctctcttccaaaagaaatcgtgcacaagatccatgtcfaat  
 tggctccctcctatgctccattacttactgaaaaatctatctatctattgagaacatcaatcccaagaagat  
 ataccagaatagtaaacgaaaggattgctcctgctttatgtaacttagcatttgttcatgctcttatccaaagg  
 agttacaaccaacagctgcatcagttgtctacaagaggataatagccggctgctcaggtattctcacagagc  
 tagagcgtgataggaattgctctctatgtatgagtgagtgggcggcaacattccggaatctgaagaaaaatctccaa  
 gaattagaacaagtgtctcagcgaaggtgataaagctgaagcattgagaattgtatggtggcgaagtatattg  
 gtacgattatgtatgtgatttgcgggttccatccaggtggttaataatcagagataacgtatttgatttccatgttc  
 taagcgttagtgaggtggagaccatttcaaaagaatttaatacattgatgatgcaaacactcaaaaggtaaaagaaga  
 tccacgcgtaaaaatcggcggtatgaaagtggtgttgagaatttagtaaggacgatctaaaaacagtgcttccgttc  
 gttccagaattatcagcgtcaaaaagaagtagcgaagctatctagaggaaggttagagaggggttaaaattggcgt  
 gcaattttatgaagaataa

Gcn5

SEQ ID No: 5

1 MVTKHQIEED HLDGATDPE VKRVKLENNV EEIQPEQAE T NKQEGTDKEN KGKFEKETER  
 61 IGGSEVVTDV EKGIVKFEFD GVEYTFKERP SVVEBENEGKI EFRVVMNDNT KENMMVLTGL  
 121 KNI FQKQLPK MPKEYIARLV YDRSHLSMAV IRKPLTVVGG IYRPFDKRE FAEIVFCAIS  
 181 STEQVRGYGA HLMNHLKDYV RNTSNIKYFL TYADNYAIGY FKKQGFTEI TLDKSIWMGY  
 241 IKDYEGGTLM QCSMLPRIRY LDAGKILLQ EALRRKIRT ISKSHIVRPG LEQFKDLNNI  
 301 KPIDPMTIPG LKEAGWTPPEM DALAQRPKRG PHDAAIQNIL TELQNHAAAW PFLQPVNKEE  
 361 VPDYYDFIKE PMDLSTMEIK LESNKYQKME DFYDARLVF NNCRMVNGEN TSYYYKANRL  
 421 EKFFNNKVK E IPEYSHLID

Gcn5

SEQ ID No: 6

tcttaaacacttagggcagcaaaaaatgcgtcttcttccctcgtctgtgttttattgtagggcgtaattgatgtt  
 tgcttgcaaaaaatgaatcagcagaaagagaattctagccaaggcaattatggcatactgcaagtagtagtac  
 gttaacggtgctagaataaacattaaatgagatgtagcaatcgagatccttctcagtaggcttaatgctccactag  
 aattttgaccagccactatttgaatttcttctcgaactcctttcaatactcgagagcaaaagcaaaaaaataagc  
 atgtatgctgctgtatggaaaagaatttaatagaactttcaaacgcgctgttaaacagggcatatttaaggtttg

-continued

Sequence Listing

acctaacaatatatcgactattgaaattcttaccgcaagattttttatagttggatattcatatattcttacaact
ctctctactttcagttttttgaagctatatgtatcattatatacgtttatggatttttcaaacctaaacaattata
ctcggtaaatggttgatgaagcaataaataaaaaaaaggattggtaagggagaccgtgagccgccaaaagtct
tcagttaacccaggttcgtatctacattagatggtcacaaaacatcagattgaagaggatcacttggatggagct
acgacggatcccgaagttaaacgggttaaaattgaaaaacaacgttgaagaaatacaacctgagcaggctgagacca
ataaacagagggccaccgataaagagaataaaggaaagtccgagaaagaaactgagagaataggaggatctgaagt
ggttacagatgtggaaaaaggaattgtcaaatttgaatttgatgggttgtaacacattcaagagagaccaggt
gtcgtagaggaaaatacgaaggttaaaattgagtttaggggtggtaaatgataactaaagaaaacatgatgggtcc
taactggattaaaaaacattttcaaaagcaattaccaaaatgccaaagaatacatgcccaggttagtctatga
tcgaagtcattctccatggctgcattaggaagccattgactgctgtaggtggcataaacatcgaccttctgat
aagagagaattccgcacaagttgtttctgcccacagttcgacggaaacaggtacgctggttaggtgctcatctaa
tgaatcacttaaaagactatgtagaataacctcgaacataaaatatttttgacatgacagataattacgctat
tggatactttaaagcaagggctcactaaagaaatcacgttggataaaagtataaggatgggatataaaagat
tggaaggtggtagcagctgacgaatgtctatgttaccagaatacagatattggagcaggttaagattctatatt
tacaagaagcggccctcgaagaaaaataagaacgatttcgaaatcgcatattgtaaggcctggttagagcaatt
caagacttaaaaacatcaaacgctgtagcacaatgactattcctggctgaaagaagcggctggactcccgag
atggatcgctggcacaagctcccaagcgtgggtccacacgtagcagcaatacagaataatactcagagctacaaa
atcatgcagcagctggccctcttacaacccgttaataaagaggaggctcccgactattatgatttatacaaga
gccaatggacttgagcaccatggaataaaaatagagagcaacaaaatcagaagatggaagacttcatatagat
gagagattgggtgttaacaattgcccgaatgtacaatggcagagaatcagctcgtattacaagatgctaataaggctag
agaaattcttcaataaataagtaaaagaaatacctgaaatattctcacctatttgatgaatgctagaagaagctt
tcgctactattccttccgagaagaataaattgttagtagcggcagagcagatgtgatcaattgaggtattttac
tactttcctttcattttgtaagggtttctttcttggtagtgcagctggattttacctttatgtaactatata

Tor1

SEQ ID No: 7

1 MEPHEEQIWK SKLLKAANND MDMDRNVPLA PNLNVNMMK MNASRNGDEF GLTSSRFDGV
61 VIGSNGDVNF KPILEKIFRE LTSYKBEERK LASISLFDLL VSLEHELSIE EFQAVSNDIN
121 NKILELVHTK KTSRTRVAVL SIDTLISFYA YTERLPNETS RLAGYLRLGI PSNDVEVMRL
181 AAKTLGKLA V PGGYTSDFV EFEIKSCLEW LTASTEKNSF SSSKPDHAKH RALLIITALA
241 ENCPYLLYQY LNSILDNIWR ALRDPHLVIR IDASITLAKC LSTLRNRDPQ LTSQWVQRLA
301 TSCEYGFQVN TLECIHASLL VYKEILFLKD PFLNQVFDQM CLNCIAYENH KAKMIREKIY
361 QIVPLLASFN PQLPAGKYLH QIMDNYLEIL TNAPAKKIPH LKDDKPQILI SIGDIAYEVG
421 PDIAPYVKQI LDYIEHDLQT KFKFRKKFEN EIFYICIRLA VPLGVPVGLK LNRNILDLMF
481 KCPLSDYMQE TFQLLTERIP SLGPKINDEL LNLVCSLTS TPFIQPGSPM EIPSPSRERA
541 REWRNKSLQ KTGESNDNN DIKIIQAFR MLKNIKSRFS LVFVFRIVAL SYIEHTDPRV
601 RKLAAALTSCE IYVKDNICKQ TSLHSLNTVS EVLSKLLAIT IADPLQDIRL EVLKNLNPFC
661 DPQLAQPDNL RLLPIALHDE SFNIQSNAME LVGRLSSVNP AVVIPSIRKI LLELLTKLKF
721 STSSREKET ASLLCTLIRS SKDVAKPYIE PLLNVLLPKF QDTSSTVAST ALRTIGELSV
781 VGGEDMKIYL KDLFPLIKT FQDQNSFKR EAALKALGQL AASSGVVIDP LLDYPPELLGI
841 LVNILKTENS QNIRRTVTL IGILGADPY RQKEREVTS TDISTEQNAP PIDIALLMQO
901 MSPSNDEYTT TVVIHCLLKI LKDPSSLSSYH TAVIQAIMHI FQTLGLKCVS FLDQIIPITL
961 DVMRTCSQSL LEFYFQQLCS LIIIVRQHIR PHVDSIFQAI KDFSSVAKLQ ITLVSVIEAI
1021 SKALEGEFKR LVPPLTLFLF VILENDKSSD KVLRRVRLR LESFGPNLEG YSHLITPKIV
1081 QMAEFTSGNL QRSAITIGK LAKDVLDFEM SSRIVHSLLR VLSSTTSDEL SKVIMNTLSL
1141 LLIQMGTSFA IFIPVINEVL MKKHIQHTIY DDLTNRILNN DVLPTKILEA NTTDYKPAEQ
1201 MEAADAGVAK LPINQSVLKS AWNSSQORTK EDWQEWKRL SIQLLKESPS HALRACSMLA
1261 SMYYPLAKEL FNTAFACVWT ELYSQYQEDL IESLCIALSS PLNPPETHQT LLNLVFEFMEH
1321 DDKALPIPTQ SLGEYAEERH AYAKALHYKE IKFIKEPENS TIESLISINN QLNQTDAAIG
1381 ILKHAQQHHS LQLEKTWFEK LERWEDALHA YNEREKAGDT SVSVTLGKMR SLHALAEWEQ
1441 LSQLAARKWK VSKLQTKKLI APLAAGARGG SGEWDMLEDE ISVMKPKSPD KEFFDAILYL
1501 HKNDYDNASK HILNARDLLV TEISALINES YNRAYSVIVR TQIITEFEEI IKYKQLPPNS
1561 EKKLHYQNLW TKRLDGCQKN VDLWQVRLRI RSLVIKPKQD LQIWIKPANL CRKSGRMRLA
1621 NKALNMLEG GTILVYQIRS KPPPPVYQA LKYIWATGAY KEALNHLIGF TSRLAHDGLL
1681 DPNNMIAQSV KLSASTAPY VEEYTKLLAR CFLKQGEWRI ATQPNWRNTN PDAILGSYLL
1741 ATHFDKNWYK AWHNVALANF EVISMVQEEET KLNGGKNDD DDTAVNNDNV RIDGSILGSG
1801 SLTINGNRY P LELIQRHVVP AIKGFPHSIS LLETSCLODT LRLSTLLFNF GGIKEVSQAM
1861 YEGFNLKIE NWLEVLPLI SRIHQPDPTV SNSLLSLLSD LGKAHPQALV YPLTVAIKSE
1921 SVSRQKAALS IEKIRIHSP VLVNQAEVLS HELIRVAVLW HELWYEGLED ASRQPFVEHN
1981 IEKMFSTLEP LHKHLGNBPQ TLSEVSFQKS FGRDLNDAYE WLNMYKKS KD INNLNQAWDI
2041 YNVFRKTR QIPQLQTLQ QHVSPQLLAT HDLELAVPGT YFPKPTIRI AKFEPLFSVI
2101 SSKQRPRKFS KIGLDGKDYK YVLKGHEDIR QDSLVMQLFG LVNTLLKNSD ECFKRHLDIQ
2161 QYPAIPLSPK SGLLGWVNS DTFHVLIREH RDAKKIPLNI EHWVMLQMAP DYENLTLLOK
2221 IEVFYALDN TKGDLYLIL WLKRSSETW LERRTTYTRS LAVMSMTGYI LGLGDRHPSN
2281 LMLDRITGKV IHIDFGCFE AAILREKYPE KVPFRLTRML TYAMEVSGIE GSFRTICENV
2341 MRVLRDNKES LMAILEAFAL DPLIHWGFDL PPQKLTQGTG IPLPLINPSE LLRKGAITVE
2401 EANMEAEQQ NETRNARAML VLRRITDKLT GNDIKRFNEL DVPEQVDKLI QQATSIERLC
2461 QHYIGWCPFW

Tor1

SEQ ID No: 8

>YJR066W Chr 10
atggaaccgcatgaggagcagatttggagagtaaacctttgaaagcggctaacacgataggacatggatagaa
atgtgccgttggcaccgaactctgaatgtgaatagaacatgaaatgaaatgacgagcaggaacggggatgaattcgg
ctcgaactctcagtaggtttgatggagtggtgattggcagtaatggggatgtaaattttaagccattttggagaaa
attttccgcgaattaacagtgattcaagagggaacgaaaatggccagatttcatatttgatctactagat
ccttggacaatgattgctgatacgaagagttccaagcagttcaaatgacataaacataagatttggagctggct
ccatcaaaaaaacgagcactagggtaggggctgtctatccatagacactttgatttcatctacgcatatatac

-continued

## Sequence Listing

gaaagggttgctaacgaaacttcacgactggctgggtaccttcgagggtcaatacctctaatgatgtagagggtca  
 tgagactcgtcgcaaaagactctgggcaagttagcgttccaggagggtacatataacctctgatctcgtggaatttg  
 gataaagctcttgcttagaattggcttactgcctccacggaaagaattcattctcagagtgcagccagaccatgct  
 aaacatgctgcgctctcgtattataacagcgttggcagagaattgctcctatttactctaccaatacttgaattcca  
 tactagataaacatttgagagacatcaagagaccacatttgggtgacagaattgatgcggtccattacattggccaa  
 atgtctttccaccctacgaaatagggatcctcagtttaactagccagtggtgcagagattggctacaagttgtgaa  
 tacggatttccaagt aaacacattagaatgcattccatgcaagtttggtttataggaaatcttggttttgagg  
 atcccttttgaatcaaatgtctcagaaatgtgtcaaatgcatagcttataaaatcagaaatcagaaatgat  
 tagaagaaagattaccagattgttccctattagcattcgttcaatcctcaattatttggctggcaaatattgac  
 caaattatggacaactatttagagattttaaaccatgctccagcaaaataaaat accacatctcaaaatgacaaac  
 cacagatttttaaatcagatttggctgatttgcattatgaaatgaggtcgggcccagatatacgcaccttattgta  
 acaaatctt  
 tgattatattgaaatgatattacagacgaaatcaaatcagaaagaatttgaaaatgaaatttctactgcactc  
 ggaagattggcagttcccttgggcccgttctaggttaattataaacagaaatatactggactgatgttcaaat  
 ggcctcttccgactatagcaggaaacgtttcaaatctgactgagagaatcactcactgccccaaaataaaa  
 tgacgagttgcttaacctagtctgttcaaccttactggaacaccttataccagccagggtcaccatggagata  
 ccatcgttttcgagagaaagagcaagagaatggagaaataaaaacatctacagaaaactggtaaggtaacgatg  
 ataaatgatataaaaatcattatacaagcttttagaatttataaaaatacaaaagcagatttctgctggaggaa  
 attcgtgagaattgttgcactttctacattgagcattacagatccagagtaaggaaactagctcgttgcattct  
 tggtaatttcaagcaaggtatactctgcaaaacacacatcactacactctctgaaactctctctgaaactctct  
 caagcttctagccattacgatttggctggcagccttacaagatatacgttttagaagttttaaagaatcttaact  
 cctat  
 ttctgatccccagttggccacaacagataatttgagactcttggttactgcactgcacgatgagtcgttcaatatt  
 cagtcagtagcaatggagcttctcgttaggttctctcgttaaaccttgcatacgtcactccatcgataagaaaa  
 tactctggaactgctaacaaaataaaaatctcaactctctcgcagaaaggaagaactcgcagtttggttatg  
 tactcttactcaggtcagtaaaagattgtgcaaaccttatacgaacctctttaaattgtcttaccaaaattc  
 caagatacctctcaacgggttgcattcaactgcactgagaactataggtgagctatctgttggtagggggcgaag  
 atggaatatacttaaggtatttcttcttaattatacaaaacatctcaggatcaatacaactcttcaagagaga  
 agctgcacttaaggcccttggctcaactgcagcctcattcgttactgactgatagctcttactcagactatccgaa  
 ttattgggtatattgggtgaaatattgaaagacagaaactctcaaaatattaggagacaaacagtcactttgatag  
 gtatactgggagctatcgaccatatacgccaaaagaacgtgaggttaccctactacagatatactacagaaca  
 gaacgccccgctatcgacattgctctctcatgcagggtcattctcctcgaatgatgagttataccactgctt  
 gtcattcactgcctgctaaaaactctaaaagatccatccctatcatttaccacactgcccgtgatccaagcatta  
 tgcaatttttcaaaccttggctcaaaatgtgtttcattcttggacagatcattcccaactatttggagcgaat  
 gcgtacatgctctcagtcactattagaatttacttccaacagcttggctcttggattattatcgttaaggcaacac  
 ataaagcctcatgctgattctataatccagggtatacaagattttcttctcgttgctaaagctcaaaataacgctt  
 gaagtttataagcaaatcaaaagctctggaggggtgaaatcaaaagattggctccctctactctgactctgctt  
 ccttgaattttggagaatgacaagcttagtgacagggtcctctccagaagggtatgagactgtagaattcgtt  
 ggtcctaacttagaaggttatacgcatttgattacacccaagatagttcaaatggcagaattcaccagcgggaac  
 tacaaggctcgaattactatctgcaaaactggcgaaggtggtgaccttttgagatgctccaagaattgt  
 tcaactcttacttagggtactaagttcaaacacagagtgacgaactctcaaaagtcattatgaaactttaagttca  
 ctgctaatacaaaatgggcacatccttctgctatcttcaatccctgctcaatgaagttttaatgaaagaacatattc  
 aacacacatataatgactgacaaacagaaatataaaacaaatgatgtttaccacaaaaatcttgaagcaaa  
 tacaacggattataagcccggaacaacaaatggaggcagcagatgctggggtcgcaaaatcactataaaccaatca  
 gttttgaaaagtgatggaattctagcccaacaaagaactaaagaagattggcaggaatggagcaaacgctctacca  
 tcaattataaaagagtcacccctccatgctcaagagcttggttcaaatcttgcaagcagtagttatccactagc  
 caaagaacttttaataccgcatctcgatggtttggaccgaaacttataagccaatcaagaagatttaattggg  
 tcaattatgtagccttactctctcccttaaatccaccagaaatatacaaacattgttaaacctggtagaattta  
 tggaaacagtagcaaaaggtataccaataccaactcaaaagcctgggagagtagctgaaagatgcaagcctatgc  
 caaagcgtacattataaaagagattaaatttataaaagagcctgagaactcaactattgaaatcattgatcagcatt  
 aacaaccagctgaaatcaaacggatgctgcaatttgggtatataaaagatgcccacaacacattcactcaattaa  
 aggagacatgggttgaaaaatagagcgttgggaagatgcatcactgctataatgaacgtgaaaagcaggttg  
 tacttccgtgagcgttcaactcgttaagatgagatccctctcatgcccctggcgaatgggaacagttgtcgaattg  
 gcagctgaaagtggaaggttgcgaagctcaaaactaagaagctaaatagctccctggcagctggtgctgctggg  
 ggttgggagagtggtatgcttgagcaaatatacagcgttatgaaacctaaatctccagatagaagaaatttttga  
 tgcattttatactgcaagaatgattacgacaatgctagtaagcattataaaagcagagatttggcttgg  
 actgaaatttccgctgtagcaatgaaagttataatagagcattatagcgttattgttagaactcaaaataaacag  
 agtttgaggaaatcattcaagttatacaaatgcccactaatccgagaaaaaaactcactatacaaaatcttggac  
 aaaaagactgctgggctgcaaaaaaatgctgatttggcaaaagagtgcttagagtaagatttgggttaataag  
 cccaagcaagactgcaaaataggataaaatttgcaaaatttggcagaaaaatctggtagaattgggtagcaaaat  
 agcattgaaatgcaatagcaatagaggaggcagcagcctagtttaccaaatcagttcaaaagctccctcccccagtt  
 ttacgcgcaactaaaatataatgggctacaggagcttataaaagcattaaaccacttgataggatttaccatcc  
 aggttagcgcattgatttgggttggatccgaataatagatcgcgcaaaagtgcaaacctcaagtgcaagtagct  
 ctccgtatgttgaggaatacacaacaaatattagctcagattttttaaagcaaggtgagtgagaaatagcaacaca  
 accgaaactggagaacacaacaaatccgattgcaattcttgggtctctattctattggctacacatttgcataaaaat  
 tgg  
 tacaaggcattggcataaattgggcttagctaaatttgaagtaataatccatgggtcaggaagagactaagctcaacg  
 gaggtaagaatgatgatgatgacacggcagtttaataatgataatgtcgggattgacggtgattatcctagggaag  
 tggttcttggactataatggcaacagataccgctagagcttataaaagacattggttccagcagatcaagggc  
 tttttctcattcaatctctattagaacaaagttggttgcgaagacagttgaggttattgactctttatttaact  
 ttgggtggtataaagaagctcacaagcctgtagaaggttcaatttggatgaaatagagaactggcttgaagtt  
 cttaaccagattgattctcgtatatacagccagatcctacgggtgagtaattcccttttggctgcttctgat  
 ttagggaagactcaccacaagctctcgtgtatcctttaaactgtcgcagatcaagctcgaattcgtttcaagacaaa  
 aagcgcctcttcaataatagagatacaacaaataggattcattagtcagctcctggtaaacagggcagaatagtt  
 agtca  
 cgagttgatcagagtagccgttctatggcagcaattatggtatgaaggactggaagatgagagccgcaattttc  
 gttgaaacataacatagaaaaatgtttctactttagaaccttatacaaacacttaggcaatgagcctcaaacgt  
 taagtgaggtatcgtttcagaactcatttggtagagatttgaacgagctcagcaatgggtgaataaactcaaaaa  
 gtcaaaagacatcaaatattgaaacaaagcttgggattattataaacctctcagaaaaataaacagctcaaat  
 ccacagttacaacacttagacttacagcattgttctcccagctctcggctactcagatctcgaattggctggtc  
 ctgggacataattcccagaaaaactcacttagaataagcgaagttgagccattatttctgctgctctcgaa  
 gcaaggccagaataattctccatcaagggtagcagcgttaagattataaacgttttaaagggacatgaagat

-continued

## Sequence Listing

ataagacaagatagccttggtatgcaattatgtggtctagttaaacactttggtgagaatgattcagagtggttca  
 agagacattgggatcccaacaataccggctatccattgtcgctaaatctggttactaggatgggtaccaaa  
 tagtgacacattccacgctttgatcagagaacacgctgatgcaaaaaaatccgctgacattgacattgggt  
 atgtacaaatggccccgatgatgagaatttgactctttacaaaaatggaagtattcactgacgctttagata  
 atacaaaaggccaagaccttataaaatattatgggttaaagagtaggctcgtcagagacatggctagaacgtagaac  
 aactatacagagatcttagcagttatgctcatgactggttatattctgggactaggatgctccatccaagcaac  
 ctgatctagatagaatcacgggtaaagttatccacattgatttcggcgatggtttgaaagctgccatcttaagag  
 aaaagtatccagaaaaagtgccatttagactaaactaggatgtaacatacgaatggaagttagtggaattgaaag  
 cagtttccgaattacttggtaaatgtcatgagagcttaagagataataaagaatcattaatggcgatctggaa  
 gcttttggcgttgatcctttgatccatggggatttgatttaccgccacaaaaactactgagcaaacctggaattc  
 ctttggcgttgattaatcctagtgaattattaaggaagggggcaattactgtcgaagaagcggcaaatatggaagc  
 agaacaacaaaaatgagaccaaaaacggcagagcaatgcttggtttggagcgtattacagataaataacgggcaat  
 gatatacagaggttcaatgaattagacgctcctgagcaggttgataaactgatccaacaagccactctattgaaa  
 ggttatgtcaacattatattggatggtgccattctgggtga

Ubp8

SEQ ID No: 9

1 MSICPHIQV FQNEKSKDGV LKTCNAARYI LNHSVPKEKF LNTMKCGTCH EINSGATPMC  
 61 LQCGFCGCWN HSHFLSHSKQ IGHIFGINSN NGLLFCFKCE DYIGNIDLIN DAILAKYWDD  
 121 VCTKTMVPSM ERRDGLSLGI NMGSTCFMSS ILQCLIHNPY FIRHMSQIH SNNCKVRSFD  
 181 KCFSCALDKI VHELYGALNT KQASSSTST NRQTGFYLL TCWAKINQNL AGYSQDAHE  
 241 FWQFIINQIH QSYVLDLPNA KEVSRANKQ CECIVHTVPE GSLESSIVCP GCQNNKTTI  
 301 DFFLDLSLDI KDKKLYECL DSFHKKEQLK DFNHYHCECN STQDAIKQLG IHLKPSVLVL  
 361 QLKRFEHLN GSNRKLDDFI EPPTYLNMKN YCSTKEKDKH SENGKVPDII YELIGIVSHK  
 421 GTVNEGHYIA FCKISGGQWF KFNDMSVSSI SQEEVLKEQA YLLFYTIRQV N

Ubp8

&gt;YMR223W Chr 13

SEQ ID No: 10

atgagcatttgtccacatatcacgaagatattcagaatgaaaagcttaaagatggggttctaaaaactgcaatg  
 ctgccaggtatataataatcatccgtaccacaggaaaaattcttaaacaccatgaaatgtggtacatgccacga  
 aataaaactctggcgcaactttcatgtgtctacaatgtggattttgtggatgttggaaaccattcgactttctctc  
 cacagttaaacagattgggtcacatatttggtatcaactcaataatggccttttattttgcttcaaatgtgaggact  
 atatagggaatctgatctgattaacgatgctatcctagcgaagtattgggacgacgctgtgcacaaagaccatggt  
 tcttagcatggaaagaagatgggctttctggcctgatcaacatgggatccacttctcatgagtagtattctc  
 caatgtcctaatccataaaccttatttaggcactcaatgagtcataatcattctataaattgtaaagtgcgtt  
 ctccagataaatgttttcatgtgcactcgataaaattgttcatgaaacttattggagcgtgaaatacaaaagcaagc  
 ttcttctgcatctacatctactaatcggcaaacccggatctacataatctttaaactgtgctggaaaatcaatcaa  
 aatctagcaggggtattcacacaagaatgctcatgaaattttggcagtttataatcaacaaaatccacaaagctatg  
 ttcttgatttgcaaaatgccaaaggaagtcagcagagcaaaataaagcagtgatgcatagtgcatactgtgtt  
 tgagggtccttggaaagtctatgtgtgtccagggtgtcaaaataatcaaaagacaaccattgatccattcttg  
 gatcttctcttgatatacaaggaataagaaaaactttatgaatgtcttgacagtttccataaaaaagaacagttga  
 aggatttcaactatcattgtggggagtgtaacagcactcaagatgcaataaagcaactaggcatcacaaaattacc  
 atcggtttgggttttgcattgaaaagattcgaacacctactaatggaagtaacagaaaaactagacgattttat  
 gaatttccaacttatttaaatgaaaaatctactgttcaacgaaggaagaaagataagcattctgaaaatggcaagg  
 tccagacatttttcaagataatcggattgtttcccaagggggcaggttaagagggacattatattgcat  
 ttgtaaaatttctggagggcaatggtttaaattcaatgatccatggtctctctctataatctcaagaagaggtttta  
 aaggaacagggcatatttatttctacaccattctgcaagtaaatgta

Spt7

SEQ ID No: 11

1 MTERIPIKNY QRTNAKALLK LTEKLFKNKF FDLYLTSQQL VVLEYLLSIS SEEDKLAWD  
 61 YFLKGNIALN VEKSFPLTQE EEHGAVSPA VDRSDDVSS QTIKDNNTN TNTSISNENH  
 121 VENEIEDKGD NAIANEDNFV NNDESNDVEE DLFKLDLEDL KQIQSGTRFI GNLSLKIRYV  
 181 LWQCAIDYIY CDRNEFGDEN DTEYTLDDVE EKEEEEIGKN EKPQNKEGIS KFAEDEDYDD  
 241 EDENYDEDST DVKNVDDPPK NLDSSISSNI EIDDERRLVL NISISKETLS KLKTNVVEEI  
 301 MGNWNKIYHS FEYDKETMIK RLKLEESDKM IEKGGKRSR SDLEAATDEQ DRENTNDEPD  
 361 TNQKLPTEG STFSDTGNKR PKQSNLDLTV NLGIENLSLK HLLSSIQQKK SQLGISDYEL  
 421 KHLIMDVKNR RSKWTSDBRI GQEELYEACE KVVLELRNYT EHSTPFLNKV SKREAPNYHQ  
 481 IIKKSMDLNT VLKLLKSFQY DSKQEFVDDI MLIWKNCLTY NSDPSSHFLRG HAIAMQKKS  
 541 QLIRMIPNIT IRNRADLEKE IEDMEKDKDY ELDEEEVAVG SGRKGLNMGA HMLAKENGV  
 601 SEKSSKTVK DEAPTNDKLL TSVIPEGEKE KDKTASSTVT VHENVNKNEI KENGNKEEQD  
 661 MVEESSKTED SSKDADAACK DTEGLQDKT AENKEAGENN EEEEEDDDED EDEDMVDSQS  
 721 YLLEKDDDRD DLEISVWKTV TAKVRAEICL KRTEYFKNGK LNSDSEAFK NPQRMKRPDQ  
 781 LFLEYKEQKA LESYRQIEQ NSIMKNGFGT VLKQEDDDQL QPHNDHSLNG NEAFKQPNP  
 841 IELDDTRFLQ EYDISNAIPD IVYEGVNTKT LDKMEDASVD RMLQNGINKQ SRFLANKDLG  
 901 LTPKMNQNT LIQQIRHICH KISLIRMLQS PLSAQNSRSN PNAFLMNHY NYTIIDDSL  
 961 IDPVSQPLPH DYKNRRELIW KFMHKNISKV AMANGPETAH PSAINMLTEI AGDYLSNLK  
 1021 TLKLLHHTNS LNRTNVEML QTLLLENGIN RPDDLFSYVE SEFGKTKKL QDIKQKLESF  
 1081 LRALLRPTLQ ELSENFEDS SQSFFTGDFE SELTGEDFFG FRELGLEKEF GVLSSSVPLQ  
 1141 LLTTQFQTV GETKVQAKKI QPEESDIVY KKITKGLMDA GSFWNTLLPL LQKDYERSKA  
 1201 YIAKQSKSSA NDKTSMTSTE DNSFALLEED QFVSKKTATK ARLPPTGKIS TTYKKKPIAS  
 1261 AFILPEEDLE NDVKADPTT VNAKVAEND GSSFLRTP QPLDPLDMD AFDDTNMGSN  
 1321 SSFSLSLPRL NQ

-continued

Sequence Listing

Spt7  
>YER081C Chr 2

SEQ ID No: 12

atgactgaaagaatccaataaagaattatcaaagaacaaatgccaaagcttacttaaattgactgaaaaacttt  
ttaaacaagaacttttttgatctctatttaacctctcagcaattggctcgtctttgaatacctgctgctgattccaag  
tgaagaagacaaactgaaagcctgggactatctcttaagggaacatagcattaaatgtcgaaaaatcattcca  
ttaacccaagaagaacacatcagggagcgtctctcctgcccgttgacacacgatcagatgatgatcatcacaaa  
caat taaggacaataacaataactaataccaacaccagatcagcaatgaaaatcatgtgaaaaatgaaatgaaga  
taaaagcagat aacgcaatagcaaatgaagataat tttgtgaaat aatgacgaaagtgat aatgttgaagaagactt  
ttcaaaatagatctagaggatttgaatcagat aaagaactatgat aagcagat taaaacttgaagaaagcagataaaa  
gat acgtctctgtggcagtgccat agattat atatactgtgatcgt aatgagttgggtgat gaaaatgat acaga  
atacacctctattagatgttgaagagaagggaagaggaaattggtaaaatgagaagccacaaaaaaagaaggt  
atttcgaagtgcgcgaggtgaagat tacgacgatgaagacgagaactatgatgaagacagtcagacgtaaaaa  
atgtcgatgatctccaaaaaatctcgattctat ttcctctctaatatcgaaatgacgatgaacgagcctggg  
gctaaaatctcaatatacaaaagaacactgtcaaaagttaaaaaaaat aatgtagaagaat atgggaaatgg  
aacaataattaccacagtttgaatcagat aaagaactatgat aagcagat taaaacttgaagaaagcagataaaa  
tgat agagaaaggaaagaagaacgaagtcgaagtgat ttagaagcagctaccgatgaacaagatcgcgaaaatac  
aaatgatgagccagat actaatcaaaaatgcccactcctgaaggttcaacatcagcagatctgggaacagcgc  
cccaaaacaaagtattttagatttgaatcagcctcaatctaggcagcagaaaaatttatcattaaagcacctctatcatc  
tccagcaaaaaaaatcccaat taggaatcagat tacgaattaaaaatctgat ttaggagtcagaaaaaatcg  
gtcaaaaatggacatcggatgaaagaat tgggcaagagggaattatcgaagcctgtgaaaaggttgttttggaaact  
agaaactacactgagcttctacacctttctgaataaagtgaagcaaaagagaagccccaattatcatcaaatca  
tcaaaaagtccatggactgaaatctgttttaaaaaactgaaaagcttcaat atgactccaaaacagaatttgt  
agacgatattatgcaat atggaaaaatgtttgacat ataatcagatccttcacat ttttgagagggcagct  
attgctatgcagaagaactctctcagttgatcgcagatgattccaaatatacaaatccgaaacagggctgatttag  
aaaaggaaatgaaagat atggaaaagacaagaactacgaattagatgaggaagaggagttgctgggtctggaag  
aaaaggatgaaat atgggagctcat atgttggccaaagagaatggcaaggtgtagaaaaagatagctcaaaacc  
gtcaaggatgaagcccaacaaatgatgacaaaactaaactctgtcatccctgagggggaaaaagagaagataaaa  
ctgctcatctactgtaacggtacacgaaaatgtaaat aagaacgaaat aagaagaaatgggaaaaatgaagagca  
agat atgggtgaggaagatgtaagactgaggtatcacaagaatgctgatgctgccccaaaaggatcgggaagac  
ggactacaagataaaaactgcagaaaaat aaggaggctggggaaaaat aatgaagaggaagaggatgatgatcgaag  
atgaagacgaagacatggctgactcccaatctatttacttgaagaggatgacgatagagacgat ttggaaatc  
cgtgtggaaaactgt aactgcaagttcgtgcccgaat tggcttaaaaagaactgaaat ttttaaaaatggaaaa  
ttaaatagtgattcagaggggttttgaaaaaaccccaagaatgaaaaggttcgaccagcttttcttgaataa  
aagagcagaagctttagaatcatatcgtcaaaaaatagagcaaaatccat atgaaaaatggctttggaacagt  
actaaaacaggaagacgatgaccaatgacagttcacaatgatcactctttaaataggaaatgaaagcttttgaaga  
caacccaatgatattgagttagatgat accagatctcactacaggaatagatattagtaacgcttctcagacatag  
tatacagggagtaaat actaaaaacat tagacaagatggaagacgcttcgctggaccgcatgctcaaaatggat  
caacaacaagcagat tctggctacaaggat ttggactaacacctaaaaatgaacaaaaatcacactgat  
cagcaaataggcaat atgccaataatcctctgatcagaatggtacagagccttatcggctcaaaactcca  
gaagcaatcccaacgctttccttaacaaccacat ttaatactact atattgatgactcactcgatattgatcc  
gggtgcacagcttccaacgcatgattcaaaaaaacacagggagctgatggaaatcctgcatagaacatctc  
aaggttgcattggccaatgggtttgaaactgcccactccatcagcaataaacatgcttactgaaatcgccggggat  
acctatcctactgat aagactttgaagcttcatcatgaaactaacctcttaataaggagcaaaatgtggaat  
gctgcaaacacactgttggaaaacgggtatcaacagggccagacgatctatttctctatgtgaaatctgaaat  
aaaaaaactaagaaactcaggaatcaaacagaaactagaaagcttttgagagccttattaaaggccaactttgc  
aggagttgctcagagaaactttgaagacgagagccaaagctttttacaggtgactttgcccagcaatgactgg  
tgaagacttctttgggttttagagagctggattagaaaaggagttggagttttgagttcactctgtccattacag  
ttactgactactcagtttcaaacgttgacggggaaacaaagtgcaagcccaaaagatccaacgggaagaatcag  
acagcattgtgataaagaaatcaaaaaggtatgctggatgctgggttcatcttggaaatcctactctccctatt  
acaaaagat tatgaacgttccaagcctat atagcaagcaaaagcaagtcactgcaaatgataaaacctcaatg  
acttccacagaagcaattctctcgttactagaagaggatcagtttctcacaagaaaacgcaacgaagggcaa  
gattacctcctactggt aagataagtaaccacatacaaaaagaacccgatcgcaagcgcgttatacttccagaaga  
agacttggaaaacgagcgtaaaagcggatccaacaacactgtaaacgccaaagtggtgtagaaaaatgatggagat  
tcttcttatttttgcaagcctcaacctttagatcctttggat atggatgatgcttttgatgataccaatgatgg  
gcagcaatagttcattagcttgagccttctcgccttaataataa

SPT8

SEQ ID No: 13

1 MDEVDDILIN NQVVDDEEDD EEMLSGLEND SKQDLEGND GGEDEEDDDD DDEDDDDDED  
61 EREDDDEQED DDGEDDAARM DKTATPTNEH QHDEQKAAAA GAGGAGDSGD AVTKTGSEDV  
121 KLSVDVGGVG SREASSSTHE ASANGEVY EYKHLNAAQI ADSYNIYPTA AIPIQTHVNA  
181 LAVSRGLKYL FLGSSDGYIR KYDLLNTLEG KLSLTILOKH SLAESIQNAG ILQSYWENEI  
241 POKKSEMKLS ANKTDYEPKV SPVHSELVQS ECLFIIISGLQ NGGITMQGVR YMEGSIAHYF  
301 KGRNGHTQIV NILRLNGQED RFLSGSWDKR LLEWDLQTD IVNEFKKRS ELSSELMRPL  
361 YSSVDVSGNV NSKGENENAD DMDSLPGDE DEDEKQDAGN EPVETGDGSN GEENKEQISE  
421 ESLNIVYDES VFMTSGLNGS VHIWDRRMTQ SPALS LERGA GVPPWCLSA WGVGDGHVYA  
481 GRRNACVQEF DLKMPSKPIH NLKLPISIGP VSCVKAMPNN KHLCCASRDN IRLYNVEIAV  
541 DASNSTKSS KVPFLIVPGH HGGIISNLYL DPTSRFIIIST SGNRGWQNS TDTTLIYDID  
601 LE

Spt8  
>YLR055C Chr 12

SEQ ID No: 14

atggacgaggttgacgatattcctaattacaaccaggtgggtgatgacgaggaggatgacgaagagatgctgagtg  
ggctggaacagactcaaacgagacctcgagggaatgatgacgggtggtaagatgaagaggatgacgatgatga  
tgatgaggacgatgatgatgacgaggacgaacgagaggacgacgatgaacaggaggacgacgatggtaggacgac

-continued

Sequence Listing

gcccgaagaatggataaagactgctacaccgacgaatgagcaccagcatgatgagcaaaaggctgctgctgctggtg
ctggcgggtgcaggcgatagtgccgatgctgttactaagattggatccgaggatgtgaaatgagcggatgttgatgg
aggagtgggtccaggaagcatctcctctacacacgaagcctctgctaatggagaggtttatgagtactataag
cacatgttgatgcccacagattgcccgatctcgtacaatctcaccacggcagccatcccatccagacgcagc
tcaatgcttggccgtgcccagggtctcaagtaacctgttttggcggtagcggatggatacataaggaagtacga
cttctgctgaacacgcttgaggggaaactttcttaactatcctgcagaagcattcgttggtgagctctatcagaac
ggcggatcttgcaagtctgactgggaaaatgagatcccgcagaaaaatcagaaatgaaactctccgctaataga
cagattacgagcccaaggttagccccgttcatctcttggaaagtcacaaagcgaatgcctcttatactgagcgggt
acagaatggtgggattaccatgcagggcgtctgctacatggaggggagcatgcccactattttaggggcaggaat
ggacatcccaaatcgttaacatactgagattaaacggtcaagaggcaggtttttgagtggttctgggataaag
gctctttggaatgggatttcgagacgggtgacatagttaatgagtttaaaaaatcaaggtctgaattgtcatctt
ggaaatcgcccgctgtactcgtccgtggatgtgctccgtaacgtcaacagtggttaagagaatgaaatgcagat
gacgatattgattctcgtttgggtgatgaagacgaagcagaaaagcaagatgctggcaacgaaccctcgagacgg
gggattggttctaaggtgaagagaaacaaagaaacagatctgaagaatccttgaacatagctctatgatgaatccg
tttatgacctcagggttgaacggttccgtgcatatttgggaccgacgcatgacgcagtcgccagcattgtctctg
gagagaggtgcaggcgtcccaccgtggtgtttgtccgcatgtgggtgtgagatgggtgatcatgtgtatgacgga
gaaggaatgctgtgtgggagcagttgacttgaagatgcccctgaaacctccatatttgaactgctctctat
ttcaggcctgctcttctgtttaaagccatgcctaatacaagcatttactatgtgcatcgccgggataatcaga
ttgtacaacgttgaaatgagatgagcttcaaatcgactacaaagagttctaaagtgccttccatcgtgc
cgggcatcacggtggtattatatacaactataacctcgacccccactcaagatttataaagcaacaagtgccaa
cagaggtgcccaggggaaattctacggacacgaccttattacgatatagacttagaatag

Snf1

SEQ ID No: 15

1 MSSNNNTNTA PANANSSHH HHHHHHHHHH GHGGSNSTLN NPKSSLADGA HIGNYQIVKT
61 LGECSFGKVK LAYHTTTQOK VALKIINKKV LAKSDMQGRI EREISYLRLR RHPHIIKLYD
121 VIKSKDEIIM VIEYAGNELF DYIVQRDKMS EQEARRFFQO IISAVEYCHR HKIVHRDLKP
181 ENLLLDHLN VKIADFGLSN IMTDGNFLKT SCGSPNYAAP EVISGKLYAG PEVDVWSCGV
241 ILYVMLCRRL PFDDESIPLV FKNISNGVYT LPKFLSPGAA GLIKRMLIVN PLNRISIHIEI
301 MQDDWFKVDL PEYLLPDLK PHPEEENENN DSKKDGSSPD NDEIDDLVNV ILSSTMGYEK
361 DEIYESLESS EDTPAFNEIR DAYMLIKENK SLIKDMKANK SVSDELDTFL SQSPPTFQQO
421 SKSHQKSQVD HETAKQHARR MASAITQORT YHQSPFMDQY KEEDSTVSIL PLSLQIHRA
481 NMLAQGSPA SKISPLVTKK SKTRWHFGR SRSYPLDVMG EIYIALKNLG AEWAKPSEED
541 LWTIKLRWKY DIGNKTNTNE KIPDLMKMVI QLFQIETNNY LVDFKFDGWE SSYGDDTTVS
601 NISEDEMSTF SAYPFLHLTT KLIMELAVNS QSN

Snf1

YDR477W Chr 4

SEQ ID No: 16

atgagcagtaacaacaacacacacacagcaccctgccaatgcaaatctagccaccaccaccaccatcaccaccatc
accaccaccatcacgggtcatggcgggaagcaactcgacgctaaacaatcccaagtcgctctagcggatggtgcaca
tatcgggaaactaccaaatcgtcaaaacgctgggagaggggtcctttggtaaggttaaattggcattatcaccact
acgggccccaaaagtgtctctaaaaatcattaaagaaggttttggcaagagtgatagcagggcagaatgaaa
gagaaatctcttatctgagactcttaagacacccccacatcaaaactgtatgatgtatcaaatccaaagatga
aatcatatggttatagagtagcggcggaaagcaatgtttgactatattgttcagagagacaaaatgagcgagcaa
gaggcaagaagattttccagcagatcatcagtgccgtcgagtagtccataggcacaataatgtccatagagatc
tgaagcctgaaaaacttactactagatgagcatctgaatgtaaagattgcccattttggttgtcaaacatcatgac
tgatggttaattcttaagactctctgtggttctcccaatgatgcccgtcctgaaagttatcagcggtaagctgtac
gcaggcccaagtggaagctgtggtcatgtggggttatcctttatgttatgctttgtcgtcgtctaccgtttgacg
atgaaagcatcccagtcctttcaagaatacagcaacgggtgtttacacctgacctaaatttttatcctcggagc
tgctgggtaatacaaaagaatgttaactcgttaactcagcaagaataagcattcatgaaatgatgaagacgat
tggttcaaaagttgacctgccagatctacttccaccagatttgaaccacaccagaagaagagaatgaaaaa
atgactcaaaaaaggtggcagcagccagataacgatgaaatgatgacaacctgtcaaatatttatcatcgac
catgggttacgaaaaagacagagattatgagtccttagaatcatcagaagacactcctgcatcaacgaaattagg
gacgctacatgttgatgaaggagaataaaatctttgatcaaggatgaaggcaaaaaagcgtcagtgatgaac
tgataaccttctgtcccagtcacctccaactttcaacaacaaagcaaatcccatcaaaagagtcagtagatca
tgaactgcccaagcaacgcgaagaggtggcaagtgtatcactcaacaaggacatcaccatcacctctc
atggatcagataaagaagaagactctacagttccattttgctctacatctttacctcagatccacagagctaat
tgttagcacaaggttgcccagctgcccctaaaaatctcctcttgtaacgaaaaaatcaaaacagagatggcattt
tggtatcagatctcgtcatatccattagacgcttatgggtgaaatttatatgcttgaagaattgggtgcccga
tgggcaagccatctgaagagatttatggactcaaaatgaagtggaatgatattgaaacaagcaaaaca
ctaatgaaaaaatcctgatttaataaaaaatggttaattcaattatcaaatgaaaccaaatattttgggga
tttcaaatggagcggctgggaaagtgttatggagatgatactactgttctcaatatttctgaagatgaaatgagt
actttttcagcctaccattttcaatcaacaacaaaactaattatggaatagccggttaacagtcaagcaatt
ga

ACS1

SEQ ID No: 17

1 MSPSAVQSSK LEEQSSEIDK LKAKMSQSA TAQRKKEHEY EHLTSVKIVP QRPISDRLQP
61 AIATHYSPHL DGLQDYQRLH KESIEDPAKF FGSKATQFLN WSKPFDKVI PDPKTGRPSF
121 QNNAWFLNGQ LNAQYCNVDR HALKTPNKKA IIFEGDEPGO GYSITYKELL EEVCAQVAQVL
181 TYSMGVRKGD TVAVYMPMVP EAIITLLAIS RIGAIHSVVF AGFSNSLRD RINDGDSKVV
241 ITTDESNRGG VIKETKRYD DALRETPGVR HVLVYRKTNN PSVAFHAPRD LDWATEKKKY
301 KTYYPCTPVD SEDLPLFLYT SGSTGAPKV QHSTAGYLLG ALLTMRYTFD THQEDVFPFTA
361 GDIGWITGHT YVYVGPLLYG CATLVFEGTP AYPNYSRYWD IDEHKVTFQ YVAPTALRLR
421 KRAGDSYIEN HSLKSLRCLG SVGEPIAAEV WEWYSEKIGK NEIPIVDTYW QTESGSHLVT
481 PLAGGVTPMK PLSASFPFFG IDAVVLDPNT GEELNTSHAE GVLAVKAAWP SFARTIWKNH
541 DRYLDTYLNP YPGYYFTGDG AAKDKDGYIW ILGRVDDVNV VSGHRLSTAE IEAAIIEDPI

-continued

Sequence Listing

601 VAECAVVGFN DDLTGQAVAA FVVLKNKSSW STATDDELQD IKKHLVFTVR KDIGPFAAPK
661 LILVDDLPK TRSGKIMRRI LRKILAGESD QLGDVSTLSN PGIVRHLIDS VKL

Acs1

>YAL054C Chr 1

SEQ ID No: 18

atgtcgccctctgccgtacaatcatcaaaactagaagaacagtgcaagtgacaagttgaaagcaaaaatgt
cccagctcgccgccactgcgcagcagaagaaggaacatgagatgaaacattgacttcgggtcaagatcgtgccaca
acggcccatctcagatagactgcagcccgcaattgctaccactattctccacacttgacggggtgcaggactat
cagcgcttcacaaaggagctctatgaaagacccctgctaaagtcttcgggtctaaagctacccaatttttaaaactggt
ctaagccattcgataaggtggttcatccagaccctaaaacgggagccctctccagaacaatgcatggttctc
caacggccaattaacgcctggtacaactggttgacagacatgcttgaagactcctacaagaagccattatt
ttcgaaggtgacgagcctggccaaggctattccattacctacaaggaactacttgaagaagttgtcaagtgccac
aagtgctgacttactctatggggcgttcgcaaggcgatactggtgcccgtacatgctatggtcccagaagaat
cataacctgttggccatttccgctatcggtgcccattcactcctgagtccttgcggggttttctccaactcctg
agagatcgtatcaacgatggggactctaaagtgtgcatcactacagatgaatccaacagaggtggtaaagtcattg
agactaaaagaattggtgagcagcgttaagagagacccagggcgtgagacacgctctgggttatagaagaccac
caatccatctggtgcttccatgccccagagatttggattgggcaacagaaaagaagaatacaagacctactat
ccatgcaacccgttgattctgaggatccattatcttgtgtatagctctggttctactggtgccccaaagggtg
ttcaaacatttaccgcaggttacttctggtggagcttgggtgaccatgctgacactttgacactcaccagaaga
cgttttctcacagctggagacatggcgtggtacagggccacactatggtggttattggtccctactataggt
tgtgccactttggtcttgaagggactcctgcgtaccacaaattactcctggttattgggatatttattgatgaacaca
aagtcacccaattttatggtgcccactgcttggcgtttggtgaaaagagctggtgattctacatcgaaaatca
ttccttaaaactcttgcgtgcttgggttgcgtgagcgaattgctgctgaagtttgggagtggtactctgaa
aaaaataggtaaaaatgaaatcccattgtagacacactactggcaaacagaatctggttcgcatctggtcaccgcc
tggtggtggtgttacccaatgaaacggggttctgctcattccccctctcggtatgtagcagttggtcttga
ccctaacactggtgaagaacttaacaccagccacgcagaggggtgctctgcccgtcaaagctgcatggccatcatt
gcaagaactatttggaaaaatcatgataggtatctagacactatttgaacccttaccctggctactatttcaactg
gtgatggtgctgcaaaaggataaagatggttatatctggattttgggtcgtgtagacgatggtgaaagctctctgg
tcaccgtctgctaccgctgaaattgaggtgctattatcgaagatccaattgtggccgagtgctggtgtgctgga
ttcaacgatgacttgactggtcaagcagttgctgcatcttgggtgtgaaaaacaaatctagttggtccaccgcaa
cagatgatgaattacaagatataaagaagcatttggcttactggttgaaaaagacatcgggcccatttgcgcgacc
aaaattgatcatttagtgatgacttgcaccaagacaagatccggcaaaattatgagacgtattttaaagaaaatc
ctagcaggagaaagtgaccactagggcagcttctacattgtcaaacctggcatggttagacatctaattgatt
cggtcaagttgtaa

Spt7-217

SEQ ID No: 19

1 MTERIPIKYN QRTNAKALLK LTEKLFNKNF FDLYLTSQQL VVLEYLLSIS SEEDKCLKAWD
61 YFLKGNIALN VEKSFPLTQE EEHGGAVSPA VDTRSDDVSS QTIKDNNTN TNTSISNENH
121 VENEIEDKGD NAIANEDNFV NNESDNVEE DLFKLDLEDL KQOISGTRFI GNLSLKIRYV
181 LWQCAIDYIY CDRNEFGDEN DTEYTLLDVE EKEEEEI GKN EKPQNKEGIS KFAEDEDYDD
241 EDENYDEDEST DVKNVDDPPK NLDSSISSNI EIDDERLVL NISISKETLS KLKTNVVEEI
301 MGNWNKIYHS FEYDKETMIK RLKLEESDKM IEKGGKKRSR SDLEAATDEQ DRENTNDEPD
361 TNQKLPTEPG STFSDTGNKR PKQSNLDTV NLGIENLSLK HLLSSIQQKK SQLGISDYEL
421 KHLIMDVVRN RSKWTSDEI QOEELYEACE KVVLELRNYT EHSTPFLNKV SKREAPNYHQ
481 I IKKMDLNT VLKLLKSPQY DSKQEFVDDI MLWKNCLTY NSDPHFLRG HAIA MQKKS L
541 QLIRMIPNIT IRNRADLEKE IEDMEKDKDY ELDEEEVAG SGRKGLNMGA HMLAKENGV
601 SEKSSKTVK DEAPTNDK L TSVIPEGEKE KDKTASSTVT VHENVNKNEI KENKNEEQD
661 MVEESSKTED SSKDADAANK DTEDGLQDKT AENKEAGENN EEEEEDDDED EDEMDVDSQS
721 YLLEKDDDRD DLEISVWKTV TAKVRAEICL KRTEYFKNGK LNSDSEAF LK NPQMRKRFDQ
781 LFLEYKEQKA LESYRQKIEQ NSIMKNGFGT VLKQEDDDQL QFHNDHSLNG NEAFKQPNP
841 IELDDTRPLQ EYDTSNATPD IVYEGVNTKT LDKMEDASVD RMLQNGINKQ SRFLANKDLG
901 LTPKMNQNT LIQQIRHICH KISLIRMLQS PLSAQNSRSN PNAFLNHHIY NYTIIDDSL D
961 IDPVSQPLPH DYKNNRELIW KFMHKNISKV AMANGFETAH PSAINMLTEI AGDYLSNLIK
1021 TLKLLHHTET LNRGTNVEM L QTTLENGIN RPDDLFSYVE SEFGKTKKL QDIKQKLESF
1081 LRALLRPTLQ ELSERNFEDE SQSFFTGDF A SELTGEDFF

SPT7-217 DNA

SEQ ID No: 20

atgactgaaagaatccaataaagaattatcaaaagaacaaatgccaaagcttacttaaattgactgaaaaacttt
ttaacaagaactttttgactctatttaacctctcagcaattggctgctcttgaaatcctgctgctgatttcaag
tgaagaagacaaactgaaagcatgggactatttcttaagggaaacatagcattaaatgtcgaaaaatcatttcca
ttaacccaagaagaagaacatcacggagcggctctcctctgccgttgacacacgatcagatgatgatcatcacaaa
caataaaggacaataaacaactactaaacacaccagatcagcaatgaaaatcatgtgaaaaatgaaattgaaga
taagggcgttaacgcaatagcaaatgaagataatttggtaataatgacgaaagtgatgattgtgaaagaagctta
ttcaaatagatctagaggacttgaagcagcaataaagcgaacaaggtttattggaaacttactctgaaaaatca
gatacgtcttctggtgagtcggccatagattatataactgtgactgctaatgagtttgggtgataaaatgatagaca
atacaccctattagatggtgaaagagaaggaggaagaggaaattggtaaaatgagaagccacaaaaaaagaaggt
atctcgaagttcgccggagatgaagatcacgacgatgaagacgagaactatgatgaagacagtcacagcgtaaaaa
atgctgagatgactcccaaaaaatctcgattctatttctcttctaaatcagaaaatgacgatgaacgacgcttgg
gctaaatattcctaatatcaaaagaacactgtcaaaagttaaaaacaaatgagtagaagaatattgggaaattgg
aacaaaaattaccacagtttgaatcagataaagaactatgataaagcgtataaaacttgaagaagcgtataaaa
tgatagagaagaagaagaagaacgaagtcgaagtgattagaagcagctaccgatgaacaagatcgcgaaaaatc
aaatgatgagccagatataatcaaaaattgccactcctgaaggttcaacattcagcgtactgggaaacaagcgc
cccaaaaagtaatttagattcaacagctcaatctaggcatcgaataattatcattaaagcacttctatcatctca
tcagcaaaaaaaatccaataggaatcagattacgaattaaaacatctgattatggatgcagaaaaaatcgc
gtcaaaatggacatcggatgaaagaattgggcaagaggaaattacgaagcctgtgaaaggttggtttggaaactt



-continued

Sequence Listing

agaaactacactgagcattctacaccatttctgaataaagtgagcaaaagagaagcccccaattatcatcaaatca
tcaaaaagtccatggacctgaatctgttttaaaaaaactgaaaagcttcaatgactccaaacaagaatttgt
agacgatattatgctaataatggaaaaaatggttgacctataatcagatccttcacatttttgagagggtcatgct
attgctatgcagaagaatctcttcagttgatcgcatgattccaaatcacaatccgaaacagggctgatttag
aaaaggaaatggaagatattgaaaagacaaagactcgaattagatgaggaagaggaaagttgctgggtctggaag
aaaaggattgaatattgggagctcatatggtggccaaagagaatggcaagggtgcagaaaaagatagctctaaacc
gtcaaggatgaagcaccaccatgatgacaaactaactctgtcatccctgagggggaaaaagagaagaataaaa
ctgcttcacactactgtaacgggtacacgaaaaatgtaaatagaacgaaataaaagaaaaatgggaaaaatgaagagca
agataggttgaggaaagttagtaagactgaggattcatcaaaagatgctgatgctgcccanaaggatagcgaagac
ggactacaagataaaaactgcagaaaaataggagggtgggaaaaatgaagagggaagaggatgatgatgacgaag
atgaagcgaagacatggtcgactcccaatcttatttactgaaaaggatgacgatagagacgatttggaatatc
cgtggtgaaaactgtaactgccaagtctgtgcggaatttgcctaaaaagaactgaaatatttaaaaatggaaaa
ttaaatagtgattcagaggcgtttttgaaaaaccacaaaagaatgaaaaggttcgaccagcttttcttgaataa
aagagcagaaaagcttgaatatcatctgtcaaaaaatagagcaaaatccattatgaaaaatggcttggaaactg
actaaaaacaggaagacgatgaccaatgacagttcataatgatcactctttaaataggaatgaagctttgaaaag
caaccaatgatattgagttagatgataccagatccctacaggaatgatgatattgtaacgccattcctgacatag
tatacaggggagtaaatactaaaacattagacaagatggaagacgcttcggtggaccgcatgctcaaaaatggat
caacaaacaaagcagatttctggctaaacaggatttaggactaacacctaaaatgaacaaaaatcacactgatt
cagcaaataggcacatagccataaaaatccctgatcagaatggtacagagcccttatcggtcaaaaactcca
gaagcaatcccaacgcttcccttaaccaaccacattataatcacactatttgatgactcactcgatttgatcc
gggtgacacagcttccaacgcatgatatacaaaaacacagggagctgatattggaattcatgcatagaacatattc
aagggtgctatggccaatgggttgaaactgcccatccatcagcaataaacatgcttactgaaatcgccggggat
acctatctaactcgataaagactttgaaacttcaactcctcatcagaaactaacctttaaataagaggaaacaaatg
gtaaatgctgcaaacactggttgaaaacgggtatcaacaggccagacgatctatttccctatggtgaaatctgaa
taaaactaagaaactcaggaatcaaacagaaactagaaagctttttgagagccttattaggccaactttgc
aggagtgtccgagagaaacttgaagacgagagccaaagctttttacaggtgactttgcccagcgaattgactgg
tgaagacttcttt

Spt3

SEQ ID No: 21

1 MMDKHKYRVE IQQMMFVSGE INDPVETTS LIEDIVRGQV IEILLQSNKT AHLRGRSIL
61 PEDVIFLIRH DKAKVNLRLT YLSWKDLRKN AKDQDASAGV ASGTGNPGAG GEDDLKKGAG
121 GEKDEKDGGN MMKVKSQIK LPWELQPMFN EHPLENDDN DDMEDEREA NIVTLKRLKM
181 ADDRTRNMTK EEYVHWSDCR QASFTFRKNK RPKDWSGISQ LTEGKPHDDV IDILGLTFE
241 IVCSLTETAL KIKQREQVLQ TQKDKSQSS QDNTNFEFAS STLHRKRLF DGPENVINPL
301 KPRHIEEAWR VLQITDMRHR ALTNFKGRL SSKPIIM

Spt3

SEQ ID No: 22

atgatggacaagcataaagtatcgtgtggagattcaacagatgatgtttgtctctgggtgaaataaacgaccaccctgaa
accacatcactgatagaagatagtgaggggtcaagtgatagaatcctttacagtcaaaacaaacgggcatcttagg
ggaagtaggagcattctcctgaagacgctatttcttgatcagacacgacaaggccaaagtcaatcgtttgagaacat
ctgtcatggaaggatttgcgtaaaaacgccaaggaccaagatgctagtgcgggtgtagcagtgccactggaaatcctggg
gcaggtggtgaagatgattgaaaaagcaggtggtggcgagaagacgaaaaagatgggtggaacatgatgaaggtcaag
aaatcccaaatgaagctgccatgggaattgcagtttatgttcaatgaacatcctttgaaaaatgacgcaaatgatgat
atggatgaggatgaacgagaagctcaatatagtcactttgaaaaggctgaaaaatggctgacgatagaacacgaaacatgact
aaagaggagtacgtgcatggtccgatgtgcagagccaagttttacatttaggaagaataaaagggtcaaggactggtct
ggaatttcgcaattaaactgaggggaaaccccatgatgatgtgatgataactgggtttctaaactttgagattgtctgt
tctttgacggaaacagctctgaaatcaaaacaaagagacaggtattacagactcaaaaggcaaaatcccagcaatctagc
caagataaactaactttgaatttgcacatccacattacatagaaagaaaagattatttgatggacctgaaaatggtata
aaccgctcaaaccaaggcatatagaggaagcctggagagtactacaacaattgacatgagcagatagggtttgaccac
ttaaagggtgtagactcagttctaaaccaattatcatgtaa

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 22

<210> SEQ ID NO 1
<211> LENGTH: 824
<212> TYPE: PRT
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 1

Met Met Asn Phe Phe Thr Ser Lys Ser Ser Asn Gln Asp Thr Gly Phe
1 5 10 15
Ser Ser Gln His Gln His Pro Asn Gly Gln Asn Asn Gly Asn Asn Asn
20 25 30
Ser Ser Thr Ala Gly Asn Asp Asn Gly Tyr Pro Cys Lys Leu Val Ser
35 40 45

-continued

---

Ser Gly Pro Cys Ala Ser Ser Asn Asn Gly Ala Leu Phe Thr Asn Phe  
 50 55 60  
 Thr Leu Gln Thr Ala Thr Pro Thr Thr Ala Ile Ser Gln Asp Leu Tyr  
 65 70 75 80  
 Ala Met Gly Thr Thr Gly Ile Thr Ser Glu Asn Ala Leu Phe Gln Met  
 85 90 95  
 Lys Ser Met Asn Asn Gly Ile Ser Ser Val Asn Asn Asn Asn Ser Asn  
 100 105 110  
 Thr Pro Thr Ile Ile Thr Thr Ser Gln Glu Glu Thr Asn Ala Gly Asn  
 115 120 125  
 Val His Gly Asp Thr Gly Gly Asn Ser Leu Gln Asn Ser Glu Asp Asp  
 130 135 140  
 Asn Phe Ser Ser Ser Ser Thr Thr Lys Cys Leu Leu Ser Ser Thr Ser  
 145 150 155 160  
 Ser Leu Ser Ile Asn Gln Arg Glu Ala Ala Ala Ala Tyr Gly Pro  
 165 170 175  
 Asp Thr Asp Ile Pro Arg Gly Lys Leu Glu Val Thr Ile Ile Glu Ala  
 180 185 190  
 Arg Asp Leu Val Thr Arg Ser Lys Asp Ser Gln Pro Tyr Val Val Cys  
 195 200 205  
 Thr Phe Glu Ser Ser Glu Phe Ile Ser Asn Gly Pro Glu Ser Leu Gly  
 210 215 220  
 Ala Ile Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Gln His Asn Gln  
 225 230 235 240  
 Asn Gln His Ile Asn Asn Asn Asn Glu Asn Thr Asn Pro Asp Ala Ala  
 245 250 255  
 Ser Gln His His Asn Asn Asn Ser Gly Trp Asn Gly Ser Gln Leu Pro  
 260 265 270  
 Ser Ile Lys Glu His Leu Lys Lys Lys Pro Leu Tyr Thr His Arg Ser  
 275 280 285  
 Ser Ser Gln Leu Asp Gln Leu Asn Ser Cys Ser Ser Val Thr Asp Pro  
 290 295 300  
 Ser Lys Arg Ser Ser Asn Ser Ser Ser Gly Ser Ser Asn Gly Pro Lys  
 305 310 315 320  
 Asn Asp Ser Ser His Pro Ile Trp His His Lys Thr Thr Phe Asp Val  
 325 330 335  
 Leu Gly Ser His Ser Glu Leu Asp Ile Ser Val Tyr Asp Ala Ala His  
 340 345 350  
 Asp His Met Phe Leu Gly Gln Val Arg Leu Tyr Pro Met Ile His Asn  
 355 360 365  
 Leu Ala His Ala Ser Gln His Gln Trp His Ser Leu Lys Pro Arg Val  
 370 375 380  
 Ile Asp Glu Val Val Ser Gly Asp Ile Leu Ile Lys Trp Thr Tyr Lys  
 385 390 395 400  
 Gln Thr Lys Lys Arg His Tyr Gly Pro Gln Asp Phe Glu Val Leu Arg  
 405 410 415  
 Leu Leu Gly Lys Gly Thr Phe Gly Gln Val Tyr Gln Val Lys Lys Lys  
 420 425 430  
 Asp Thr Gln Arg Ile Tyr Ala Met Lys Val Leu Ser Lys Lys Val Ile  
 435 440 445  
 Val Lys Lys Asn Glu Ile Ala His Thr Ile Gly Glu Arg Asn Ile Leu  
 450 455 460  
 Val Thr Thr Ala Ser Lys Ser Ser Pro Phe Ile Val Gly Leu Lys Phe

-continued

465		470		475		480
Ser Phe Gln Thr	Pro Thr Asp Leu Tyr	Leu Val Thr Asp Tyr Met Ser	485	490	495	
Gly Gly Glu Leu Phe Trp His Leu Gln Lys Glu Gly Arg Phe Ser Glu			500	505	510	
Asp Arg Ala Lys Phe Tyr Ile Ala Glu Leu Val Leu Ala Leu Glu His			515	520	525	
Leu His Asp Asn Asp Ile Val Tyr Arg Asp Leu Lys Pro Glu Asn Ile			530	535	540	
Leu Leu Asp Ala Asn Gly Asn Ile Ala Leu Cys Asp Phe Gly Leu Ser			545	550	555	560
Lys Ala Asp Leu Lys Asp Arg Thr Asn Thr Phe Cys Gly Thr Thr Glu			565	570	575	
Tyr Leu Ala Pro Glu Leu Leu Leu Asp Glu Thr Gly Tyr Thr Lys Met			580	585	590	
Val Asp Phe Trp Ser Leu Gly Val Leu Ile Phe Glu Met Cys Cys Gly			595	600	605	
Trp Ser Pro Phe Phe Ala Glu Asn Asn Gln Lys Met Tyr Gln Lys Ile			610	615	620	
Ala Phe Gly Lys Val Lys Phe Pro Arg Asp Val Leu Ser Gln Glu Gly			625	630	635	640
Arg Ser Phe Val Lys Gly Leu Leu Asn Arg Asn Pro Lys His Arg Leu			645	650	655	
Gly Ala Ile Asp Asp Gly Arg Glu Leu Arg Ala His Pro Phe Phe Ala			660	665	670	
Asp Ile Asp Trp Glu Ala Leu Lys Gln Lys Lys Ile Pro Pro Pro Phe			675	680	685	
Lys Pro His Leu Val Ser Glu Thr Asp Thr Ser Asn Phe Asp Pro Glu			690	695	700	
Phe Thr Thr Ala Ser Thr Ser Tyr Met Asn Lys His Gln Pro Met Met			705	710	715	720
Thr Ala Thr Pro Leu Ser Pro Ala Met Gln Ala Lys Phe Ala Gly Phe			725	730	735	
Thr Phe Val Asp Glu Ser Ala Ile Asp Glu His Val Asn Asn Asn Arg			740	745	750	
Lys Phe Leu Gln Asn Ser Tyr Phe Met Glu Pro Gly Ser Phe Ile Pro			755	760	765	
Gly Asn Pro Asn Leu Pro Pro Asp Glu Asp Val Ile Asp Asp Asp Gly			770	775	780	
Asp Glu Asp Ile Asn Asp Gly Phe Asn Gln Glu Lys Asn Met Asn Asn			785	790	795	800
Ser His Ser Gln Met Asp Phe Asp Gly Asp Gln His Met Asp Asp Glu			805	810	815	
Phe Val Ser Gly Arg Phe Glu Ile			820			

<210> SEQ ID NO 2  
 <211> LENGTH: 2475  
 <212> TYPE: DNA  
 <213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 2

atgatgaatt tttttacatc aaaatcgctcg aatcaggata ctggatttag ctctcaacac	60
caacatccaa atggacagaa caatggaaac aataatagca gcaccgctgg caacgacaac	120

-continued

---

ggatacccat gtaaactggt gtccagtggg cctgcgctt catcaaataa tggtgccctt	180
tttacgaatt ttactttaca aactgcaacg cggaccaccg ctattagtca ggacttatat	240
gcaatgggca caacaggaat aacatcagaa aatgcccttt ttcaaatgaa gtcfaatgaat	300
aatggaatat catcagttaa taataacaac agcaacaccc ctacgattat taccacgtca	360
caggaagaaa ctaatgctgg aaatgtacat ggcgataccg gtggcaattc tttgcaaaat	420
tctgaagatg acaacttttc ttccagtctc accaccaaat gcttactctc ttccacttct	480
tcgctatcaa taaatcaacg agaagcagca gcagctgctt atggtccaga taccgatatt	540
cctaggggta aactagaagt tacaataata gaagcagctg acctagtcaac tagatcaaag	600
gattcacagc cttatgttgt ttgtactttt gagagttcag agttcatttc taatggctct	660
gagtcaactag gcgccattaa taataacaac aataacaaca acaataatca gcataatcaa	720
aaccagcata ttaacaacaa caacgaaaat accaacctcg acgctgctag ccagcatcat	780
aataataaca gtggttgtaa cggttctcag ttaccatcga taaagagca cttgaagaaa	840
aaaccctttt atacacacag atcatcttcc caattagatc agctaaactc ttgctcttca	900
gtaaccgatc cgagcaaacg ttcttctaat tcttcgctgg gttcttcaaa tggctcaaag	960
aatgatagtt cacatccaat atggcatcac aagacaacgt ttgatgtttt gggatctcac	1020
tcggaattag atatttctgt ttatgatgct gcccacgacc atatgttctt aggccaagtt	1080
agactgtatc caatgattca taatttagca catgcttccc aacaccaatg gcacagtttg	1140
aaacctcgcg ttattgatga agttgtgtcc ggtgatattt taatcaaatg gacttacaaa	1200
cagacaaaga aaagacatta tggcccacaa gattttgaag ttcttcgatt attgggtaag	1260
ggtacttttg gccaaagtca ccaagttaag aagaaagaca ctcaagaat ttatgcaatg	1320
aaagtctctc ccaagaaagt tattgtcaag aaaaatgaga tcgcccacac aattggcgaa	1380
agaaatatcc tagtcacgac agcgtccaaa tcgtcccat tcattgtcgg attgaagttt	1440
tcctttcaaa caccaacaga tctgtatttg gtcaactgatt atatgagtgg tggagaatta	1500
ttctggcatt tacaaaagga gggccgtttt tcggaagaca gagcgaatc ctatctcgtc	1560
gagttagtcc tagcgttaga acatttacac gataacgata tcgtttacag ggacctaaag	1620
cctgaaaaca ttctactcga tgccaacggg aacatcgtc tttcggattt tggctttctc	1680
aaagctgact tgaagatag aacaaacaca ttttgcgca ccacggaata cctggcacca	1740
gaattgttac tggacgaaac cggctacacc aaaatggtcg atttctggtc tctagtggtt	1800
ttgatatttg aaatgtgttg tgggtgttcc cctttctttg cggaaaataa tcaaaaaatg	1860
tacaaaaaaa ttgccttttg taaagtcaaa ttccccagag acgtactgtc acaagagggg	1920
aggctctttg taaagggttt actaaacaga aaccccaaac atagactcgg tgccattgat	1980
gatggaagag aactacgagc tcatccattt ttccgagata tcgactggga ggcttgaag	2040
cagaaaaaaaa ttccaccacc tttcaaacct cacctagtct cggagacgga tacctcgaat	2100
tttgaccag agttcacaac agcttcaact tcatacatga acaagcacca gccgatgatg	2160
actgtaccce cgctatctcc agccatgcaa gcaaaagtgt ctggtttcac ctttgttgat	2220
gagtcggcca tcgatgaaca cgttaataac aacagaaaat tcctacaaaa ctctactttt	2280
atggaacctg gttcctttat cccgggaaat ccaaaactac ctccagacga agatgtcatc	2340
gatgatgagc gggacgagga catcaatgat ggattcaacc aagagaaaaa tatgaacaac	2400
agccatctgc agatggactt cgacggcgac caacacatgg atgacgaatt tgcagtgga	2460
agattcgaaa tatga	2475

-continued

---

```

<210> SEQ ID NO 3
<211> LENGTH: 588
<212> TYPE: PRT
<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 3

Met Ser Thr Leu Ser Asp Ser Asp Thr Glu Thr Glu Val Val Ser Arg
1          5          10          15
Asn Leu Cys Gly Ile Val Asp Ile Gly Ser Asn Gly Ile Arg Phe Ser
20          25          30
Ile Ser Ser Lys Ala Ala His His Ala Arg Ile Met Pro Cys Val Phe
35          40          45
Lys Asp Arg Val Gly Leu Ser Leu Tyr Glu Val Gln Tyr Asn Thr His
50          55          60
Thr Asn Ala Lys Cys Pro Ile Pro Arg Asp Ile Ile Lys Glu Val Cys
65          70          75
Ser Ala Met Lys Arg Phe Lys Leu Ile Cys Asp Asp Phe Gly Val Pro
85          90          95
Glu Thr Ser Val Arg Val Ile Ala Thr Glu Ala Thr Arg Asp Ala Ile
100         105         110
Asn Ala Asp Glu Phe Val Asn Ala Val Tyr Gly Ser Thr Gly Trp Lys
115         120         125
Val Glu Ile Leu Gly Gln Glu Asp Glu Thr Arg Val Gly Ile Tyr Gly
130         135         140
Val Val Ser Ser Phe Asn Thr Val Arg Gly Leu Tyr Leu Asp Val Ala
145         150         155
Gly Gly Ser Thr Gln Leu Ser Trp Val Ile Ser Ser His Gly Glu Val
165         170         175
Lys Gln Ser Ser Lys Pro Val Ser Leu Pro Tyr Gly Ala Gly Thr Leu
180         185         190
Leu Arg Arg Met Arg Thr Asp Asp Asn Arg Ala Leu Phe Tyr Glu Ile
195         200         205
Lys Glu Ala Tyr Lys Asp Ala Ile Glu Lys Ile Gly Ile Pro Gln Glu
210         215         220
Met Ile Asp Asp Ala Lys Lys Glu Gly Gly Phe Asp Leu Trp Thr Arg
225         230         235
Gly Gly Gly Leu Arg Gly Met Gly His Leu Leu Tyr Gln Ser Glu
245         250         255
Gly Tyr Pro Ile Gln Thr Ile Ile Asn Gly Tyr Ala Cys Thr Tyr Glu
260         265         270
Glu Phe Ser Ser Met Ser Asp Tyr Leu Phe Leu Lys Gln Lys Ile Pro
275         280         285
Gly Ser Ser Lys Glu His Lys Ile Phe Lys Val Ser Asp Arg Arg Ala
290         295         300
Leu Gln Leu Pro Ala Val Gly Leu Phe Met Ser Ala Val Phe Glu Ala
305         310         315
Ile Pro Gln Ile Lys Ala Val His Phe Ser Glu Gly Gly Val Arg Glu
325         330         335
Gly Ser Leu Tyr Ser Leu Leu Pro Lys Glu Ile Arg Ala Gln Asp Pro
340         345         350
Leu Leu Ile Ala Ser Arg Pro Tyr Ala Pro Leu Leu Thr Glu Lys Tyr
355         360         365
Leu Tyr Leu Leu Arg Thr Ser Ile Pro Gln Glu Asp Ile Pro Glu Ile
370         375         380

```

-continued

---

Val Asn Glu Arg Ile Ala Pro Ala Leu Cys Asn Leu Ala Phe Val His  
385 390 395 400

Ala Ser Tyr Pro Lys Glu Leu Gln Pro Thr Ala Ala Leu His Val Ala  
405 410 415

Thr Arg Gly Ile Ile Ala Gly Cys His Gly Leu Ser His Arg Ala Arg  
420 425 430

Ala Leu Ile Gly Ile Ala Leu Cys Ser Arg Trp Gly Gly Asn Ile Pro  
435 440 445

Glu Ser Glu Glu Lys Tyr Ser Gln Glu Leu Glu Gln Val Val Leu Arg  
450 455 460

Glu Gly Asp Lys Ala Glu Ala Leu Arg Ile Val Trp Trp Thr Lys Tyr  
465 470 475 480

Ile Gly Thr Ile Met Tyr Val Ile Cys Gly Val His Pro Gly Gly Asn  
485 490 495

Ile Arg Asp Asn Val Phe Asp Phe His Val Ser Lys Arg Ser Glu Val  
500 505 510

Glu Thr Ser Leu Lys Glu Leu Ile Ile Asp Asp Ala Asn Thr Thr Lys  
515 520 525

Val Lys Glu Glu Ser Thr Arg Lys Asn Arg Gly Tyr Glu Val Val Val  
530 535 540

Arg Ile Ser Lys Asp Asp Leu Lys Thr Ser Ala Ser Val Arg Ser Arg  
545 550 555 560

Ile Ile Thr Leu Gln Lys Lys Val Arg Lys Leu Ser Arg Gly Ser Val  
565 570 575

Glu Arg Val Lys Ile Gly Val Gln Phe Tyr Glu Glu  
580 585

&lt;210&gt; SEQ ID NO 4

&lt;211&gt; LENGTH: 1767

&lt;212&gt; TYPE: DNA

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 4

```

atgtcaacac ttagcgatag tgataccgag actgaggtcg tgtcgagaaa cttgtgtgga    60
atcgtcgaca taggttctaa tggatttcgt tttagtatat cttccaaggc tgcacatcat    120
gcaagaatta tgccctgtgt ttttaaagat agggttggtc tttctctata cgaagttaa    180
tataatacac atacgaacgc aaaatgcctt attcccagag atattataaa agaggtttgt    240
tctgccatga agagattcaa attaatattg gatgattttg gtgtacctga aactagtgtc    300
agagtaattg caacagaagc cacgcgagat gctattaacg cggatgaatt tgttaatgct    360
gtttacggta gcactggctg gaaagtagaa atattaggcc aggaagatga aactagggtc    420
ggcatatatg gtgtgttttc ctcatttaat acagtaagag gtctatatct agatgtggca    480
gggtgtagta ctcagttatc atgggtaata agctcgcacg gagaagtcaa gcaatccagc    540
aaacctgtat ctttgccata tggagctgga actcttttga gaagaatgag aacagatgat    600
aatagggcac tttttatgta gattaaagaa gcgtacaaag atgcgattga aaaaattggt    660
atacctcaag aatgattgta tgacgccaag aaagaagggt gatttgacct ttggaccctg    720
gggggtggtt taagaggatg gggacatctg cttctttacc agtcggaagg ttatcccatc    780
caacaataa ttaacggata tgcttgacct tatgaagaat tctcgtctat gtcagattat    840
ctattcctaa aacaaaaaat accaggttct tcaaaagagc ataaaatatt taaggtttct    900
gatagaaggg ctttacaact tcctgccgtt ggtttgttca tgagtgtgtg ttttgaagcg    960
attcccaga tcaaaagtgt acattttagt gaggtgtgtg ttcgagaggg ttcactttat   1020

```

-continued

```

tctcttcttc caaaagaaat tcgtgcacaa gatccattgc taattgcgtc ccgctcttat 1080
gctccattac ttactgaaaa atatctatat ctattgagaa catcaatccc acaagaagat 1140
ataccagaaa tagtaaacga aaggattgct cctgctttat gtaacttagc atttggtcat 1200
gcctcttate caaaggagtt acaaccaaca gctgcattac atgttgctac aagagggata 1260
atagccggct gtcattgatt atctcacaga gctagagcgc tgataggaat tgctctatgt 1320
agtagatggg gcggcaacat tccggaatct gaagaaaaat actccaaga attagaacaa 1380
gtagttctac gcgaagtga taaagctgaa gcattgagaa ttgtatggtg gacgaagtat 1440
attggtacga ttatgtatgt gatttgccgt gttcatccag gtggaatat cagagataac 1500
gtatttgatt tccatgttct taagcgtagt gaggtggaga ccagttttaa agaattaatc 1560
attgatgatg caaacactac aaaggtaaaa gaagaatcca cgcgtaaaaa tcgcggttat 1620
gaagtgggtg tgagaattag taaggacgat cttaaaacaa gtgcttccgt tcgttccaga 1680
attatcacgc tacaagaaga agtacgcaag ctatctagag gaagtgtaga gagggttaaa 1740
attggcgtgc aattttatga agaataa 1767

```

&lt;210&gt; SEQ ID NO 5

&lt;211&gt; LENGTH: 439

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 5

```

Met Val Thr Lys His Gln Ile Glu Glu Asp His Leu Asp Gly Ala Thr
1           5           10          15
Thr Asp Pro Glu Val Lys Arg Val Lys Leu Glu Asn Asn Val Glu Glu
20          25          30
Ile Gln Pro Glu Gln Ala Glu Thr Asn Lys Gln Glu Gly Thr Asp Lys
35          40          45
Glu Asn Lys Gly Lys Phe Glu Lys Glu Thr Glu Arg Ile Gly Gly Ser
50          55          60
Glu Val Val Thr Asp Val Glu Lys Gly Ile Val Lys Phe Glu Phe Asp
65          70          75          80
Gly Val Glu Tyr Thr Phe Lys Glu Arg Pro Ser Val Val Glu Glu Asn
85          90          95
Glu Gly Lys Ile Glu Phe Arg Val Val Asn Asn Asp Asn Thr Lys Glu
100         105         110
Asn Met Met Val Leu Thr Gly Leu Lys Asn Ile Phe Gln Lys Gln Leu
115         120         125
Pro Lys Met Pro Lys Glu Tyr Ile Ala Arg Leu Val Tyr Asp Arg Ser
130         135         140
His Leu Ser Met Ala Val Ile Arg Lys Pro Leu Thr Val Val Gly Gly
145         150         155         160
Ile Thr Tyr Arg Pro Phe Asp Lys Arg Glu Phe Ala Glu Ile Val Phe
165         170         175
Cys Ala Ile Ser Ser Thr Glu Gln Val Arg Gly Tyr Gly Ala His Leu
180         185         190
Met Asn His Leu Lys Asp Tyr Val Arg Asn Thr Ser Asn Ile Lys Tyr
195         200         205
Phe Leu Thr Tyr Ala Asp Asn Tyr Ala Ile Gly Tyr Phe Lys Lys Gln
210         215         220
Gly Phe Thr Lys Glu Ile Thr Leu Asp Lys Ser Ile Trp Met Gly Tyr
225         230         235         240

```

-continued

Ile Lys Asp Tyr Glu Gly Gly Thr Leu Met Gln Cys Ser Met Leu Pro  
 245 250 255

Arg Ile Arg Tyr Leu Asp Ala Gly Lys Ile Leu Leu Leu Gln Glu Ala  
 260 265 270

Ala Leu Arg Arg Lys Ile Arg Thr Ile Ser Lys Ser His Ile Val Arg  
 275 280 285

Pro Gly Leu Glu Gln Phe Lys Asp Leu Asn Asn Ile Lys Pro Ile Asp  
 290 295 300

Pro Met Thr Ile Pro Gly Leu Lys Glu Ala Gly Trp Thr Pro Glu Met  
 305 310 315 320

Asp Ala Leu Ala Gln Arg Pro Lys Arg Gly Pro His Asp Ala Ala Ile  
 325 330 335

Gln Asn Ile Leu Thr Glu Leu Gln Asn His Ala Ala Ala Trp Pro Phe  
 340 345 350

Leu Gln Pro Val Asn Lys Glu Glu Val Pro Asp Tyr Tyr Asp Phe Ile  
 355 360 365

Lys Glu Pro Met Asp Leu Ser Thr Met Glu Ile Lys Leu Glu Ser Asn  
 370 375 380

Lys Tyr Gln Lys Met Glu Asp Phe Ile Tyr Asp Ala Arg Leu Val Phe  
 385 390 395 400

Asn Asn Cys Arg Met Tyr Asn Gly Glu Asn Thr Ser Tyr Tyr Lys Tyr  
 405 410 415

Ala Asn Arg Leu Glu Lys Phe Phe Asn Asn Lys Val Lys Glu Ile Pro  
 420 425 430

Glu Tyr Ser His Leu Ile Asp  
 435

<210> SEQ ID NO 6  
 <211> LENGTH: 2128  
 <212> TYPE: DNA  
 <213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE: 6

tcttaaacac ttatgggagc caaaaaatgc gtctttcttc cctcgtctgt tgttttatgt 60  
 agggcgtaat gatgtttgct tgtcaacaaa tgaatcagta cagaagagaa ttctagccaa 120  
 ggcaattatt gcatactgca agtactgagt acgttaacgt tgctagaata acattaaatg 180  
 agatgtagca atgcagatcc ttcctcagta ggcttaatgc tccactagaa tttttgacca 240  
 gccactatct gctttttctc caatcctttt caatactcga gagcaaagac aaaaaaata 300  
 agacatgtag tgcgctgtat ggaaaagaat taattagaac tttacaaacg cgtgttaaac 360  
 aggcataatc aagtgtttgg acctaaacaa tatatcgact attgaaattc ttacgcaaga 420  
 ttttttatag ttggatattc atatatctct acaactctct ctactttcag ttttttgaag 480  
 ctatatgtat cattatatac gtttatggat ttttcaaacc taaacaatta tactgcgtaa 540  
 atgtttgatt aagcaataaa taaaaacaaa ggattggtaa gggagaccg tgagccgccc 600  
 aaaagtcttc agttaactca ggttcgtatt ctacattaga tggtcacaaa acatcagatt 660  
 gaagaggatc acttggatgg agctacgacg gatcccgaag ttaaacgggt aaaattagaa 720  
 aacaacgctg aagaaataca acctgagcag gctgagacca ataaacaaga gggcaccgat 780  
 aaagagaata aaggaaagt cagaaaagaa actgagagaa taggagatc tgaagtgggt 840  
 acagatgtag aaaaaggaat tgtcaaatc gaatttgatg gtgttgaata cacattcaaa 900  
 gagagacca gtgtcgtaga ggaaaatgaa ggtaaaattg agtttagggt ggtgaataat 960  
 gataatacta aagaaacat gatggtccta actggattaa aaaacatctt tcaaaaagca 1020



-continued

```

ttacaaaaa tgcccaaaga atacattgcc aggttagtct atgatcgaag tcatctttcc 1080
atggctgtca ttaggaagcc attgactgtc gtaggtggca taacatatcg accttcgat 1140
aagagagaat tcgcagaaat tgttttctgt gccatcagtt cgacggaaca ggtacgcggt 1200
tatggtgcgc atctaataaa tcaactaaaa gactatgtta gaaatacctc gaacataaaa 1260
tattttttga catatgcaga taattacgct attggatact ttaaaaagca aggcttcact 1320
aaagaaatca cgttgataaa aagtatatgg atgggatata ttaagatta tgaaggtggt 1380
acgctgatgc aatgttctat gttaccaaga atacgatatt tggacgcagg taagattcta 1440
ttattacaag aagcggccct gcgaagaaaa ataagaacga tttcgaaatc gcatattgta 1500
aggcctggtt tagagcaatt caaagactta aacaatatca aaccgattga tccaatgact 1560
attcctggct tgaagaagc cggctggact cccgagatgg atgcgctggc acaacgtccc 1620
aagcgtggtc cacacgatgc agcaatacag aatatactca cagagctaca aaatcatgca 1680
gcagcttggc cttcttaca acccgtaat aaagaggagg tccccgacta ttatgatttt 1740
atcaaagagc caatggactt gagcaccatg gaaataaaat tagagagcaa caaatatcag 1800
aagatggaag acttcatata tgatgccaga ttggtgttta acaattgccg aatgtacaat 1860
ggcgagaata cgctgtatta caagtatgct aataggctag agaaattctt caataataaa 1920
gtaaagaaa tactgaata ttctcacctt attgattaat gcgtagaaga agcttttccg 1980
ctactattcc tttcgaagaa gaaataaatg tttagtacgg cgagacgatg tgatcaattg 2040
aggttatttt actacttttc ctttcatttt tgtaaggttt tctttctttg ttagtgtgac 2100
gttggtattt acctttatgt aactatat 2128

```

&lt;210&gt; SEQ ID NO 7

&lt;211&gt; LENGTH: 2470

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 7

```

Met Glu Pro His Glu Glu Gln Ile Trp Lys Ser Lys Leu Leu Lys Ala
1          5          10          15
Ala Asn Asn Asp Met Asp Met Asp Arg Asn Val Pro Leu Ala Pro Asn
20          25          30
Leu Asn Val Asn Met Asn Met Lys Met Asn Ala Ser Arg Asn Gly Asp
35          40          45
Glu Phe Gly Leu Thr Ser Ser Arg Phe Asp Gly Val Val Ile Gly Ser
50          55          60
Asn Gly Asp Val Asn Phe Lys Pro Ile Leu Glu Lys Ile Phe Arg Glu
65          70          75          80
Leu Thr Ser Asp Tyr Lys Glu Glu Arg Lys Leu Ala Ser Ile Ser Leu
85          90          95
Phe Asp Leu Leu Val Ser Leu Glu His Glu Leu Ser Ile Glu Glu Phe
100         105         110
Gln Ala Val Ser Asn Asp Ile Asn Asn Lys Ile Leu Glu Leu Val His
115         120         125
Thr Lys Lys Thr Ser Thr Arg Val Gly Ala Val Leu Ser Ile Asp Thr
130         135         140
Leu Ile Ser Phe Tyr Ala Tyr Thr Glu Arg Leu Pro Asn Glu Thr Ser
145         150         155         160
Arg Leu Ala Gly Tyr Leu Arg Gly Leu Ile Pro Ser Asn Asp Val Glu
165         170         175

```

-continued

---

Val Met Arg	Leu Ala Ala	Lys Thr	Leu Gly Lys	Leu Ala Val	Pro Gly		
	180		185		190		
Gly Thr Tyr	Thr Ser Asp	Phe Val	Glu Phe Glu	Ile Lys Ser	Cys Leu		
	195		200		205		
Glu Trp Leu	Thr Ala Ser	Thr Glu	Lys Asn Ser	Phe Ser Ser	Ser Lys		
	210		215		220		
Pro Asp His	Ala Lys His	Arg Ala	Leu Leu Ile	Ile Thr Ala	Leu Ala		
225		230		235			240
Glu Asn Cys	Pro Tyr Leu	Leu Tyr	Gln Tyr Leu	Asn Ser Ile	Leu Asp		
	245		250		255		
Asn Ile Trp	Arg Ala Leu	Arg Asp	Pro His Leu	Val Ile Arg	Ile Asp		
	260		265		270		
Ala Ser Ile	Thr Leu Ala	Lys Cys	Leu Ser Thr	Leu Arg Asn	Arg Asp		
	275		280		285		
Pro Gln Leu	Thr Ser Gln	Trp Val	Gln Arg Leu	Ala Thr Ser	Cys Glu		
	290		295		300		
Tyr Gly Phe	Gln Val Asn	Thr Leu	Glu Cys Ile	His Ala Ser	Leu Leu		
305		310		315			320
Val Tyr Lys	Glu Ile Leu	Phe Leu	Lys Asp Pro	Phe Leu Asn	Gln Val		
	325		330		335		
Phe Asp Gln	Met Cys Leu	Asn Cys	Ile Ala Tyr	Glu Asn His	Lys Ala		
	340		345		350		
Lys Met Ile	Arg Glu Lys	Ile Tyr	Gln Ile Val	Pro Leu Leu	Ala Ser		
	355		360		365		
Phe Asn Pro	Gln Leu Phe	Ala Gly	Lys Tyr Leu	His Gln Ile	Met Asp		
	370		375		380		
Asn Tyr Leu	Glu Ile Leu	Thr Asn	Ala Pro Ala	Lys Lys Ile	Pro His		
385		390		395			400
Leu Lys Asp	Asp Lys Pro	Gln Ile	Leu Ile Ser	Ile Gly Asp	Ile Ala		
	405		410		415		
Tyr Glu Val	Gly Pro Asp	Ile Ala	Pro Tyr Val	Lys Gln Ile	Leu Asp		
	420		425		430		
Tyr Ile Glu	His Asp Leu	Gln Thr	Lys Phe Lys	Phe Arg Lys	Lys Phe		
	435		440		445		
Glu Asn Glu	Ile Phe Tyr	Cys Ile	Gly Arg Leu	Ala Val Pro	Leu Gly		
	450		455		460		
Pro Val Leu	Gly Lys Leu	Leu Asn	Arg Asn Ile	Leu Asp Leu	Met Phe		
465		470		475			480
Lys Cys Pro	Leu Ser Asp	Tyr Met	Gln Glu Thr	Phe Gln Ile	Leu Thr		
	485		490		495		
Glu Arg Ile	Pro Ser Leu	Gly Pro	Lys Ile Asn	Asp Glu Leu	Leu Asn		
	500		505		510		
Leu Val Cys	Ser Thr Leu	Ser Gly	Thr Pro Phe	Ile Gln Pro	Gly Ser		
	515		520		525		
Pro Met Glu	Ile Pro Ser	Phe Ser	Arg Glu Arg	Ala Arg Glu	Trp Arg		
	530		535		540		
Asn Lys Ser	Ile Leu Gln	Lys Thr	Gly Glu Ser	Asn Asp Asp	Asn Asn		
545		550		555			560
Asp Ile Lys	Ile Ile Ile	Gln Ala	Phe Arg Met	Leu Lys Asn	Ile Lys		
	565		570		575		
Ser Arg Phe	Ser Leu Val	Glu Phe	Val Arg Ile	Val Ala Leu	Ser Tyr		
	580		585		590		
Ile Glu His	Thr Asp Pro	Arg Val	Arg Lys Leu	Ala Ala Leu	Thr Ser		
	595		600		605		

-continued

---

Cys Glu Ile Tyr Val Lys Asp Asn Ile Cys Lys Gln Thr Ser Leu His  
 610 615 620  
 Ser Leu Asn Thr Val Ser Glu Val Leu Ser Lys Leu Leu Ala Ile Thr  
 625 630 635 640  
 Ile Ala Asp Pro Leu Gln Asp Ile Arg Leu Glu Val Leu Lys Asn Leu  
 645 650 655  
 Asn Pro Cys Phe Asp Pro Gln Leu Ala Gln Pro Asp Asn Leu Arg Leu  
 660 665 670  
 Leu Phe Ile Ala Leu His Asp Glu Ser Phe Asn Ile Gln Ser Val Ala  
 675 680 685  
 Met Glu Leu Val Gly Arg Leu Ser Ser Val Asn Pro Ala Tyr Val Ile  
 690 695 700  
 Pro Ser Ile Arg Lys Ile Leu Leu Glu Leu Leu Thr Lys Leu Lys Phe  
 705 710 715 720  
 Ser Thr Ser Ser Arg Glu Lys Glu Glu Thr Ala Ser Leu Leu Cys Thr  
 725 730 735  
 Leu Ile Arg Ser Ser Lys Asp Val Ala Lys Pro Tyr Ile Glu Pro Leu  
 740 745 750  
 Leu Asn Val Leu Leu Pro Lys Phe Gln Asp Thr Ser Ser Thr Val Ala  
 755 760 765  
 Ser Thr Ala Leu Arg Thr Ile Gly Glu Leu Ser Val Val Gly Gly Glu  
 770 775 780  
 Asp Met Lys Ile Tyr Leu Lys Asp Leu Phe Pro Leu Ile Ile Lys Thr  
 785 790 795 800  
 Phe Gln Asp Gln Ser Asn Ser Phe Lys Arg Glu Ala Ala Leu Lys Ala  
 805 810 815  
 Leu Gly Gln Leu Ala Ala Ser Ser Gly Tyr Val Ile Asp Pro Leu Leu  
 820 825 830  
 Asp Tyr Pro Glu Leu Leu Gly Ile Leu Val Asn Ile Leu Lys Thr Glu  
 835 840 845  
 Asn Ser Gln Asn Ile Arg Arg Gln Thr Val Thr Leu Ile Gly Ile Leu  
 850 855 860  
 Gly Ala Ile Asp Pro Tyr Arg Gln Lys Glu Arg Glu Val Thr Ser Thr  
 865 870 875 880  
 Thr Asp Ile Ser Thr Glu Gln Asn Ala Pro Pro Ile Asp Ile Ala Leu  
 885 890 895  
 Leu Met Gln Gly Met Ser Pro Ser Asn Asp Glu Tyr Tyr Thr Thr Val  
 900 905 910  
 Val Ile His Cys Leu Leu Lys Ile Leu Lys Asp Pro Ser Leu Ser Ser  
 915 920 925  
 Tyr His Thr Ala Val Ile Gln Ala Ile Met His Ile Phe Gln Thr Leu  
 930 935 940  
 Gly Leu Lys Cys Val Ser Phe Leu Asp Gln Ile Ile Pro Thr Ile Leu  
 945 950 955 960  
 Asp Val Met Arg Thr Cys Ser Gln Ser Leu Leu Glu Phe Tyr Phe Gln  
 965 970 975  
 Gln Leu Cys Ser Leu Ile Ile Ile Val Arg Gln His Ile Arg Pro His  
 980 985 990  
 Val Asp Ser Ile Phe Gln Ala Ile Lys Asp Phe Ser Ser Val Ala Lys  
 995 1000 1005  
 Leu Gln Ile Thr Leu Val Ser Val Ile Glu Ala Ile Ser Lys Ala  
 1010 1015 1020  
 Leu Glu Gly Glu Phe Lys Arg Leu Val Pro Leu Thr Leu Thr Leu

-continued

1025	1030	1035
Phe Leu Val Ile Leu Glu Asn Asp Lys Ser Ser Asp Lys Val Leu 1040	1045	1050
Ser Arg Arg Val Leu Arg Leu Leu Glu Ser Phe Gly Pro Asn Leu 1055	1060	1065
Glu Gly Tyr Ser His Leu Ile Thr Pro Lys Ile Val Gln Met Ala 1070	1075	1080
Glu Phe Thr Ser Gly Asn Leu Gln Arg Ser Ala Ile Ile Thr Ile 1085	1090	1095
Gly Lys Leu Ala Lys Asp Val Asp Leu Phe Glu Met Ser Ser Arg 1100	1105	1110
Ile Val His Ser Leu Leu Arg Val Leu Ser Ser Thr Thr Ser Asp 1115	1120	1125
Glu Leu Ser Lys Val Ile Met Asn Thr Leu Ser Leu Leu Leu Ile 1130	1135	1140
Gln Met Gly Thr Ser Phe Ala Ile Phe Ile Pro Val Ile Asn Glu 1145	1150	1155
Val Leu Met Lys Lys His Ile Gln His Thr Ile Tyr Asp Asp Leu 1160	1165	1170
Thr Asn Arg Ile Leu Asn Asn Asp Val Leu Pro Thr Lys Ile Leu 1175	1180	1185
Glu Ala Asn Thr Thr Asp Tyr Lys Pro Ala Glu Gln Met Glu Ala 1190	1195	1200
Ala Asp Ala Gly Val Ala Lys Leu Pro Ile Asn Gln Ser Val Leu 1205	1210	1215
Lys Ser Ala Trp Asn Ser Ser Gln Gln Arg Thr Lys Glu Asp Trp 1220	1225	1230
Gln Glu Trp Ser Lys Arg Leu Ser Ile Gln Leu Leu Lys Glu Ser 1235	1240	1245
Pro Ser His Ala Leu Arg Ala Cys Ser Asn Leu Ala Ser Met Tyr 1250	1255	1260
Tyr Pro Leu Ala Lys Glu Leu Phe Asn Thr Ala Phe Ala Cys Val 1265	1270	1275
Trp Thr Glu Leu Tyr Ser Gln Tyr Gln Glu Asp Leu Ile Glu Ser 1280	1285	1290
Leu Cys Ile Ala Leu Ser Ser Pro Leu Asn Pro Pro Glu Ile His 1295	1300	1305
Gln Thr Leu Leu Asn Leu Val Glu Phe Met Glu His Asp Asp Lys 1310	1315	1320
Ala Leu Pro Ile Pro Thr Gln Ser Leu Gly Glu Tyr Ala Glu Arg 1325	1330	1335
Cys His Ala Tyr Ala Lys Ala Leu His Tyr Lys Glu Ile Lys Phe 1340	1345	1350
Ile Lys Glu Pro Glu Asn Ser Thr Ile Glu Ser Leu Ile Ser Ile 1355	1360	1365
Asn Asn Gln Leu Asn Gln Thr Asp Ala Ala Ile Gly Ile Leu Lys 1370	1375	1380
His Ala Gln Gln His His Ser Leu Gln Leu Lys Glu Thr Trp Phe 1385	1390	1395
Glu Lys Leu Glu Arg Trp Glu Asp Ala Leu His Ala Tyr Asn Glu 1400	1405	1410
Arg Glu Lys Ala Gly Asp Thr Ser Val Ser Val Thr Leu Gly Lys 1415	1420	1425

-continued

---

Met Arg	Ser Leu His Ala Leu	Ala Glu Trp Glu Gln	Leu Ser Gln
1430	1435	1440	
Leu Ala	Ala Arg Lys Trp Lys	Val Ser Lys Leu Gln	Thr Lys Lys
1445	1450	1455	
Leu Ile	Ala Pro Leu Ala Ala	Gly Ala Arg Gly Gly	Ser Gly Glu
1460	1465	1470	
Trp Asp	Met Leu Asp Glu Tyr	Ile Ser Val Met Lys	Pro Lys Ser
1475	1480	1485	
Pro Asp	Lys Glu Phe Phe Asp	Ala Ile Leu Tyr Leu	His Lys Asn
1490	1495	1500	
Asp Tyr	Asp Asn Ala Ser Lys	His Ile Leu Asn Ala	Arg Asp Leu
1505	1510	1515	
Leu Val	Thr Glu Ile Ser Ala	Leu Ile Asn Glu Ser	Tyr Asn Arg
1520	1525	1530	
Ala Tyr	Ser Val Ile Val Arg	Thr Gln Ile Ile Thr	Glu Phe Glu
1535	1540	1545	
Glu Ile	Ile Lys Tyr Lys Gln	Leu Pro Pro Asn Ser	Glu Lys Lys
1550	1555	1560	
Leu His	Tyr Gln Asn Leu Trp	Thr Lys Arg Leu Leu	Gly Cys Gln
1565	1570	1575	
Lys Asn	Val Asp Leu Trp Gln	Arg Val Leu Arg Ile	Arg Ser Leu
1580	1585	1590	
Val Ile	Lys Pro Lys Gln Asp	Leu Gln Ile Trp Ile	Lys Phe Ala
1595	1600	1605	
Asn Leu	Cys Arg Lys Ser Gly	Arg Met Arg Leu Ala	Asn Lys Ala
1610	1615	1620	
Leu Asn	Met Leu Leu Glu Gly	Gly Thr Ile Leu Val	Tyr Gln Ile
1625	1630	1635	
Arg Ser	Lys Pro Pro Pro Pro	Val Val Tyr Ala Gln	Leu Lys Tyr
1640	1645	1650	
Ile Trp	Ala Thr Gly Ala Tyr	Lys Glu Ala Leu Asn	His Leu Ile
1655	1660	1665	
Gly Phe	Thr Ser Arg Leu Ala	His Asp Leu Gly Leu	Asp Pro Asn
1670	1675	1680	
Asn Met	Ile Ala Gln Ser Val	Lys Leu Ser Ser Ala	Ser Thr Ala
1685	1690	1695	
Pro Tyr	Val Glu Glu Tyr Thr	Lys Leu Leu Ala Arg	Cys Phe Leu
1700	1705	1710	
Lys Gln	Gly Glu Trp Arg Ile	Ala Thr Gln Pro Asn	Trp Arg Asn
1715	1720	1725	
Thr Asn	Pro Asp Ala Ile Leu	Gly Ser Tyr Leu Leu	Ala Thr His
1730	1735	1740	
Phe Asp	Lys Asn Trp Tyr Lys	Ala Trp His Asn Trp	Ala Leu Ala
1745	1750	1755	
Asn Phe	Glu Val Ile Ser Met	Val Gln Glu Glu Thr	Lys Leu Asn
1760	1765	1770	
Gly Gly	Lys Asn Asp Asp Asp	Asp Asp Thr Ala Val	Asn Asn Asp
1775	1780	1785	
Asn Val	Arg Ile Asp Gly Ser	Ile Leu Gly Ser Gly	Ser Leu Thr
1790	1795	1800	
Ile Asn	Gly Asn Arg Tyr Pro	Leu Glu Leu Ile Gln	Arg His Val
1805	1810	1815	
Val Pro	Ala Ile Lys Gly Phe	Phe His Ser Ile Ser	Leu Leu Glu
1820	1825	1830	

-continued

---

Thr	Ser	Cys	Leu	Gln	Asp	Thr	Leu	Arg	Leu	Ser	Thr	Leu	Leu	Phe
1835						1840					1845			
Asn	Phe	Gly	Gly	Ile	Lys	Glu	Val	Ser	Gln	Ala	Met	Tyr	Glu	Gly
1850						1855					1860			
Phe	Asn	Leu	Met	Lys	Ile	Glu	Asn	Trp	Leu	Glu	Val	Leu	Pro	Gln
1865						1870					1875			
Leu	Ile	Ser	Arg	Ile	His	Gln	Pro	Asp	Pro	Thr	Val	Ser	Asn	Ser
1880						1885					1890			
Leu	Leu	Ser	Leu	Leu	Ser	Asp	Leu	Gly	Lys	Ala	His	Pro	Gln	Ala
1895						1900					1905			
Leu	Val	Tyr	Pro	Leu	Thr	Val	Ala	Ile	Lys	Ser	Glu	Ser	Val	Ser
1910						1915					1920			
Arg	Gln	Lys	Ala	Ala	Leu	Ser	Ile	Ile	Glu	Lys	Ile	Arg	Ile	His
1925						1930					1935			
Ser	Pro	Val	Leu	Val	Asn	Gln	Ala	Glu	Leu	Val	Ser	His	Glu	Leu
1940						1945					1950			
Ile	Arg	Val	Ala	Val	Leu	Trp	His	Glu	Leu	Trp	Tyr	Glu	Gly	Leu
1955						1960					1965			
Glu	Asp	Ala	Ser	Arg	Gln	Phe	Phe	Val	Glu	His	Asn	Ile	Glu	Lys
1970						1975					1980			
Met	Phe	Ser	Thr	Leu	Glu	Pro	Leu	His	Lys	His	Leu	Gly	Asn	Glu
1985						1990					1995			
Pro	Gln	Thr	Leu	Ser	Glu	Val	Ser	Phe	Gln	Lys	Ser	Phe	Gly	Arg
2000						2005					2010			
Asp	Leu	Asn	Asp	Ala	Tyr	Glu	Trp	Leu	Asn	Asn	Tyr	Lys	Lys	Ser
2015						2020					2025			
Lys	Asp	Ile	Asn	Asn	Leu	Asn	Gln	Ala	Trp	Asp	Ile	Tyr	Tyr	Asn
2030						2035					2040			
Val	Phe	Arg	Lys	Ile	Thr	Arg	Gln	Ile	Pro	Gln	Leu	Gln	Thr	Leu
2045						2050					2055			
Asp	Leu	Gln	His	Val	Ser	Pro	Gln	Leu	Leu	Ala	Thr	His	Asp	Leu
2060						2065					2070			
Glu	Leu	Ala	Val	Pro	Gly	Thr	Tyr	Phe	Pro	Gly	Lys	Pro	Thr	Ile
2075						2080					2085			
Arg	Ile	Ala	Lys	Phe	Glu	Pro	Leu	Phe	Ser	Val	Ile	Ser	Ser	Lys
2090						2095					2100			
Gln	Arg	Pro	Arg	Lys	Phe	Ser	Ile	Lys	Gly	Ser	Asp	Gly	Lys	Asp
2105						2110					2115			
Tyr	Lys	Tyr	Val	Leu	Lys	Gly	His	Glu	Asp	Ile	Arg	Gln	Asp	Ser
2120						2125					2130			
Leu	Val	Met	Gln	Leu	Phe	Gly	Leu	Val	Asn	Thr	Leu	Leu	Lys	Asn
2135						2140					2145			
Asp	Ser	Glu	Cys	Phe	Lys	Arg	His	Leu	Asp	Ile	Gln	Gln	Tyr	Pro
2150						2155					2160			
Ala	Ile	Pro	Leu	Ser	Pro	Lys	Ser	Gly	Leu	Leu	Gly	Trp	Val	Pro
2165						2170					2175			
Asn	Ser	Asp	Thr	Phe	His	Val	Leu	Ile	Arg	Glu	His	Arg	Asp	Ala
2180						2185					2190			
Lys	Lys	Ile	Pro	Leu	Asn	Ile	Glu	His	Trp	Val	Met	Leu	Gln	Met
2195						2200					2205			
Ala	Pro	Asp	Tyr	Glu	Asn	Leu	Thr	Leu	Leu	Gln	Lys	Ile	Glu	Val
2210						2215					2220			
Phe	Thr	Tyr	Ala	Leu	Asp	Asn	Thr	Lys	Gly	Gln	Asp	Leu	Tyr	Lys

-continued

2225	2230	2235
Ile Leu Trp Leu Lys Ser Arg Ser Ser Glu Thr Trp Leu Glu Arg 2240 2245 2250		
Arg Thr Thr Tyr Thr Arg Ser Leu Ala Val Met Ser Met Thr Gly 2255 2260 2265		
Tyr Ile Leu Gly Leu Gly Asp Arg His Pro Ser Asn Leu Met Leu 2270 2275 2280		
Asp Arg Ile Thr Gly Lys Val Ile His Ile Asp Phe Gly Asp Cys 2285 2290 2295		
Phe Glu Ala Ala Ile Leu Arg Glu Lys Tyr Pro Glu Lys Val Pro 2300 2305 2310		
Phe Arg Leu Thr Arg Met Leu Thr Tyr Ala Met Glu Val Ser Gly 2315 2320 2325		
Ile Glu Gly Ser Phe Arg Ile Thr Cys Glu Asn Val Met Arg Val 2330 2335 2340		
Leu Arg Asp Asn Lys Glu Ser Leu Met Ala Ile Leu Glu Ala Phe 2345 2350 2355		
Ala Leu Asp Pro Leu Ile His Trp Gly Phe Asp Leu Pro Pro Gln 2360 2365 2370		
Lys Leu Thr Glu Gln Thr Gly Ile Pro Leu Pro Leu Ile Asn Pro 2375 2380 2385		
Ser Glu Leu Leu Arg Lys Gly Ala Ile Thr Val Glu Glu Ala Ala 2390 2395 2400		
Asn Met Glu Ala Glu Gln Gln Asn Glu Thr Arg Asn Ala Arg Ala 2405 2410 2415		
Met Leu Val Leu Arg Arg Ile Thr Asp Lys Leu Thr Gly Asn Asp 2420 2425 2430		
Ile Lys Arg Phe Asn Glu Leu Asp Val Pro Glu Gln Val Asp Lys 2435 2440 2445		
Leu Ile Gln Gln Ala Thr Ser Ile Glu Arg Leu Cys Gln His Tyr 2450 2455 2460		
Ile Gly Trp Cys Pro Phe Trp 2465 2470		

&lt;210&gt; SEQ ID NO 8

&lt;211&gt; LENGTH: 7413

&lt;212&gt; TYPE: DNA

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 8

```

atggaaccgc atgaggagca gatttggaa agtaaacttt tgaagcggc taacaacgat      60
atggacatgg atagaaatgt gccgttgca ccgaatctga atgtgaatat gaacatgaaa    120
atgaatgcca gcaggaacgg ggatgaattc ggtctgactt ctagtagggt tgatggagtg    180
gtgattggca gtaatgggga tgtaaatttt aagcccattt tggagaaaat tttccgcaaa    240
ttaaccagtg attacaagga ggaacgaaaa ttggccagta tttcattatt tgatctacta    300
gtatccttgg aacatgaatt gtcgatagaa gagttccaag cagtttcaaa tgacataaac    360
aataagattt tggagctggt ccatacaaaa aaaacgagca ctagggtagg ggctgttcta    420
tccatagaca ctttgatttc attctacgca tatactgaaa gggtgcctaa cgaaacttca    480
cgactggctg gttaccttgc agggctaata ccttctaata atgtagaggt catgagactc    540
gctgcaaaga ctctgggcaa gttagccgtt ccaggaggtg catatactc tgatttcgtg    600
gaatttgaga taaagtcttg cttagaatgg cttactgcct ccacggaaaa gaattcattc    660

```

-continued

---

tcgagttcga agccagacca tgctaaacat gctgcgcttc tgattataac agcgttgga	720
gagaattgtc cttatttact ctaccaatc ttgaattcca tactagataa catttgga	780
gcactaagag acccacattt ggtgatcaga attgatgcgt ccattacatt ggccaaatgt	840
ctttccacc tacgaaatag ggatcctcag ttaactagcc agtgggtgca gagattggct	900
acaagttgtg aatacggatt tcaagtaaac acattagaat gcaccatgc aagtttgtg	960
gtttataag aaatcttgtt ttgaaaggat cctttttga atcaagtgt cgaccaaatg	1020
tgtctaaatt gcatagctta tgaaaatcat aaagcgaata tgattagaga aaagatttac	1080
cagattgttc ccctattagc atcgttcaat cctcaattat ttgctggcaa atatttgac	1140
caaattatgg acaactattt agagatttta accaatgctc cagcaataa aataccacat	1200
ctcaaagatg acaaaccaca gattttaata tcgattgggtg atattgcata tgaagtcggg	1260
cccgatatcg caccttatgt gaaacaaatt cttgattata ttgaacatga tttacagacg	1320
aaattcaaat tcagaagaa atttgaaat gaaatctct actgcacgg aagattggca	1380
gttcccttgg gccccgttct aggtaaatta ttaaacagaa atatactgga cctgatgttc	1440
aaatgccttc tttccgacta tatgcaggaa acgtttcaa ttctgactga gagaatacca	1500
tcactaggcc ccaaaataa tgacgagttg cttaacctag tctgttcaac cttatctgga	1560
acaccattta tccagccagg gtcaccaatg gagataccat cgttttcgag agaagagca	1620
agagaatgga gaaataaaaa catcctacag aaaactggtg aaagtaacga tgataataat	1680
gatataaaaa tcattataca agctttttag atgttaaaaa atatacaaaag cagattttcg	1740
ttggtggaat tcgtgagaat tgttgcaact tcttaccattg agcatacaga tcccagagta	1800
aggaaactag ctgcgttgac atcctgtgaa atttacgtca aggataacat ctgcaaaaa	1860
acatcactac actcctgaa cactgtatct gaagtgttat caaagcttct agccattacg	1920
attgctgacc ctttacaaga tatccgttta gaagttttaa agaactttaa tccatgtttc	1980
gatccccagt tggcacaacc agataatttg agactcctgt ttactgcact gcacgatgag	2040
tcgttcaata ttcagtcagt agcaatggag cttgtcgtgta ggtgtcttc cgtaaaccct	2100
gcatacgtca tcccctcgat aagaaaaata ctactggaac tgctaacaaa attaaaattc	2160
tcaacttctt ctcgagaaaa ggaagaaact gccagtttgt tatgtactct tatcaggtcg	2220
agtaaagatg ttgcgaaacc ttatatcgaa cctcttttaa atgttctttt accaaaattc	2280
caagatacct cttcaacggt tgcacaaact gcactgagaa ctataggtga gctatctgtt	2340
gtagggggcg aagatatgaa gatatatctt aaggatttgt ttcctttaat tatcaaaaa	2400
ttcaggatc aatcaaaact tttcaagaga gaagctgcac ttaaggccct tggtaactt	2460
gcagcctcat ctggttacgt gatagatcct ttactcgact atcccgaatt attgggtata	2520
ttggtgaata tattgaagac agaaaactct caaaatatta ggagacaaac agtcaacttg	2580
ataggtatac tgggagctat cgaccatata cgccaaaag aacgtgaggt tacctctact	2640
accgatatat ctacagaaca gaacgccccg cctatcgaca ttgctcttct catgcagggc	2700
atgtctcctt cgaatgatga gtattatacc actgttgtca ttactgcct gctaaaaatc	2760
ctaaaagatc catccctatc atcttaccac actgccgtga tccaagcgat tatgcatatt	2820
tttcaaaccc ttggtctaaa atgtgtttca ttcttgacc agatcatccc aactattttg	2880
gacgtaatgc gtacatgctc tcagtcacta ttagaatttt acttccaaca gctttgctct	2940
ttgattatta tcgtaaggca acacataaga cctcatgtcg attctatatt ccaggctatc	3000
aaagattttt ctccggttgc taagctacaa ataacgcttg taagtgttat tgaagcaata	3060



-continued

---

tcaaaggctc	tgagggtga	attcaaaaga	ttggtcctc	ttactctgac	cttgttcctt	3120
gtaattttg	agaatgacaa	gtctagtgc	aaggtcctc	ccagaagggt	attgagactg	3180
ttagaatcgt	ttggctctaa	cttagaaggt	tattcgcatt	tgattacacc	caagatagtt	3240
caaatggcag	aattcaccag	cggaaccta	caaaggctc	caataattac	tattggcaaa	3300
ctggccaagg	atgttgacct	ttttgagatg	tcctcaagaa	ttgttcactc	tttacttagg	3360
gtactaagtt	caacaacgag	tgacgaactc	tcaaaagtca	ttatgaatac	tttaagtcta	3420
ctgctaatac	aaatgggcac	atcctttgct	atcttcatcc	ctgtcattaa	tgaagtttta	3480
atgaagaaac	atattcaaca	cacaatata	gatgacttga	caaacagaat	attaacaat	3540
gatgttttac	ccacaaaaat	tcttgaagca	aatacaacgg	attataagcc	cgcggaacaa	3600
atggaggcag	cagatgctgg	ggtcgcaaaa	ttacctataa	accaatcagt	ttgaaaagt	3660
gcatggaatt	ctagccaaca	aagaactaaa	gaagattggc	aggaatggag	caaacgtcta	3720
tccattcaat	tattaaaga	gtcacctcc	catgctctaa	gagcttgctc	aaatcttgca	3780
agcatgtatt	atccactagc	caaagaactt	tttaataccg	cattcgcag	tgtttggacc	3840
gaactttata	gccaatatca	agaagattta	attgggctcat	tatgtatagc	cttatcttct	3900
cccttaaate	caccagaaat	acatcaaa	ttgttaaacc	tggtagaatt	tatggaacac	3960
gatgacaagg	cattaccaat	accaactcaa	agcctggg	agtatgctga	aagatgtcac	4020
gcctatgcca	aagcgtaca	ttataaagag	attaatatta	ttaaagagcc	tgagaactca	4080
actattgaat	cattgatcag	cattaacaac	cagctgaatc	aaacggatgc	tgcaattggt	4140
atattaaagc	atgccaaca	acatcattca	cttcaattaa	aggagacatg	gtttgaaaaa	4200
ttagagcgtt	gggaagatgc	actacatgct	tataatgaac	gtgaaaagc	aggatgatact	4260
tccgtgagcg	ttacactcgg	taagatgaga	tccttcatg	cccttgccga	atgggaacag	4320
ttgtcgcaat	tgccagctag	aaagtggaaa	gtttcgaagc	tacaaactaa	gaagctaata	4380
gtcccttgg	cagctggtgc	tgctggggg	ttgggagagt	gggatatgct	tgagcaatat	4440
atcagcgtta	tgaaacctaa	atctccagat	aaggaatatt	ttgatgcaat	ttatacttg	4500
cacaagaatg	attacgacaa	tgctagtaag	catatattaa	acgccagaga	tttgcttg	4560
actgaaat	ccgcttgat	caatgaaagt	tataatagag	catatagcgt	tattgttaga	4620
actcaataa	taacagagtt	tgaggaaatc	atcaagtata	aacaattgcc	acctaattcc	4680
gagaaaaaac	ttcactatca	aaatctttgg	acaaaaagac	tgctgggctg	ccaaaaaat	4740
gtcgatttat	ggcaaagagt	gcttagagta	agatcattgg	taataaagcc	caagcaagac	4800
ctgcaaat	ggataaaat	tgcaaat	tgcaaaaat	ctggtagaat	gaggctagca	4860
aataaggcat	tgaatatgct	actagaagga	ggcaacgac	ctagtttacc	aaatacgttc	4920
aaagctcctc	ccccagttgt	ttacgcgcaa	ctaaaatata	tttgggctac	aggagcttat	4980
aaagaagcat	taaaccactt	gataggattt	acatccaggt	tagcgcagta	tcttggtttg	5040
gatccgaata	atgatgctc	gcaaagtgc	aaactctcaa	gtgcaagtac	tgctccgtat	5100
gttgaggaat	acacaaaatt	attagctcga	tgttttttaa	agcaaggtga	gtggagaata	5160
gcaacacaac	cgaaactggag	aaacacaaat	ccgatgcaa	ttcttggttc	ttatctattg	5220
gctacacatt	tcgataaaaa	ttggtacaag	gcatggcata	attgggcctt	agctaatttt	5280
gaagtaatat	ccatggttca	ggaagagact	aagctcaacg	gaggtaaaga	tgatgatgat	5340
gatgacacgg	cagttaataa	tgataatgtg	cggattgacg	gtagtatcct	aggaagtgg	5400
tctttgacta	ttaatggcaa	cagataccgg	ctagagctta	ttcaagaca	tgttgtcca	5460

-continued

---

```

gcgatcaagg gcttttttca ttcaatatct ctattagaaa caagttgttt gcaagacacg 5520
ttgaggttat tgactctttt atttaacttt ggtggtatta aagaagtctc acaagccatg 5580
tatgaaggct tcaatttgat gaaaatagag aactggcttg aagtcttacc acagttgatc 5640
tctcgtatac atcagccaga tctacggtyg agtaattccc tttgtcgtt gctttctgat 5700
ttagggaaag ctcatccaca agctctcgtg tatcctttaa ctgtcgcgat caagtctgaa 5760
tctgtttcaa gacaaaaagc ggctctttca ataatagaga aaattaggat tcatagtcca 5820
gtcctggtaa accaggcaga attagttagt cacgagttga tcagagtagc cgttctatgg 5880
cacgaattat ggtatgaagg actggaagat gcgagccgcc aatttttctg tgaacataac 5940
atagaaaaaa tgttttctac tttagaacct ttacataaac acttaggcaa tgagcctcaa 6000
acgttaagtg aggtatcgtt tcagaaatca tttggtagag atttgaacga tgccctacgaa 6060
tggttgaata actacaaaaa gtcaaaagac atcaataatt tgaaccaagc ttgggatatt 6120
tattataacg tcttcagaaa aataaacagt caaataccac agttacaaac cttagactta 6180
cagcatgttt ctccccagct tctggctact catgatctcg aattggctgt tctctgggaca 6240
tatttcccag gaaaacctac cattagaata gcggaagttg agccattatt ttctgtgatc 6300
tcttcaagc aaaggccaag aaaatctcc atcaagggta gcgacggtaa agattataaa 6360
tacgttttaa agggacatga agatataaga caagatagcc ttgttatgca attatttgg 6420
ctagttaaca ctttgttgaa gaatgattca gagtgtttca agagacattt ggatatccaa 6480
caatacccg ctattccatt gtcgcctaaa tctggtttac taggatgggt accaaatagt 6540
gacacattcc acgttttgat cagagaacac cgtgatgcca aaaaaattcc gttgaacatt 6600
gaacattggg ttatgttaca aatggcccc gattatgaga atttgactct tttacaaaa 6660
attgaagtat tcacgtacgc tttagataat acaaaaggcc aagacctta taaaatatta 6720
tggttaaaga gtaggtcgc agagacatgg ctagaacgta gaacaactta tacgagatct 6780
ttagcagtta tgtccatgac tggttatatt ctgggactag gtgatcgcca tccaagcaac 6840
ctgatgctag atagaatcac cggtaaagtt atccacattg atttcggcga ttgttttgaa 6900
gctgcatct taagagaaaa gtatccagaa aaagtccat ttagactaac taggatgtta 6960
acatacgcaa tggaaagttg tggaaattgaa ggcagtttc gaattacttg tgaaaatgtc 7020
atgagagtct taagagataa taaagaatca ttaatggcga tcttgaagc tttgctgtt 7080
gatcctttga tccattgggg atttgattta ccgccacaaa aacttactga gcaaaactgga 7140
attcctttgc cgttgattaa tctagttaa ttattaagga agggggcaat tactgtcgaa 7200
gaagcggcaa atatggaagc agaacaacaa aatgagacca aaaacgccag agcaatgctt 7260
gttttgagac gtattacaga taaattaacg ggcaatgata tcaagagggt caatgaatta 7320
gacgtccctg agcaggttga taaactgatc caacaagcca cttctattga aaggttatgt 7380
caacattata ttggatggtg cccattctgg tga 7413

```

```

<210> SEQ ID NO 9
<211> LENGTH: 471
<212> TYPE: PRT
<213> ORGANISM: Saccharomyces cerevisiae

```

```

<400> SEQUENCE: 9

```

```

Met Ser Ile Cys Pro His Ile Gln Gln Val Phe Gln Asn Glu Lys Ser
1           5           10           15
Lys Asp Gly Val Leu Lys Thr Cys Asn Ala Ala Arg Tyr Ile Leu Asn
                20           25           30

```

-continued

---

His Ser Val Pro Lys Glu Lys Phe Leu Asn Thr Met Lys Cys Gly Thr  
 35 40 45  
 Cys His Glu Ile Asn Ser Gly Ala Thr Phe Met Cys Leu Gln Cys Gly  
 50 55 60  
 Phe Cys Gly Cys Trp Asn His Ser His Phe Leu Ser His Ser Lys Gln  
 65 70 75 80  
 Ile Gly His Ile Phe Gly Ile Asn Ser Asn Asn Gly Leu Leu Phe Cys  
 85 90 95  
 Phe Lys Cys Glu Asp Tyr Ile Gly Asn Ile Asp Leu Ile Asn Asp Ala  
 100 105 110  
 Ile Leu Ala Lys Tyr Trp Asp Asp Val Cys Thr Lys Thr Met Val Pro  
 115 120 125  
 Ser Met Glu Arg Arg Asp Gly Leu Ser Gly Leu Ile Asn Met Gly Ser  
 130 135 140  
 Thr Cys Phe Met Ser Ser Ile Leu Gln Cys Leu Ile His Asn Pro Tyr  
 145 150 155 160  
 Phe Ile Arg His Ser Met Ser Gln Ile His Ser Asn Asn Cys Lys Val  
 165 170 175  
 Arg Ser Pro Asp Lys Cys Phe Ser Cys Ala Leu Asp Lys Ile Val His  
 180 185 190  
 Glu Leu Tyr Gly Ala Leu Asn Thr Lys Gln Ala Ser Ser Ser Ser Thr  
 195 200 205  
 Ser Thr Asn Arg Gln Thr Gly Phe Ile Tyr Leu Leu Thr Cys Ala Trp  
 210 215 220  
 Lys Ile Asn Gln Asn Leu Ala Gly Tyr Ser Gln Gln Asp Ala His Glu  
 225 230 235 240  
 Phe Trp Gln Phe Ile Ile Asn Gln Ile His Gln Ser Tyr Val Leu Asp  
 245 250 255  
 Leu Pro Asn Ala Lys Glu Val Ser Arg Ala Asn Asn Lys Gln Cys Glu  
 260 265 270  
 Cys Ile Val His Thr Val Phe Glu Gly Ser Leu Glu Ser Ser Ile Val  
 275 280 285  
 Cys Pro Gly Cys Gln Asn Asn Ser Lys Thr Thr Ile Asp Pro Phe Leu  
 290 295 300  
 Asp Leu Ser Leu Asp Ile Lys Asp Lys Lys Lys Leu Tyr Glu Cys Leu  
 305 310 315 320  
 Asp Ser Phe His Lys Lys Glu Gln Leu Lys Asp Phe Asn Tyr His Cys  
 325 330 335  
 Gly Glu Cys Asn Ser Thr Gln Asp Ala Ile Lys Gln Leu Gly Ile His  
 340 345 350  
 Lys Leu Pro Ser Val Leu Val Leu Gln Leu Lys Arg Phe Glu His Leu  
 355 360 365  
 Leu Asn Gly Ser Asn Arg Lys Leu Asp Asp Phe Ile Glu Phe Pro Thr  
 370 375 380  
 Tyr Leu Asn Met Lys Asn Tyr Cys Ser Thr Lys Glu Lys Asp Lys His  
 385 390 395 400  
 Ser Glu Asn Gly Lys Val Pro Asp Ile Ile Tyr Glu Leu Ile Gly Ile  
 405 410 415  
 Val Ser His Lys Gly Thr Val Asn Glu Gly His Tyr Ile Ala Phe Cys  
 420 425 430  
 Lys Ile Ser Gly Gly Gln Trp Phe Lys Phe Asn Asp Ser Met Val Ser  
 435 440 445  
 Ser Ile Ser Gln Glu Glu Val Leu Lys Glu Gln Ala Tyr Leu Leu Phe  
 450 455 460

-continued

Tyr Thr Ile Arg Gln Val Asn  
465 470

<210> SEQ ID NO 10  
<211> LENGTH: 1416  
<212> TYPE: DNA  
<213> ORGANISM: *Saccharomyces cerevisiae*

<400> SEQUENCE: 10

```

atgagcattt gtccacatat acagcaagta tttcagaatg aaaagtctaa agatgggggtt    60
ctaaaaacgt gcaatgctgc caggtatata ttaaatcatt ccgtacccaa ggaaaaattc    120
ttaaaccacca tgaatgtggg tacatgccac gaaataaact ctggtgcaac tttcatgtgt    180
ctacaatgtg gattttgtgg atggttggaa cattcgcatt ttctctctca cagtaaacag    240
attggtcaca tattttggtat caactcaaat aatggccttt tattttgctt caaatgtgag    300
gactatatag ggaatatcga tctgattaac gatgctatcc tagcgaagta ttgggacgac    360
gtgtgcacaa agaccatggt tcttagcatg gaaagaagag atgggctttc tggcctgatc    420
aacatgggat ccacttggtt catgagtagt attctccaat gtctaateca taacccttac    480
tttattagcg actcaatgag tcaaattcat tctaataatt gtaaagtgcg ttctccagat    540
aaatgttttt catgtgcact cgataaaatt gttcatgaac tttatggagc gctgaatata    600
aagcaagctt cttcgtcacc tacatctact aatcggcaaa ccggattcat atatctttta    660
acttgtgcct ggaaaatcaa tcaaaatcta gcagggtatt cacaacaaga tgctcatgaa    720
ttttggcagt ttataattaa ccaaatccac caaagctatg ttcttgattt gccaaatgcc    780
aaggaagtca gcagagcaaa taataagcag tgtgaatgca tagtgcatac tgtgtttgag    840
ggctccttgg aaagtctcat tgtgtgtcca ggctgtcaaa ataattcaaa gacaaccatt    900
gatccattct tggatcttcc tctggatacc aaggataaga aaaaacttta tgaatgtctt    960
gacagtttcc ataaaaaaga acagttgaag gatttcaact atcattgtgg ggagtgtaac   1020
agcactcaag atgcaataaa gcaactaggc atacacaaat taccatcggg tttggttttg   1080
caattgaaaa gattcgaaca cctacttaat ggaagtaaca gaaaactaga cgattttatt   1140
gaatttccaa cttatttaaa tatgaaaaat tactgttcaa cgaaggaaaa agataagcat   1200
tctgaaaatg gcaaggttcc agacattatt tacgaattaa tcggtattgt ttcccacaag   1260
gggacgggta atgaggggaca ttatatgca ttttgtaaaa tttctggagg gcaatggttt   1320
aaattcaatg attccatggt ctctctata tctcaagaag aggttttaaa ggaacaggca   1380
tatttattat tctacaccat tcgtcaagta aattga                               1416

```

<210> SEQ ID NO 11  
<211> LENGTH: 1332  
<212> TYPE: PRT  
<213> ORGANISM: *Saccharomyces cerevisiae*

<400> SEQUENCE: 11

```

Met Thr Glu Arg Ile Pro Ile Lys Asn Tyr Gln Arg Thr Asn Ala Lys
1      5      10      15
Ala Leu Leu Lys Leu Thr Glu Lys Leu Phe Asn Lys Asn Phe Phe Asp
20     25     30
Leu Tyr Leu Thr Ser Gln Gln Leu Val Val Leu Glu Tyr Leu Leu Ser
35     40     45
Ile Ser Ser Glu Glu Asp Lys Leu Lys Ala Trp Asp Tyr Phe Leu Lys
50     55     60

```

-continued

---

Gly	Asn	Ile	Ala	Leu	Asn	Val	Glu	Lys	Ser	Phe	Pro	Leu	Thr	Gln	Glu	
65					70					75					80	
Glu	Glu	His	His	Gly	Ala	Val	Ser	Pro	Ala	Val	Asp	Thr	Arg	Ser	Asp	
				85					90					95		
Asp	Val	Ser	Ser	Gln	Thr	Ile	Lys	Asp	Asn	Asn	Asn	Thr	Asn	Thr	Asn	
			100					105					110			
Thr	Ser	Ile	Ser	Asn	Glu	Asn	His	Val	Glu	Asn	Glu	Ile	Glu	Asp	Lys	
		115					120					125				
Gly	Asp	Asn	Ala	Ile	Ala	Asn	Glu	Asp	Asn	Phe	Val	Asn	Asn	Asp	Glu	
	130					135					140					
Ser	Asp	Asn	Val	Glu	Glu	Asp	Leu	Phe	Lys	Leu	Asp	Leu	Glu	Asp	Leu	
145				150						155					160	
Lys	Gln	Gln	Ile	Ser	Gly	Thr	Arg	Phe	Ile	Gly	Asn	Leu	Ser	Leu	Lys	
				165					170					175		
Ile	Arg	Tyr	Val	Leu	Trp	Gln	Cys	Ala	Ile	Asp	Tyr	Ile	Tyr	Cys	Asp	
			180					185					190			
Arg	Asn	Glu	Phe	Gly	Asp	Glu	Asn	Asp	Thr	Glu	Tyr	Thr	Leu	Leu	Asp	
		195					200					205				
Val	Glu	Glu	Lys	Glu	Glu	Glu	Glu	Ile	Gly	Lys	Asn	Glu	Lys	Pro	Gln	
	210					215					220					
Asn	Lys	Glu	Gly	Ile	Ser	Lys	Phe	Ala	Glu	Asp	Glu	Asp	Tyr	Asp	Asp	
225					230					235					240	
Glu	Asp	Glu	Asn	Tyr	Asp	Glu	Asp	Ser	Thr	Asp	Val	Lys	Asn	Val	Asp	
				245					250					255		
Asp	Pro	Pro	Lys	Asn	Leu	Asp	Ser	Ile	Ser	Ser	Ser	Asn	Ile	Glu	Ile	
			260					265					270			
Asp	Asp	Glu	Arg	Arg	Leu	Val	Leu	Asn	Ile	Ser	Ile	Ser	Lys	Glu	Thr	
		275					280					285				
Leu	Ser	Lys	Leu	Lys	Thr	Asn	Asn	Val	Glu	Glu	Ile	Met	Gly	Asn	Trp	
	290					295					300					
Asn	Lys	Ile	Tyr	His	Ser	Phe	Glu	Tyr	Asp	Lys	Glu	Thr	Met	Ile	Lys	
305				310						315					320	
Arg	Leu	Lys	Leu	Glu	Glu	Ser	Asp	Lys	Met	Ile	Glu	Lys	Gly	Lys	Lys	
				325					330					335		
Lys	Arg	Ser	Arg	Ser	Asp	Leu	Glu	Ala	Ala	Thr	Asp	Glu	Gln	Asp	Arg	
			340					345					350			
Glu	Asn	Thr	Asn	Asp	Glu	Pro	Asp	Thr	Asn	Gln	Lys	Leu	Pro	Thr	Pro	
		355					360					365				
Glu	Gly	Ser	Thr	Phe	Ser	Asp	Thr	Gly	Asn	Lys	Arg	Pro	Lys	Gln	Ser	
	370					375					380					
Asn	Leu	Asp	Leu	Thr	Val	Asn	Leu	Gly	Ile	Glu	Asn	Leu	Ser	Leu	Lys	
385					390					395					400	
His	Leu	Leu	Ser	Ser	Ile	Gln	Gln	Lys	Lys	Ser	Gln	Leu	Gly	Ile	Ser	
				405					410					415		
Asp	Tyr	Glu	Leu	Lys	His	Leu	Ile	Met	Asp	Val	Arg	Lys	Asn	Arg	Ser	
		420						425					430			
Lys	Trp	Thr	Ser	Asp	Glu	Arg	Ile	Gly	Gln	Glu	Glu	Leu	Tyr	Glu	Ala	
		435					440					445				
Cys	Glu	Lys	Val	Val	Leu	Glu	Leu	Arg	Asn	Tyr	Thr	Glu	His	Ser	Thr	
	450					455					460					
Pro	Phe	Leu	Asn	Lys	Val	Ser	Lys	Arg	Glu	Ala	Pro	Asn	Tyr	His	Gln	
465					470					475					480	
Ile	Ile	Lys	Lys	Ser	Met	Asp	Leu	Asn	Thr	Val	Leu	Lys	Lys	Leu	Lys	
				485					490					495		

-continued

---

Ser Phe Gln Tyr Asp Ser Lys Gln Glu Phe Val Asp Asp Ile Met Leu  
500 505 510  
Ile Trp Lys Asn Cys Leu Thr Tyr Asn Ser Asp Pro Ser His Phe Leu  
515 520 525  
Arg Gly His Ala Ile Ala Met Gln Lys Lys Ser Leu Gln Leu Ile Arg  
530 535 540  
Met Ile Pro Asn Ile Thr Ile Arg Asn Arg Ala Asp Leu Glu Lys Glu  
545 550 555 560  
Ile Glu Asp Met Glu Lys Asp Lys Asp Tyr Glu Leu Asp Glu Glu Glu  
565 570 575  
Glu Val Ala Gly Ser Gly Arg Lys Gly Leu Asn Met Gly Ala His Met  
580 585 590  
Leu Ala Lys Glu Asn Gly Lys Val Ser Glu Lys Asp Ser Ser Lys Thr  
595 600 605  
Val Lys Asp Glu Ala Pro Thr Asn Asp Asp Lys Leu Thr Ser Val Ile  
610 615 620  
Pro Glu Gly Glu Lys Glu Lys Asp Lys Thr Ala Ser Ser Thr Val Thr  
625 630 635 640  
Val His Glu Asn Val Asn Lys Asn Glu Ile Lys Glu Asn Gly Lys Asn  
645 650 655  
Glu Glu Gln Asp Met Val Glu Glu Ser Ser Lys Thr Glu Asp Ser Ser  
660 665 670  
Lys Asp Ala Asp Ala Ala Lys Lys Asp Thr Glu Asp Gly Leu Gln Asp  
675 680 685  
Lys Thr Ala Glu Asn Lys Glu Ala Gly Glu Asn Asn Glu Glu Glu Glu  
690 695 700  
Asp Asp Asp Asp Glu Asp Glu Asp Glu Asp Met Val Asp Ser Gln Ser  
705 710 715 720  
Tyr Leu Leu Glu Lys Asp Asp Asp Arg Asp Asp Leu Glu Ile Ser Val  
725 730 735  
Trp Lys Thr Val Thr Ala Lys Val Arg Ala Glu Ile Cys Leu Lys Arg  
740 745 750  
Thr Glu Tyr Phe Lys Asn Gly Lys Leu Asn Ser Asp Ser Glu Ala Phe  
755 760 765  
Leu Lys Asn Pro Gln Arg Met Lys Arg Phe Asp Gln Leu Phe Leu Glu  
770 775 780  
Tyr Lys Glu Gln Lys Ala Leu Glu Ser Tyr Arg Gln Lys Ile Glu Gln  
785 790 795 800  
Asn Ser Ile Met Lys Asn Gly Phe Gly Thr Val Leu Lys Gln Glu Asp  
805 810 815  
Asp Asp Gln Leu Gln Phe His Asn Asp His Ser Leu Asn Gly Asn Glu  
820 825 830  
Ala Phe Glu Lys Gln Pro Asn Asp Ile Glu Leu Asp Asp Thr Arg Phe  
835 840 845  
Leu Gln Glu Tyr Asp Ile Ser Asn Ala Ile Pro Asp Ile Val Tyr Glu  
850 855 860  
Gly Val Asn Thr Lys Thr Leu Asp Lys Met Glu Asp Ala Ser Val Asp  
865 870 875 880  
Arg Met Leu Gln Asn Gly Ile Asn Lys Gln Ser Arg Phe Leu Ala Asn  
885 890 895  
Lys Asp Leu Gly Leu Thr Pro Lys Met Asn Gln Asn Ile Thr Leu Ile  
900 905 910  
Gln Gln Ile Arg His Ile Cys His Lys Ile Ser Leu Ile Arg Met Leu

-continued

915					920					925					
Gln	Ser	Pro	Leu	Ser	Ala	Gln	Asn	Ser	Arg	Ser	Asn	Pro	Asn	Ala	Phe
930						935					940				
Leu	Asn	Asn	His	Ile	Tyr	Asn	Tyr	Thr	Ile	Ile	Asp	Asp	Ser	Leu	Asp
945				950					955						960
Ile	Asp	Pro	Val	Ser	Gln	Leu	Pro	Thr	His	Asp	Tyr	Lys	Asn	Asn	Arg
			965					970						975	
Glu	Leu	Ile	Trp	Lys	Phe	Met	His	Lys	Asn	Ile	Ser	Lys	Val	Ala	Met
		980					985						990		
Ala	Asn	Gly	Phe	Glu	Thr	Ala	His	Pro	Ser	Ala	Ile	Asn	Met	Leu	Thr
	995					1000						1005			
Glu	Ile	Ala	Gly	Asp	Tyr	Leu	Ser	Asn	Leu	Ile	Lys	Thr	Leu	Lys	
1010						1015					1020				
Leu	His	His	Glu	Thr	Asn	Ser	Leu	Asn	Arg	Gly	Thr	Asn	Val	Glu	
1025					1030						1035				
Met	Leu	Gln	Thr	Thr	Leu	Leu	Glu	Asn	Gly	Ile	Asn	Arg	Pro	Asp	
1040					1045						1050				
Asp	Leu	Phe	Ser	Tyr	Val	Glu	Ser	Glu	Phe	Gly	Lys	Lys	Thr	Lys	
1055					1060						1065				
Lys	Leu	Gln	Asp	Ile	Lys	Gln	Lys	Leu	Glu	Ser	Phe	Leu	Arg	Ala	
1070					1075						1080				
Leu	Leu	Arg	Pro	Thr	Leu	Gln	Glu	Leu	Ser	Glu	Arg	Asn	Phe	Glu	
1085					1090						1095				
Asp	Glu	Ser	Gln	Ser	Phe	Phe	Thr	Gly	Asp	Phe	Ala	Ser	Glu	Leu	
1100					1105						1110				
Thr	Gly	Glu	Asp	Phe	Phe	Gly	Phe	Arg	Glu	Leu	Gly	Leu	Glu	Lys	
1115					1120						1125				
Glu	Phe	Gly	Val	Leu	Ser	Ser	Ser	Val	Pro	Leu	Gln	Leu	Leu	Thr	
1130					1135						1140				
Thr	Gln	Phe	Gln	Thr	Val	Asp	Gly	Glu	Thr	Lys	Val	Gln	Ala	Lys	
1145					1150						1155				
Lys	Ile	Gln	Pro	Glu	Glu	Ser	Asp	Ser	Ile	Val	Tyr	Lys	Lys	Ile	
1160					1165						1170				
Thr	Lys	Gly	Met	Leu	Asp	Ala	Gly	Ser	Phe	Trp	Asn	Thr	Leu	Leu	
1175					1180						1185				
Pro	Leu	Leu	Gln	Lys	Asp	Tyr	Glu	Arg	Ser	Lys	Ala	Tyr	Ile	Ala	
1190					1195						1200				
Lys	Gln	Ser	Lys	Ser	Ser	Ala	Asn	Asp	Lys	Thr	Ser	Met	Thr	Ser	
1205					1210						1215				
Thr	Glu	Asp	Asn	Ser	Phe	Ala	Leu	Leu	Glu	Glu	Asp	Gln	Phe	Val	
1220					1225						1230				
Ser	Lys	Lys	Thr	Ala	Thr	Lys	Ala	Arg	Leu	Pro	Pro	Thr	Gly	Lys	
1235					1240						1245				
Ile	Ser	Thr	Thr	Tyr	Lys	Lys	Lys	Pro	Ile	Ala	Ser	Ala	Phe	Ile	
1250					1255						1260				
Leu	Pro	Glu	Glu	Asp	Leu	Glu	Asn	Asp	Val	Lys	Ala	Asp	Pro	Thr	
1265					1270						1275				
Thr	Thr	Val	Asn	Ala	Lys	Val	Gly	Ala	Glu	Asn	Asp	Gly	Asp	Ser	
1280					1285						1290				
Ser	Leu	Phe	Leu	Arg	Thr	Pro	Gln	Pro	Leu	Asp	Pro	Leu	Asp	Met	
1295					1300						1305				
Asp	Asp	Ala	Phe	Asp	Asp	Thr	Asn	Met	Gly	Ser	Asn	Ser	Ser	Phe	
1310					1315						1320				

-continued

---

Ser Leu Ser Leu Pro Arg Leu Asn Gln  
1325 1330

<210> SEQ ID NO 12

<211> LENGTH: 3999

<212> TYPE: DNA

<213> ORGANISM: *Saccharomyces cerevisiae*

<400> SEQUENCE: 12

atgactgaaa gaataccaat aaagaattat caaagaacaa atgccaaagc tttacttaaa 60  
 ttgactgaaa aactttttaa caagaacttt tttgatctct atttaacctc tcagcaattg 120  
 gtcgttcttg aatacctgct gtcgatttca agtgaagaag acaaaactgaa agcatgggac 180  
 tatttcttaa agggaaacat agcattaaat gtcgaaaaat catttccatt aaccaagaa 240  
 gaagaacatc acggagcggg ctctcctgcc gttgacacac gatcagatga tgtatcatca 300  
 caaacaatta aggacaataa caatactaata accaacacca gtatcagcaa tgaaaatcat 360  
 gttgaaaatg aaattgaaga taaaggcgat aacgcaatag caaatgaaga taattttgtg 420  
 aataatgacg aaagtgataa tgttgaagaa gacttattca aattagatct agaggacttg 480  
 aagcagcaaa taagcggaac aaggtttatt ggaaacttat ccttgaaaat cagatacgtc 540  
 ttgtggcagt gcgccataga ttatatatac tgtgatcgta atgagtttgg tgatgaaaat 600  
 gatacagaat acaccctatt agatgttgaa gagaaggagg aagaggaaat tggtaaaaat 660  
 gagaagccac aaaacaaaga aggtatttctg aagttcgcgg aggatgaaga ttacgacgat 720  
 gaagacgaga actatgatga agacagtaca gacgtaaaa atgtcgatga tcttccaaaa 780  
 aatctcgatt ctatttcctc ttctaataac gaaattgacg atgaacgacg cttggtgcta 840  
 aatatctcaa tatcaaaaga aacactgtca aagttaaaa caaataatgt agaagaatt 900  
 atgggaaatt ggaacaaaat ttaccacagt tttgaatacg ataaagaaac tatgataaag 960  
 cgataaaac ttgaagaag cgataaaatg atagagaaag gaaagaagaa acgaagtcca 1020  
 agtgatttag aagcagctac cgatgaacaa gatcgcgaaa atacaatga tgagccagat 1080  
 actaatcaaa aattgccac tcttgaaggt tcaacattca gcgatactgg gaacaagcgc 1140  
 cccaacaaa gtaatttaga ttaaacagtc aatctaggca tcgaaaattt atcattaaag 1200  
 caccttctat catctatcca gcaaaaaaaaa tccaattag gaatcaga ttacgaatta 1260  
 aaacatctga ttatggatgt cagaaaaaat cggtaaaaat ggacatcgga tgaagaatt 1320  
 gggcaagagg aattatacga agcctgtgaa aaggttgttt tggaaacttag aaactacact 1380  
 gagcatttca caccatttct gaataaagtg agcaaaagag aagcccccaa ttatcatcaa 1440  
 atcatcaaaa agtccatgga cctgaatact gttttaaaa aactgaaaag ctttcaatat 1500  
 gactccaaac aagaatttgt agacgatatt atgctaatat ggaaaaattg tttgacctat 1560  
 aattcagatc cttcacattt tttgagaggg catgctattg ctatgcagaa gaaatctctt 1620  
 cagttgattc gcatgattcc aaatatcaca atccgaaaca gggctgattt agaaaaggaa 1680  
 attgaagata tggaaaaaga caaagactac gaattagatg aggaagagga agttgctggt 1740  
 tctggaagaa aaggattgaa tatgggagct catatgttgg ccaaaagaa tggcaagggt 1800  
 tcagaaaaag atagctctaa aaccgtcaag gatgaagcac caaccaatga tgacaaacta 1860  
 acttctgtca tccttggagg gaaaaagag aaagataaaa ctgcttcatc tactgtaacg 1920  
 gtacacgaaa atgtaataaa gaacgaaata aaagaaaatg gaaaaaatga agagcaagat 1980  
 atgggtgagg aaagtagtaa gactgaggat tcatcaaaag atgctgatgc tgccaaaaag 2040  
 gatacggaag acggactaca agataaaact gcagaaaaata aggaggctgg gaaaaataat 2100



-continued

---

```

gaagaggaag aggatgatga tgacgaagat gaagacgaag acatggtcga ctcccaatct 2160
tatttacttg aaaaggatga cgatagagac gatttgaaa tatccgtgtg gaaaactgta 2220
actgccaaag ttcgtgcgga aatttgctta aaaagaactg aatattttaa aaatggaaaa 2280
ttaaatagtg attcagaggc gtttttgaaa aaccacaaaa gaatgaaaag gttcgaccag 2340
ctttttcttg aatataaaga gcagaaagct ttagaatcat atcgtcaaaa aatagagcaa 2400
aattccatta tgaaaaatgg ctttggaaaca gtactaaac aggaagacga tgaccaattg 2460
cagtttcata atgatcactc tttaaatgga aatgaagctt ttgaaaagca acccaatgat 2520
attgagttag atgataccag attcctacag gaatatgata ttagtaacgc cattcctgac 2580
atagtatacg agggagtaaa tactaaaaca ttagacaaga tggaagacgc ttcctgggac 2640
cgcagtcttc aaatgggat caacaacaa agcagatttc tggctaacia ggatttagga 2700
ctaacaccta aaatgaacca aaatatcaca ctgattcagc aaattaggca catatgccat 2760
aaaaatccc tgatcagaat gttacagagc cctttatcgg ctcaaaactc cagaagcaat 2820
cccaacgctt tccttaacaa ccacatttat aattacacta ttattgatga ctactcgat 2880
attgatccgg tgtcacagct tccaacgcat gattacaaaa acaacagggg gctgatatgg 2940
aaattcatgc ataagaacat atctaaggtt gctatggcca atgggttga aactgcccat 3000
ccatcagcaa taaacatgct tactgaaatc gccggggatt acctatctaa tctgataaag 3060
actttgaagc ttcacatga aactaactcc ttaaataagag gaacaaatgt ggaatgctg 3120
caaacacac tgttgaaaa cggtatcaac aggccagacg atctatttcc ctatgttgaa 3180
tctgaatttg gtaaaaaaac taagaaactt caggacatca aacagaaact agaaagcttt 3240
ttgagagcct tattaaggcc aactttgcag gagttgtccg agagaaactt tgaagacgag 3300
agccaaaagct tttttacagg tgactttgcc agcgaattga ctggtgaaga cttctttggt 3360
tttagagagc ttggattaga aaaggagttt ggagtttga gttcatctgt tccattacag 3420
ttactgacta ctcaagtcca aactgttgac ggggaaacca aagtgcaggc caaaaagatc 3480
caaccggaag aatcagacag cattgtgtat aagaaaatta caaaaggat gctggatgct 3540
ggttcattct ggaatactct acttccccta ttacaaaaag attatgaacg ttccaaggcc 3600
tatatagcaa agcaaagcaa gtcacatgca aatgataaaa cctcaatgac ttccacagaa 3660
gacaattctt tcgctttact agaagaggat cagtttgtct caaagaaaac cgcaacgaag 3720
gcaagattac ctctactgag taagataagt accacataca aaaagaaacc gatcgcaagc 3780
gcgcttatac ttccagaaga agacttggaa aacgacgtaa aagcggatcc aacaacaact 3840
gtaaacgcca aagtgggtgc agaaaatgat ggagattctt ccttattttt gccaacgcct 3900
caaccttag atcctttgga tatggatgat gcttttgatg ataccaatat gggcagcaat 3960
agttcattta gcttgagcct tcctgcctt aatcaataa 3999

```

&lt;210&gt; SEQ ID NO 13

&lt;211&gt; LENGTH: 602

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 13

```

Met Asp Glu Val Asp Asp Ile Leu Ile Asn Asn Gln Val Val Asp Asp
1           5           10          15

```

```

Glu Glu Asp Asp Glu Glu Met Leu Ser Gly Leu Glu Asn Asp Ser Lys
           20           25           30

```

```

Gln Asp Leu Glu Gly Asn Asp Asp Gly Gly Glu Asp Glu Glu Asp Asp

```

-continued

35				40				45					
Asp	Asp	Asp	Glu	Asp	Asp	Asp	Asp	Glu	Asp	Glu	Arg	Glu	Asp
50				55				60					
Asp	Asp	Glu	Gln	Glu	Asp	Asp	Gly	Glu	Asp	Ala	Ala	Arg	Met
65				70				75				80	
Asp	Lys	Thr	Ala	Thr	Pro	Thr	Asn	Glu	His	Gln	His	Asp	Glu
			85					90				95	
Ala	Ala	Ala	Ala	Gly	Ala	Gly	Gly	Ala	Gly	Asp	Ser	Gly	Asp
			100					105				110	
Thr	Lys	Ile	Gly	Ser	Glu	Asp	Val	Lys	Leu	Ser	Asp	Val	Asp
			115					120				125	
Val	Gly	Ser	Arg	Glu	Ala	Ser	Ser	Ser	Thr	His	Glu	Ala	Ser
							135				140		
Gly	Glu	Val	Tyr	Glu	Tyr	Lys	His	Met	Leu	Asn	Ala	Ala	Gln
145				150				155					160
Ala	Asp	Ser	Tyr	Asn	Ile	Tyr	Pro	Thr	Ala	Ala	Ile	Pro	Ile
				165				170					175
His	Val	Asn	Ala	Leu	Ala	Val	Ser	Arg	Gly	Leu	Lys	Tyr	Leu
			180					185				190	
Gly	Gly	Ser	Asp	Gly	Tyr	Ile	Arg	Lys	Tyr	Asp	Leu	Leu	Asn
			195				200				205		
Glu	Gly	Lys	Leu	Ser	Leu	Thr	Ile	Leu	Gln	Lys	His	Ser	Leu
			210				215				220		
Ser	Ile	Gln	Asn	Ala	Gly	Ile	Leu	Gln	Ser	Tyr	Trp	Glu	Asn
225				230				235					240
Pro	Gln	Lys	Lys	Ser	Glu	Met	Lys	Leu	Ser	Ala	Asn	Lys	Thr
				245				250					255
Glu	Pro	Lys	Val	Ser	Pro	Val	His	Ser	Leu	Glu	Val	Gln	Ser
			260					265				270	
Leu	Phe	Ile	Leu	Ser	Gly	Leu	Gln	Asn	Gly	Gly	Ile	Thr	Met
			275				280					285	
Val	Arg	Tyr	Met	Glu	Gly	Ser	Ile	Ala	His	Tyr	Phe	Lys	Gly
			290				295				300		
Gly	His	Thr	Gln	Ile	Val	Asn	Ile	Leu	Arg	Leu	Asn	Gly	Gln
305				310				315					320
Arg	Phe	Leu	Ser	Gly	Ser	Trp	Asp	Lys	Arg	Leu	Leu	Glu	Trp
				325				330					335
Gln	Thr	Gly	Asp	Ile	Val	Asn	Glu	Phe	Lys	Lys	Ser	Arg	Ser
			340				345					350	
Ser	Ser	Leu	Glu	Met	Arg	Pro	Leu	Tyr	Ser	Ser	Val	Asp	Val
			355				360					365	
Asn	Val	Asn	Ser	Gly	Lys	Glu	Asn	Glu	Asn	Ala	Asp	Asp	Met
			370				375				380		385
Ser	Leu	Phe	Gly	Asp	Glu	Asp	Glu	Asp	Glu	Lys	Gln	Asp	Ala
385				390				395					400
Glu	Pro	Val	Glu	Thr	Gly	Asp	Gly	Ser	Asn	Gly	Glu	Glu	Asn
			405					410					415
Gln	Ile	Ser	Glu	Glu	Ser	Leu	Asn	Ile	Val	Tyr	Asp	Glu	Ser
			420					425				430	
Met	Thr	Ser	Gly	Leu	Asn	Gly	Ser	Val	His	Ile	Trp	Asp	Arg
			435				440					445	
Thr	Gln	Ser	Pro	Ala	Leu	Ser	Leu	Glu	Arg	Gly	Ala	Gly	Val
			450				455					460	

-continued

---

Trp Cys Leu Ser Ala Cys Trp Gly Val Asp Gly Asp His Val Tyr Ala  
 465 470 475 480  
 Gly Arg Arg Asn Ala Cys Val Glu Gln Phe Asp Leu Lys Met Pro Ser  
 485 490 495  
 Lys Pro Ile His Asn Leu Lys Leu Pro Ser Ile Ser Gly Pro Val Ser  
 500 505 510  
 Cys Val Lys Ala Met Pro Asn Asn Lys His Leu Leu Cys Ala Ser Arg  
 515 520 525  
 Asp Asn Ile Arg Leu Tyr Asn Val Glu Ile Ala Val Asp Ala Ser Asn  
 530 535 540  
 Ser Thr Thr Lys Ser Ser Lys Val Pro Phe Leu Ile Val Pro Gly His  
 545 550 555 560  
 His Gly Gly Ile Ile Ser Asn Leu Tyr Leu Asp Pro Thr Ser Arg Phe  
 565 570 575  
 Ile Ile Ser Thr Ser Gly Asn Arg Gly Trp Gln Gly Asn Ser Thr Asp  
 580 585 590  
 Thr Thr Leu Ile Tyr Asp Ile Asp Leu Glu  
 595 600

&lt;210&gt; SEQ ID NO 14

&lt;211&gt; LENGTH: 1809

&lt;212&gt; TYPE: DNA

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 14

atggacgagg ttgacgatat tctaattaac aaccaggtgg tggatgacga ggaggatgac 60  
 gaagagatgc tgagtgggct ggaaaacgac tcaaagcagg acctcgaggg gaatgatgac 120  
 ggtggtgaag atgaagagga tgacgatgat gatgatgagg acgatgatga tgacgaggac 180  
 gaacgagagg acgacgatga acaggaggac gacgatggtg aggacgacgc cgcaagaatg 240  
 gataagactg ctacaccgac gaatgagcac cagcatgatg agcaaaaggc tgctgctgct 300  
 ggtgctggcg gtgcaggcga tagtggcgat gctgttacta agattggatc cgaggatgtg 360  
 aaattgagcg atgttgatgg aggagtgggg tocaggaag catcttctc tacacacgaa 420  
 gcctctgcta atggagaggt ttatgagtac tataagcaca tgttgaatgc cgcacagatt 480  
 gcggattcgt acaatatcta ccccacgca gccataccca tccagacgca cgtcaatgcg 540  
 ttggccgtgt ccaggggtct caagtacctg tttttggcg gtacggatgg atacataagg 600  
 aagtacgact tgctgaacac gcttgagggg aaactttctc taactatcct gcagaagcat 660  
 tcgttggtg agtctattca gaacgcgggt atcttgacgt cgtactggga aaatgagatc 720  
 ccgcagaaaa aatcagaaat gaaactctcc gctaataaga cagattacga gcccaaagtt 780  
 agccccgttc attctttgga agtccaaagc gaatgcctct ttatactgag cgggctacag 840  
 aatggtggga ttaccatgca gggcgttcgc tacatggagg ggagcattgc gcactathtt 900  
 aagggcagga atggacatac ccaaactcgtt aacatactga gattaaacgg tcaagaggac 960  
 aggtttttga gtggttcctg ggataagcgt cttttggaat gggatttgca gacgggtgac 1020  
 atagttaatg agtttaaaaa atcaaggtct gaattgtcat ctttggaat gcggccgctg 1080  
 tactcgtccg tggatgtgtc cggtaacgtc aacagtggta aagagaatga aaatgcagat 1140  
 gacgatatgg attctctggt tggatgatga gacgaagacg aaaagcaaga tgctggcaac 1200  
 gaacccgtcg agacggggga tggttctaag ggtgaagaga acaagaaca gatattctgaa 1260  
 gaatctttga acatagtcta tgatgaatcc gttttatga cctcaggggt gaacggttcc 1320  
 gtgcataatt gggaccgacg catgaocgag tcgccagcat tgtctctgga gagaggtgca 1380

-continued

---

```

ggcgtccac cgtggtgttt gtccgcatgt tggggtgtag atggtgatca tgtgatgca 1440
gggagaagga atgcctgtgt ggagcagttt gacttgaaga tgcctcgaac acctatccat 1500
aatttgaaac tgccttctat ttcagggcct gtctcttctg ttaaagccat gcctaataac 1560
aagcatttac tatgtgcacg cggggataat atcagattgt acaacgttga aattgcagta 1620
gatgcttcga attcgactac aaagagtctt aaagtgccgt tcctcatcgt gccgggccat 1680
cacggtggtta ttatatcaaa cttatacctc gaccccaact caagatttat aataagcaca 1740
agtggcaaca gaggctggca ggggaattct acggacacga cccttattta cgatatagac 1800
ttagaatag 1809

```

&lt;210&gt; SEQ ID NO 15

&lt;211&gt; LENGTH: 633

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 15

```

Met Ser Ser Asn Asn Asn Thr Asn Thr Ala Pro Ala Asn Ala Asn Ser
1           5           10           15

Ser His His His His His His His His His His His His His Gly His
                20           25           30

Gly Gly Ser Asn Ser Thr Leu Asn Asn Pro Lys Ser Ser Leu Ala Asp
        35           40           45

Gly Ala His Ile Gly Asn Tyr Gln Ile Val Lys Thr Leu Gly Glu Gly
        50           55           60

Ser Phe Gly Lys Val Lys Leu Ala Tyr His Thr Thr Thr Gly Gln Lys
65           70           75           80

Val Ala Leu Lys Ile Ile Asn Lys Lys Val Leu Ala Lys Ser Asp Met
        85           90           95

Gln Gly Arg Ile Glu Arg Glu Ile Ser Tyr Leu Arg Leu Leu Arg His
        100          105          110

Pro His Ile Ile Lys Leu Tyr Asp Val Ile Lys Ser Lys Asp Glu Ile
        115          120          125

Ile Met Val Ile Glu Tyr Ala Gly Asn Glu Leu Phe Asp Tyr Ile Val
        130          135          140

Gln Arg Asp Lys Met Ser Glu Gln Glu Ala Arg Arg Phe Phe Gln Gln
145          150          155          160

Ile Ile Ser Ala Val Glu Tyr Cys His Arg His Lys Ile Val His Arg
        165          170          175

Asp Leu Lys Pro Glu Asn Leu Leu Leu Asp Glu His Leu Asn Val Lys
        180          185          190

Ile Ala Asp Phe Gly Leu Ser Asn Ile Met Thr Asp Gly Asn Phe Leu
        195          200          205

Lys Thr Ser Cys Gly Ser Pro Asn Tyr Ala Ala Pro Glu Val Ile Ser
        210          215          220

Gly Lys Leu Tyr Ala Gly Pro Glu Val Asp Val Trp Ser Cys Gly Val
225          230          235          240

Ile Leu Tyr Val Met Leu Cys Arg Arg Leu Pro Phe Asp Asp Glu Ser
        245          250          255

Ile Pro Val Leu Phe Lys Asn Ile Ser Asn Gly Val Tyr Thr Leu Pro
        260          265          270

Lys Phe Leu Ser Pro Gly Ala Ala Gly Leu Ile Lys Arg Met Leu Ile
        275          280          285

Val Asn Pro Leu Asn Arg Ile Ser Ile His Glu Ile Met Gln Asp Asp

```

-continued

290	295	300
Trp Phe Lys Val Asp 305	Leu Pro Glu Tyr Leu 310	Leu Pro Pro Asp Leu Lys 315
Pro His Pro Glu Glu 325	Asn Glu Asn Asp Ser Lys Lys Asp Gly 330	
Ser Ser Pro Asp Asn Asp 340	Glu Ile Asp Asp Asn Leu Val Asn Ile Leu 345	
Ser Ser Thr Met Gly Tyr 355	Glu Lys Asp Glu Ile Tyr Glu Ser Leu Glu 360	
Ser Ser Glu Asp Thr Pro 370	Ala Phe Asn Glu Ile Arg Asp Ala Tyr Met 375	
Leu Ile Lys Glu Asn Lys Ser 385	Leu Ile Lys Asp Met Lys Ala Asn Lys 390	
Ser Val Ser Asp Glu Leu Asp 405	Thr Phe Leu Ser Gln Ser Pro Pro Thr 410	
Phe Gln Gln Gln Ser Lys Ser 420	His Gln Lys Ser Gln Val Asp His Glu 425	
Thr Ala Lys Gln His Ala Arg 435	Arg Met Ala Ser Ala Ile Thr Gln Gln 440	
Arg Thr Tyr His Gln Ser Pro 450	Phe Met Asp Gln Tyr Lys Glu Glu Asp 455	
Ser Thr Val Ser Ile Leu Pro 465	Thr Ser Leu Pro Gln Ile His Arg Ala 470	
Asn Met Leu Ala Gln Gly Ser Pro 485	Ala Ala Ser Lys Ile Ser Pro Leu 490	
Val Thr Lys Lys Ser Lys Thr Arg 500	Trp His Phe Gly Ile Arg Ser Arg 505	
Ser Tyr Pro Leu Asp Val Met 515	Gly Glu Ile Tyr Ile Ala Leu Lys Asn 520	
Leu Gly Ala Glu Trp Ala Lys Pro 530	Ser Glu Glu Asp Leu Trp Thr Ile 535	
Lys Leu Arg Trp Lys Tyr Asp Ile 545	Gly Asn Lys Thr Asn Thr Asn Glu 550	
Lys Ile Pro Asp Leu Met Lys Met 565	Val Ile Gln Leu Phe Gln Ile Glu 570	
Thr Asn Asn Tyr Leu Val Asp 580	Phe Lys Phe Asp Gly Trp Glu Ser Ser 585	
Tyr Gly Asp Asp Thr Thr Val 595	Ser Asn Ile Ser Glu Asp Glu Met Ser 600	
Thr Phe Ser Ala Tyr Pro Phe 610	Leu His Leu Thr Thr Lys Leu Ile Met 615	
Glu Leu Ala Val Asn Ser Gln Ser 625	Asn 630	

&lt;210&gt; SEQ ID NO 16

&lt;211&gt; LENGTH: 1902

&lt;212&gt; TYPE: DNA

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 16

atgagcagta acaacaacac aaacacagca cctgccaatg caaattctag ccaccaccac	60
caccatcacc accatcacca ccaccatcac ggtcatggcg gaagcaactc gacgctaaac	120
aatcccaagt cgtccttagc ggatgggtgca catatcggga actaccaaact cgtcaaaaacg	180
ctgggagagg ggtcctttgg taaagttaaa ttggcatatc ataccactac gggccaaaaa	240

-continued

---

```

gttgctctaa aaatcattaa taagaaggtt ttggcaaaga gtgatatgca gggcagaatt 300
gaaagagaaa tatcttatct gagactctta agacaccccc acatcatcaa actgtatgat 360
gttatcaaat ccaaagatga aatcattatg gttatagagt acgccgggaa cgaattgttt 420
gactatattg ttcagagaga caaaatgagc gagcaagagg caagaagatt tttccagcag 480
atcatcagtg ccgctcgagta ctgccatagc cacaaaattg tccatagaga tctgaagcct 540
gaaaacttac tactagatga gcatctgaat gtaaagattg ccgattttgg tttgtcaaac 600
atcatgactg atggtaattt cttaaagact tcttgtgggt ctcccaatta tgcggctcct 660
gaagttatca gcggttaagct gtacgcaggc ccagaagtgg acgtgtggtc atgtgggggt 720
atcctttatg ttatgctttg tgcctgctta ccgtttgacg atgaaagcat cccagtgtct 780
ttcaagaata tcagcaacgg tgtttacacc ttgcctaaat ttttatctcc tggagctgct 840
gggctaatac aaagaatgtt aatcgttaat ccattgaaca gaataagcat tcatgaaatt 900
atgcaagacg attggttcaa agttgacctg ccagaataac tacttccacc agatttgaaa 960
ccacaccagc aagaagagaa tgaataaat gactcaaaaa aggatggcag cagccagat 1020
aacgatgaaa ttgatgacaa ccttgtcaat atttatcat cgaccatggg ttacgaaaaa 1080
gacgagattt atgagtcctt agaatcatca gaagacactc ctgcattcaa cgaattagg 1140
gacgcgtaca tgttgattaa ggagaataaa tctttgatca aggatatgaa ggcaaacaaa 1200
agcgtcagtg atgaactgga tacctttctg tcccagtcac ctccaacttt tcaacaacaa 1260
agcaaatccc atcaaaagag tcaagtagat catgaaactg ccaagcaaca cgcaagaagg 1320
atggcaagtg ctatcactca acaaaggaca taccaccaat cacccttcat ggatcagtat 1380
aaagaagaag actctacagt ttccattttg cctacatctt tacctcagat ccacagagct 1440
aatatgttag cacaagggtc gccagctgcc tctaaaatat ctctcttgt aacgaaaaaa 1500
tctaaaacga gatggcattt tggatataca tctcgtctcat atccattaga cgttatgggt 1560
gaaatttata ttgccttgaa gaatttgggt gccgaatggg ccaagccatc tgaagaggat 1620
ttatggacta tcaaattaag gtggaaatat gatattgaa acaagacaaa cactaatgaa 1680
aaaatacctg atttaatgaa aatggtaatt caattattc aaattgaaac caataattat 1740
ttggtggatt tcaaatttga cggctgggaa agtagttatg gagatgatac tactgtttct 1800
aatatttctg aagatgaaat gagtactttt tcagcctacc catttttaca tttacaacaa 1860
aaactaatta tggaattagc cgtaaacagt caaagcaatt ga 1902

```

&lt;210&gt; SEQ ID NO 17

&lt;211&gt; LENGTH: 713

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 17

```

Met Ser Pro Ser Ala Val Gln Ser Ser Lys Leu Glu Glu Gln Ser Ser
1           5           10           15
Glu Ile Asp Lys Leu Lys Ala Lys Met Ser Gln Ser Ala Ala Thr Ala
20          25          30
Gln Arg Lys Lys Glu His Glu Tyr Glu His Leu Thr Ser Val Lys Ile
35          40          45
Val Pro Gln Arg Pro Ile Ser Asp Arg Leu Gln Pro Ala Ile Ala Thr
50          55          60
His Tyr Ser Pro His Leu Asp Gly Leu Gln Asp Tyr Gln Arg Leu His
65          70          75          80

```

-continued

---

Lys Glu Ser Ile Glu Asp Pro Ala Lys Phe Phe Gly Ser Lys Ala Thr  
 85 90 95  
 Gln Phe Leu Asn Trp Ser Lys Pro Phe Asp Lys Val Phe Ile Pro Asp  
 100 105 110  
 Pro Lys Thr Gly Arg Pro Ser Phe Gln Asn Asn Ala Trp Phe Leu Asn  
 115 120 125  
 Gly Gln Leu Asn Ala Cys Tyr Asn Cys Val Asp Arg His Ala Leu Lys  
 130 135 140  
 Thr Pro Asn Lys Lys Ala Ile Ile Phe Glu Gly Asp Glu Pro Gly Gln  
 145 150 155 160  
 Gly Tyr Ser Ile Thr Tyr Lys Glu Leu Leu Glu Glu Val Cys Gln Val  
 165 170 175  
 Ala Gln Val Leu Thr Tyr Ser Met Gly Val Arg Lys Gly Asp Thr Val  
 180 185 190  
 Ala Val Tyr Met Pro Met Val Pro Glu Ala Ile Ile Thr Leu Leu Ala  
 195 200 205  
 Ile Ser Arg Ile Gly Ala Ile His Ser Val Val Phe Ala Gly Phe Ser  
 210 215 220  
 Ser Asn Ser Leu Arg Asp Arg Ile Asn Asp Gly Asp Ser Lys Val Val  
 225 230 235 240  
 Ile Thr Thr Asp Glu Ser Asn Arg Gly Gly Lys Val Ile Glu Thr Lys  
 245 250 255  
 Arg Ile Val Asp Asp Ala Leu Arg Glu Thr Pro Gly Val Arg His Val  
 260 265 270  
 Leu Val Tyr Arg Lys Thr Asn Asn Pro Ser Val Ala Phe His Ala Pro  
 275 280 285  
 Arg Asp Leu Asp Trp Ala Thr Glu Lys Lys Lys Tyr Lys Thr Tyr Tyr  
 290 295 300  
 Pro Cys Thr Pro Val Asp Ser Glu Asp Pro Leu Phe Leu Leu Tyr Thr  
 305 310 315 320  
 Ser Gly Ser Thr Gly Ala Pro Lys Gly Val Gln His Ser Thr Ala Gly  
 325 330 335  
 Tyr Leu Leu Gly Ala Leu Leu Thr Met Arg Tyr Thr Phe Asp Thr His  
 340 345 350  
 Gln Glu Asp Val Phe Phe Thr Ala Gly Asp Ile Gly Trp Ile Thr Gly  
 355 360 365  
 His Thr Tyr Val Val Tyr Gly Pro Leu Leu Tyr Gly Cys Ala Thr Leu  
 370 375 380  
 Val Phe Glu Gly Thr Pro Ala Tyr Pro Asn Tyr Ser Arg Tyr Trp Asp  
 385 390 395 400  
 Ile Ile Asp Glu His Lys Val Thr Gln Phe Tyr Val Ala Pro Thr Ala  
 405 410 415  
 Leu Arg Leu Leu Lys Arg Ala Gly Asp Ser Tyr Ile Glu Asn His Ser  
 420 425 430  
 Leu Lys Ser Leu Arg Cys Leu Gly Ser Val Gly Glu Pro Ile Ala Ala  
 435 440 445  
 Glu Val Trp Glu Trp Tyr Ser Glu Lys Ile Gly Lys Asn Glu Ile Pro  
 450 455 460  
 Ile Val Asp Thr Tyr Trp Gln Thr Glu Ser Gly Ser His Leu Val Thr  
 465 470 475 480  
 Pro Leu Ala Gly Gly Val Thr Pro Met Lys Pro Gly Ser Ala Ser Phe  
 485 490 495  
 Pro Phe Phe Gly Ile Asp Ala Val Val Leu Asp Pro Asn Thr Gly Glu  
 500 505 510

-continued

Glu Leu Asn Thr Ser His Ala Glu Gly Val Leu Ala Val Lys Ala Ala  
           515  520  525  
 Trp Pro Ser Phe Ala Arg Thr Ile Trp Lys Asn His Asp Arg Tyr Leu  
           530  535  540  
 Asp Thr Tyr Leu Asn Pro Tyr Pro Gly Tyr Tyr Phe Thr Gly Asp Gly  
   545  550  555  560  
 Ala Ala Lys Asp Lys Asp Gly Tyr Ile Trp Ile Leu Gly Arg Val Asp  
   565  570  575  
 Asp Val Val Asn Val Ser Gly His Arg Leu Ser Thr Ala Glu Ile Glu  
   580  585  590  
 Ala Ala Ile Ile Glu Asp Pro Ile Val Ala Glu Cys Ala Val Val Gly  
   595  600  605  
 Phe Asn Asp Asp Leu Thr Gly Gln Ala Val Ala Ala Phe Val Val Leu  
           610  615  620  
 Lys Asn Lys Ser Ser Trp Ser Thr Ala Thr Asp Asp Glu Leu Gln Asp  
   625  630  635  640  
 Ile Lys Lys His Leu Val Phe Thr Val Arg Lys Asp Ile Gly Pro Phe  
   645  650  655  
 Ala Ala Pro Lys Leu Ile Ile Leu Val Asp Asp Leu Pro Lys Thr Arg  
   660  665  670  
 Ser Gly Lys Ile Met Arg Arg Ile Leu Arg Lys Ile Leu Ala Gly Glu  
   675  680  685  
 Ser Asp Gln Leu Gly Asp Val Ser Thr Leu Ser Asn Pro Gly Ile Val  
           690  695  700  
 Arg His Leu Ile Asp Ser Val Lys Leu  
   705  710

&lt;210&gt; SEQ ID NO 18

&lt;211&gt; LENGTH: 2142

&lt;212&gt; TYPE: DNA

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 18

atgtcgccct ctgccgtaca atcatcaaaa ctagaagaac agtcaagtga aattgacaag 60  
 ttgaaagcaa aaatgtccca gtctgccgcc actgcgcagc agaagaagga acatgagtat 120  
 gaacatttga cttcgggtcaa gatcgtgccca caacggccca tctcagatag actgcagccc 180  
 gcaattgcta cccactattc tccacacttg gacgggttgc aggactatca gcgcttgcac 240  
 aaggagtcta ttgaagacc tgctaagttc ttcggttcta aagctaccca atttttaaac 300  
 tgggtctaagc cattcgataa ggtgttcac ccagacccta aaacgggcag gccctccttc 360  
 cagaacaatg catggttcct caacggccca ttaaagcct gttacaactg tgttgacaga 420  
 catgccttga agactcctaa caagaagacc attattttcg aaggtgacga gcctggccaa 480  
 ggctattcca ttacctacaa ggaactactt gaagaagttt gtcaagtggc acaagtgtg 540  
 acttactcta tggcgcttgc caagggcgat actgttgcg tgtacatgcc tatgggtcca 600  
 gaagcaatca taacctgtt ggccatttcc cgtatcggtg ccattcactc cgtagtcttt 660  
 gccgggtttt ctccaactc cttgagagat cgtatcaac atggggactc taaagttgtc 720  
 atcactacag atgaatccaa cagaggtggg aaagtcattg agactaaaag aattgttgat 780  
 gacgcgctaa gagagacccc aggcgtgaga cacgtcttgg tttatagaaa gaccaacaat 840  
 ccatctgttg ctttccatgc cccagagat ttggattggg caacagaaaa gaagaaatac 900  
 aagacctact atccatgcac acccgttgat tctgaggatc cattattcct gttgtatacg 960



-continued

---

```

tctggttcta ctggtgcccc caagggtgtt caacattcta cgcaggtta cttgctggga 1020
gctttgttga ccatgcgcta cacttttgac actcaccaag aagacgtttt cttcacagct 1080
ggagacattg gctggattac aggccacact tatgtggttt atggtccctt actatatggt 1140
tgtgccactt tggctcttga agggactcct gcgtacccaa attactcccg ttattgggat 1200
attattgatg aacacaaagt cacccaatth tatgttgcgc caactgcttt gcgtttgttg 1260
aaaagagctg gtgattccta catcgaaaat cattccttaa aatctttgcg ttgcttgggt 1320
tcggtcggty agccaattgc tgctgaagtt tgggagtggg actctgaaaa aataggtaaa 1380
aatgaaatcc ccattgtaga cacctactgg caaacagaat ctggttcgca tctggtcacc 1440
ccgctggctg gtggtgttac accaatgaaa cggggttctg cctcattccc cttcttcggt 1500
attgatgcag ttgttcttga ccctaacact ggtgaagaac ttaacaccag ccacgcagag 1560
ggtgtccttg ccgtcaaagc tgcatggcca tcatttgcaa gaactatttg gaaaaatcat 1620
gataggtatc tagacactta tttgaacctt taccctgget actatttcac tggatgatgt 1680
gctgcaaagg ataaggatgg ttatatctgg attttgggtc gtgtagacga tgtggtgaac 1740
gtctctggtc accgtctgtc taccgctgaa attgaggtct ctattatcga agatccaatt 1800
gtggccgagt gtgctgttgt cggattcaac gatgacttga ctggtcaagc agttgctgca 1860
tttgggtgt tgaaaaaaaa atctagtgtg tccaccgcaa cagatgatga attacaagat 1920
atcaagaagc atttggctct tactgtttaga aaagacatcg ggccatttgc cgcacaaaaa 1980
ttgatcattt tagtggatga cttgcccagg acaagatccg gcaaaattat gagacgtatt 2040
ttaagaaaaa tctagcagg agaaagtgac caactaggcg acgtttctac attgtcaaac 2100
cctggcattg ttagacatct aattgattcg gtcaagttgt aa 2142

```

&lt;210&gt; SEQ ID NO 19

&lt;211&gt; LENGTH: 1119

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 19

```

Met Thr Glu Arg Ile Pro Ile Lys Asn Tyr Gln Arg Thr Asn Ala Lys
 1           5              10             15

Ala Leu Leu Lys Leu Thr Glu Lys Leu Phe Asn Lys Asn Phe Phe Asp
 20           25             30

Leu Tyr Leu Thr Ser Gln Gln Leu Val Val Leu Glu Tyr Leu Leu Ser
 35           40             45

Ile Ser Ser Glu Glu Asp Lys Leu Lys Ala Trp Asp Tyr Phe Leu Lys
 50           55             60

Gly Asn Ile Ala Leu Asn Val Glu Lys Ser Phe Pro Leu Thr Gln Glu
 65           70             75             80

Glu Glu His His Gly Ala Val Ser Pro Ala Val Asp Thr Arg Ser Asp
 85           90             95

Asp Val Ser Ser Gln Thr Ile Lys Asp Asn Asn Asn Thr Asn Thr Asn
100          105            110

Thr Ser Ile Ser Asn Glu Asn His Val Glu Asn Glu Ile Glu Asp Lys
115          120            125

Gly Asp Asn Ala Ile Ala Asn Glu Asp Asn Phe Val Asn Asn Asp Glu
130          135            140

Ser Asp Asn Val Glu Glu Asp Leu Phe Lys Leu Asp Leu Glu Asp Leu
145          150            155            160

Lys Gln Gln Ile Ser Gly Thr Arg Phe Ile Gly Asn Leu Ser Leu Lys
165          170            175

```

-continued

---

Ile Arg Tyr Val Leu Trp Gln Cys Ala Ile Asp Tyr Ile Tyr Cys Asp  
180 185 190  
Arg Asn Glu Phe Gly Asp Glu Asn Asp Thr Glu Tyr Thr Leu Leu Asp  
195 200 205  
Val Glu Glu Lys Glu Glu Glu Glu Ile Gly Lys Asn Glu Lys Pro Gln  
210 215 220  
Asn Lys Glu Gly Ile Ser Lys Phe Ala Glu Asp Glu Asp Tyr Asp Asp  
225 230 235 240  
Glu Asp Glu Asn Tyr Asp Glu Asp Ser Thr Asp Val Lys Asn Val Asp  
245 250 255  
Asp Pro Pro Lys Asn Leu Asp Ser Ile Ser Ser Ser Asn Ile Glu Ile  
260 265 270  
Asp Asp Glu Arg Arg Leu Val Leu Asn Ile Ser Ile Ser Lys Glu Thr  
275 280 285  
Leu Ser Lys Leu Lys Thr Asn Asn Val Glu Glu Ile Met Gly Asn Trp  
290 295 300  
Asn Lys Ile Tyr His Ser Phe Glu Tyr Asp Lys Glu Thr Met Ile Lys  
305 310 315 320  
Arg Leu Lys Leu Glu Glu Ser Asp Lys Met Ile Glu Lys Gly Lys Lys  
325 330 335  
Lys Arg Ser Arg Ser Asp Leu Glu Ala Ala Thr Asp Glu Gln Asp Arg  
340 345 350  
Glu Asn Thr Asn Asp Glu Pro Asp Thr Asn Gln Lys Leu Pro Thr Pro  
355 360 365  
Glu Gly Ser Thr Phe Ser Asp Thr Gly Asn Lys Arg Pro Lys Gln Ser  
370 375 380  
Asn Leu Asp Leu Thr Val Asn Leu Gly Ile Glu Asn Leu Ser Leu Lys  
385 390 395 400  
His Leu Leu Ser Ser Ile Gln Gln Lys Lys Ser Gln Leu Gly Ile Ser  
405 410 415  
Asp Tyr Glu Leu Lys His Leu Ile Met Asp Val Arg Lys Asn Arg Ser  
420 425 430  
Lys Trp Thr Ser Asp Glu Arg Ile Gly Gln Glu Glu Leu Tyr Glu Ala  
435 440 445  
Cys Glu Lys Val Val Leu Glu Leu Arg Asn Tyr Thr Glu His Ser Thr  
450 455 460  
Pro Phe Leu Asn Lys Val Ser Lys Arg Glu Ala Pro Asn Tyr His Gln  
465 470 475 480  
Ile Ile Lys Lys Ser Met Asp Leu Asn Thr Val Leu Lys Lys Leu Lys  
485 490 495  
Ser Phe Gln Tyr Asp Ser Lys Gln Glu Phe Val Asp Asp Ile Met Leu  
500 505 510  
Ile Trp Lys Asn Cys Leu Thr Tyr Asn Ser Asp Pro Ser His Phe Leu  
515 520 525  
Arg Gly His Ala Ile Ala Met Gln Lys Lys Ser Leu Gln Leu Ile Arg  
530 535 540  
Met Ile Pro Asn Ile Thr Ile Arg Asn Arg Ala Asp Leu Glu Lys Glu  
545 550 555 560  
Ile Glu Asp Met Glu Lys Asp Lys Asp Tyr Glu Leu Asp Glu Glu Glu  
565 570 575  
Glu Val Ala Gly Ser Gly Arg Lys Gly Leu Asn Met Gly Ala His Met  
580 585 590  
Leu Ala Lys Glu Asn Gly Lys Val Ser Glu Lys Asp Ser Ser Lys Thr

-continued

595					600					605					
Val	Lys	Asp	Glu	Ala	Pro	Thr	Asn	Asp	Asp	Lys	Leu	Thr	Ser	Val	Ile
610						615					620				
Pro	Glu	Gly	Glu	Lys	Glu	Lys	Asp	Lys	Thr	Ala	Ser	Ser	Thr	Val	Thr
625					630					635					640
Val	His	Glu	Asn	Val	Asn	Lys	Asn	Glu	Ile	Lys	Glu	Asn	Gly	Lys	Asn
				645					650					655	
Glu	Glu	Gln	Asp	Met	Val	Glu	Glu	Ser	Ser	Lys	Thr	Glu	Asp	Ser	Ser
			660					665					670		
Lys	Asp	Ala	Asp	Ala	Ala	Lys	Lys	Asp	Thr	Glu	Asp	Gly	Leu	Gln	Asp
		675					680					685			
Lys	Thr	Ala	Glu	Asn	Lys	Glu	Ala	Gly	Glu	Asn	Asn	Glu	Glu	Glu	Glu
	690					695					700				
Asp	Asp	Asp	Asp	Glu	Asp	Glu	Asp	Glu	Asp	Met	Val	Asp	Ser	Gln	Ser
705					710					715					720
Tyr	Leu	Leu	Glu	Lys	Asp	Asp	Asp	Arg	Asp	Asp	Leu	Glu	Ile	Ser	Val
				725					730					735	
Trp	Lys	Thr	Val	Thr	Ala	Lys	Val	Arg	Ala	Glu	Ile	Cys	Leu	Lys	Arg
			740					745					750		
Thr	Glu	Tyr	Phe	Lys	Asn	Gly	Lys	Leu	Asn	Ser	Asp	Ser	Glu	Ala	Phe
		755				760						765			
Leu	Lys	Asn	Pro	Gln	Arg	Met	Lys	Arg	Phe	Asp	Gln	Leu	Phe	Leu	Glu
	770					775					780				
Tyr	Lys	Glu	Gln	Lys	Ala	Leu	Glu	Ser	Tyr	Arg	Gln	Lys	Ile	Glu	Gln
785					790					795					800
Asn	Ser	Ile	Met	Lys	Asn	Gly	Phe	Gly	Thr	Val	Leu	Lys	Gln	Glu	Asp
				805					810					815	
Asp	Asp	Gln	Leu	Gln	Phe	His	Asn	Asp	His	Ser	Leu	Asn	Gly	Asn	Glu
			820					825					830		
Ala	Phe	Glu	Lys	Gln	Pro	Asn	Asp	Ile	Glu	Leu	Asp	Asp	Thr	Arg	Phe
		835					840					845			
Leu	Gln	Glu	Tyr	Asp	Ile	Ser	Asn	Ala	Ile	Pro	Asp	Ile	Val	Tyr	Glu
	850					855					860				
Gly	Val	Asn	Thr	Lys	Thr	Leu	Asp	Lys	Met	Glu	Asp	Ala	Ser	Val	Asp
865					870					875					880
Arg	Met	Leu	Gln	Asn	Gly	Ile	Asn	Lys	Gln	Ser	Arg	Phe	Leu	Ala	Asn
				885					890					895	
Lys	Asp	Leu	Gly	Leu	Thr	Pro	Lys	Met	Asn	Gln	Asn	Ile	Thr	Leu	Ile
		900						905						910	
Gln	Gln	Ile	Arg	His	Ile	Cys	His	Lys	Ile	Ser	Leu	Ile	Arg	Met	Leu
		915				920						925			
Gln	Ser	Pro	Leu	Ser	Ala	Gln	Asn	Ser	Arg	Ser	Asn	Pro	Asn	Ala	Phe
		930				935					940				
Leu	Asn	Asn	His	Ile	Tyr	Asn	Tyr	Thr	Ile	Ile	Asp	Asp	Ser	Leu	Asp
945					950					955					960
Ile	Asp	Pro	Val	Ser	Gln	Leu	Pro	Thr	His	Asp	Tyr	Lys	Asn	Asn	Arg
				965					970					975	
Glu	Leu	Ile	Trp	Lys	Phe	Met	His	Lys	Asn	Ile	Ser	Lys	Val	Ala	Met
		980						985					990		
Ala	Asn	Gly	Phe	Glu	Thr	Ala	His	Pro	Ser	Ala	Ile	Asn	Met	Leu	Thr
		995					1000						1005		
Glu	Ile	Ala	Gly	Asp	Tyr	Leu	Ser	Asn	Leu	Ile	Lys	Thr	Leu	Lys	
	1010						1015						1020		

-continued

---

Leu His His Glu Thr Asn Ser Leu Asn Arg Gly Thr Asn Val Glu  
 1025 1030 1035

Met Leu Gln Thr Thr Leu Leu Glu Asn Gly Ile Asn Arg Pro Asp  
 1040 1045 1050

Asp Leu Phe Ser Tyr Val Glu Ser Glu Phe Gly Lys Lys Thr Lys  
 1055 1060 1065

Lys Leu Gln Asp Ile Lys Gln Lys Leu Glu Ser Phe Leu Arg Ala  
 1070 1075 1080

Leu Leu Arg Pro Thr Leu Gln Glu Leu Ser Glu Arg Asn Phe Glu  
 1085 1090 1095

Asp Glu Ser Gln Ser Phe Phe Thr Gly Asp Phe Ala Ser Glu Leu  
 1100 1105 1110

Thr Gly Glu Asp Phe Phe  
 1115

&lt;210&gt; SEQ ID NO 20

&lt;211&gt; LENGTH: 3357

&lt;212&gt; TYPE: DNA

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 20

```

atgactgaaa gaataccaat aaagaattat caaagaacaa atgccaaagc tttacttaaa    60
ttgactgaaa aactttttta caagaacttt tttgatctct atttaacctc tcagcaattg   120
gtcgttcttg aatacctgct gtcgatttca agtgaagaag acaaaactgaa agcatgggac   180
tatttcttaa agggaaacat agcattaaat gtcgaaaaat catttccatt aaccaagaa    240
gaagaacatc acggagcggg ctctcctgcc gttgacacac gatcagatga tgtatcatca   300
caacaatta aggacaataa caatactaata accaacacca gtatcagcaa tgaaaatcat   360
gttgaaaatg aaattgaaga taaaggcgat aacgcaatag caaatgaaga taattttgtg   420
aataatgacg aaagtgataa tgttgaagaa gacttattca aattagatct agaggacttg   480
aagcagcaaa taagcgyaac aaggtttatt ggaaacttat ccttgaaaat cagatacgtc   540
ttgtggcagt gcgccataga ttatatatac tgtgatcgta atgagtttgg tgatgaaaat   600
gatacagaat acaccctatt agatgttgaa gagaaggagg aagaggaaat tggtaaaaat   660
gagaagccac aaaacaaaga aggtatttct aagttcgcgg aggatgaaga ttacgacgat   720
gaagacgaga actatgatga agacagtaca gacgtaaaaa atgtcgatga tcctccaaaa   780
aatctcgatt ctatttcctc ttctaataac gaaattgacg atgaacgacg cttggtgcta   840
aatatctcaa tatcaaaaga aacactgtca aagttaaaaa caaataatgt agaagaaatt   900
atgggaaatt ggaacaaaat ttaccacagt tttgaatacg ataaagaaac tatgataaag   960
cgataaaaac ttgaagaaag cgataaaatg atagagaaag gaaagaagaa acgaagtcga  1020
agtgatttag aagcagctac cgatgaacaa gatcgcgaaa atacaaatga tgagccagat  1080
actaatcaaa aattgcccac tcctgaaggt tcaacattca gcgatactgg gaacaagcgc   1140
cccaaacaaa gtaatttaga ttaaacagtc aatctaggca tcgaaaattt atcattaaag   1200
caccttctat catctatcca gcaaaaaaaaa tccaatttag gaatatcaga ttacgaatta   1260
aaacatctga ttatggatgt cagaaaaaat cggtcaaaat ggacatcgga tgaagaatt   1320
gggcaagagg aattatacga agcctgtgaa aaggttgttt tggaaacttag aaactacact   1380
gagcatttcta caccatttct gaataaagtg agcaaaagag aagcccccac ttatcatcaa   1440
atcatcaaaa agtccatgga cctgaatact gttttaaaaa aactgaaaag ctttcaatat   1500
gactccaaac aagaatttgt agacgatatt atgctaatat gaaaaaattg tttgacctat   1560

```

-continued

aattcagatc cttcacattt tttgagaggg catgctattg ctatgcagaa gaaatctctt 1620  
cagttgattc gcatgattcc aaatatcaca atccgaaaca gggctgattt agaaaaggaa 1680  
attgaagata tggaaaaaga caaagactac gaattagatg aggaagagga agttgctggg 1740  
tctggaagaa aaggattgaa tatggggact catatggttg ccaagagaa tggcaagggt 1800  
tcagaaaaag atagctctaa aaccgtcaag gatgaagcac caaccaatga tgacaaacta 1860  
acttctgtca tccctgaggg ggaaaaagag aaagataaaa ctgcttcac tactgtaacg 1920  
gtacacgaaa atgtaataa gaacgaaata aaagaaaatg ggaaaaatga agagcaagat 1980  
atggttgagg aaagtagtaa gactgaggat tcatcaaaag atgctgatgc tgccaaaaag 2040  
gatacggaag acggactaca agataaaact gcagaaaata aggaggctgg ggaaaaaat 2100  
gaagaggaag aggatgatga tgacgaagat gaagacgaag acatggtcga ctcccaatct 2160  
tatttacttg aaaaggatga cgatagagac gatttggaat tatccgtgtg gaaaactgta 2220  
actgccaaag ttcgtgcgga aatttgctta aaaagaactg aatattttaa aaatggaaaa 2280  
ttaaataagt attcagagc gtttttgaat aaccacaaa gaatgaaaag gttcgaccag 2340  
cttttcttg aatataaaga gcagaaagct ttagaatcat atcgtcaaaa aatagagcaa 2400  
aattccatta tgaaaaatgg ctttggaaac gtactaaac aggaagacga tgaccaattg 2460  
cagtttcata atgatcactc ttaaatgga aatgaagctt ttgaaaagca acccaatgat 2520  
attgagttag atgataccag attcctacag gaatatgata ttagtaacgc cttcctgac 2580  
atagtatacg agggagtaaa tactaaaaca ttagacaaga tggaaagacgc tccgtggac 2640  
cgcatgcttc aaatgggat caacaacaa agcagatttc tggctaaca ggatttagga 2700  
ctaacaccta aatgaacca aaatatcaca ctgattcagc aaattaggca catatgccat 2760  
aaaaatccc tgatcagaat gttacagagc cctttatcgg ctcaaaactc cagaagcaat 2820  
cccaacgctt tccttaaca ccacattat aattacacta ttattgatga ctactcgat 2880  
attgatccgg tgtcacagct tccaacgcat gattacaaa acaacagga gctgatatgg 2940  
aaattcatgc ataagaacat atctaaggtt gctatggcca atgggttga aactgccc 3000  
ccatcagcaa taaacatgct tactgaaatc gccggggatt acctatctaa tctgataaag 3060  
actttgaagc ttcacatga aactaactcc ttaaatagag gaacaaatgt ggaatgctg 3120  
caacaacac tgttgaaaa cggtatcaac agccagagc atctatttct ctatgttga 3180  
tctgaatttg gtaaaaaac taagaaactt caggacatca aacagaaact agaaagcttt 3240  
ttgagagcct tattaaggcc aactttgcag gagttgtccg agagaaactt tgaagacgag 3300  
agccaaagct tttttacagg tgactttgcc agcgaattga ctggtgaaga cttcttt 3357

&lt;210&gt; SEQ ID NO 21

&lt;211&gt; LENGTH: 337

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 21

Met Met Asp Lys His Lys Tyr Arg Val Glu Ile Gln Gln Met Met Phe  
1 5 10 15  
Val Ser Gly Glu Ile Asn Asp Pro Pro Val Glu Thr Thr Ser Leu Ile  
20 25 30  
Glu Asp Ile Val Arg Gly Gln Val Ile Glu Ile Leu Leu Gln Ser Asn  
35 40 45  
Lys Thr Ala His Leu Arg Gly Ser Arg Ser Ile Leu Pro Glu Asp Val  
50 55 60

-continued

Ile Phe Leu Ile Arg His Asp Lys Ala Lys Val Asn Arg Leu Arg Thr  
65 70 75 80  
Tyr Leu Ser Trp Lys Asp Leu Arg Lys Asn Ala Lys Asp Gln Asp Ala  
85 90 95  
Ser Ala Gly Val Ala Ser Gly Thr Gly Asn Pro Gly Ala Gly Gly Glu  
100 105 110  
Asp Asp Leu Lys Lys Ala Gly Gly Gly Glu Lys Asp Glu Lys Asp Gly  
115 120 125  
Gly Asn Met Met Lys Val Lys Lys Ser Gln Ile Lys Leu Pro Trp Glu  
130 135 140  
Leu Gln Phe Met Phe Asn Glu His Pro Leu Glu Asn Asn Asp Asp Asn  
145 150 155 160  
Asp Asp Met Asp Glu Asp Glu Arg Glu Ala Asn Ile Val Thr Leu Lys  
165 170 175  
Arg Leu Lys Met Ala Asp Asp Arg Thr Arg Asn Met Thr Lys Glu Glu  
180 185 190  
Tyr Val His Trp Ser Asp Cys Arg Gln Ala Ser Phe Thr Phe Arg Lys  
195 200 205  
Asn Lys Arg Phe Lys Asp Trp Ser Gly Ile Ser Gln Leu Thr Glu Gly  
210 215 220  
Lys Pro His Asp Asp Val Ile Asp Ile Leu Gly Phe Leu Thr Phe Glu  
225 230 235 240  
Ile Val Cys Ser Leu Thr Glu Thr Ala Leu Lys Ile Lys Gln Arg Glu  
245 250 255  
Gln Val Leu Gln Thr Gln Lys Asp Lys Ser Gln Gln Ser Ser Gln Asp  
260 265 270  
Asn Thr Asn Phe Glu Phe Ala Ser Ser Thr Leu His Arg Lys Lys Arg  
275 280 285  
Leu Phe Asp Gly Pro Glu Asn Val Ile Asn Pro Leu Lys Pro Arg His  
290 295 300  
Ile Glu Glu Ala Trp Arg Val Leu Gln Thr Ile Asp Met Arg His Arg  
305 310 315 320  
Ala Leu Thr Asn Phe Lys Gly Gly Arg Leu Ser Ser Lys Pro Ile Ile  
325 330 335

Met

&lt;210&gt; SEQ ID NO 22

&lt;211&gt; LENGTH: 1014

&lt;212&gt; TYPE: DNA

<213> ORGANISM: *Saccharomyces cerevisiae*

&lt;400&gt; SEQUENCE: 22

atgatggaca agcataagta tcgtgtggag attcaacaga tgatgtttgt ctctggtgaa 60  
attaacgacc caccctaga aaccacatca ctgatagaag atatagttag gggtaagtg 120  
atagaaattc ttttacagtc aaacaaaacg gcgcatctta ggggaagtag gagcattctc 180  
cctgaagacg tcattttctt gatcagacac gacaaggcca aagtcaatcg tttgagaaca 240  
tatctgtcat ggaaggattt gcgtaaaaac gccaaaggacc aagatgctag tgcoggtgta 300  
gcgagtggca ctggaaatcc tggggcaggt ggtgaagatg atttgaaaaa agcaggtggt 360  
ggcgagaaag acgaaaaaga tgggtggaac atgatgaagg tcaagaaatc ccaaattaag 420  
ctgccatggg aattgcagtt tatgttcaat gaacatcctt tagaaaataa tgacgacaat 480  
gatgatatgg atgaggatga acgagaagct aatatagtca ctttgaaaag gctgaaaatg 540

-continued

---

gctgacgata gaacacgaaa catgactaaa gaggagtacg tgcattggtc cgattgtcga	600
caggcaagtt ttacatttag gaagaataaa aggttcaagg actggtctgg aatttcgcaa	660
ttaactgagg ggaaacccca tgatgatgtg attgatatac tggggtttct aacttttgag	720
attgtctggt ctttgacgga aacagctctg aaaatcaaac aaagagaaca ggtattacag	780
actcaaaagg acaaatccca gcaatctagc caagataata ctaactttga atttgcacca	840
tccacattac atagaagaa aagattatgt gatggacctg aaaatgttat aaaccgctc	900
aaaccaaggc atatagagga agcctggaga gtactacaaa caattgacat gaggcatagg	960
gctttgacca actttaaggg tggtagactc agttctaaac caattatcat gtaa	1014

---

The invention claimed is:

**1.** A method for increasing a chronological lifespan of a cell comprising disrupting a function the Spt-Ada-Gcn5-Acetyltransferase complex in said cell, wherein the complex is disrupted by disrupting the function of the Spt7 gene or homologue thereof.

**2.** The method according to claim 1 wherein the at least one complex is directly or indirectly disrupted.

**3.** The method according to claim 1, wherein the function of the gene is disrupted by iRNA.

**4.** The method according to claim 1, wherein the function of the gene is disrupted at a transcriptional/DNA level.

\* \* \* \* \*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 8,628,922 B2  
APPLICATION NO. : 13/382629  
DATED : January 14, 2014  
INVENTOR(S) : Elizabeth Jane Mellor

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

Column 111, line 23, Claim 2 should read:

2. The method according to claim 1 wherein the complex is directly or indirectly disrupted.

Signed and Sealed this  
Fifth Day of August, 2014



Michelle K. Lee  
*Deputy Director of the United States Patent and Trademark Office*